The vascular smooth muscle T-type Ca\textsuperscript{2+} channel: An anti-proliferative target for heme oxygenase-1

Hayley Duckles

Submitted in accordance with the requirements for the degree of Doctor of Philosophy.

The University of Leeds, Faculty of Medicine and Health, Leeds Institute of Genetics, Health, and Therapeutics, Division of Cardiovascular and Diabetes Research.

April 2013

The candidate confirms that the work submitted is her own and that appropriate credit has been given where reference has been made to the work of others.

This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement.
Acknowledgements

First and foremost I would like to thank my supervisors for their excellent guidance and words of encouragement throughout my PhD. Thank you Professor Chris Peers for giving me the opportunity to pursue an interesting and challenging project within a friendly and accommodating research group, and for always having an open door. Thank you Dr Karen Porter for your support in both academic and non-academic matters. And Dr Jason Scragg, thank you for always being approachable and for offering advice whenever I doubted myself.

Many thanks to Dr John Boyle for imparting knowledge and for teaching me numerous skills. Additionally, thank you for spending countless hours at the microscope with me. I very much appreciate all your advice and help over the past three years. Also, thank you to David Myers, Phillip Warburton and Dr Nadira Yuldasheva for technical assistance.

To Tania, Kirsty, Jacob, and Emily, thank you for your friendship and advice, and for keeping my spirits up.

And to my family and friends, thank you for your continued love and support throughout this challenging period. Thank you for listening to many presentation rehearsals, for your encouragement, and for always being there. I would like to convey a special thank you to my wonderful sister Karen, this would not have been possible without you.

Finally, thank you to the British Heart Foundation for providing the funding for this project.
Abstract

Pathological proliferation of vascular smooth muscle cells (VSMC) is a central feature of vascular disorders such as atherosclerosis and restenosis. During such proliferative conditions the expression of the T-type Ca\(^{2+}\) channel is increased, providing an important route for Ca\(^{2+}\) entry. The inducible stress-response protein, heme oxygenase-1 (HO-1), is also up-regulated during vascular disorders. This enzyme confers cytoprotective effects via the breakdown of free heme to produce iron, biliverdin, and carbon monoxide (CO). CO has been shown to be anti-inflammatory, anti-apoptotic, and anti-proliferative at low concentrations. Furthermore, CO is emerging as a modulator of various ion channels, and our research group has recently found that CO inhibits the T-type Ca\(^{2+}\) current via whole-cell patch clamp recordings. Therefore, the aim of this thesis was to investigate whether the VSMC T-type Ca\(^{2+}\) channel could act as an anti-proliferative target for HO-1-derived CO.

HEK293 cells over-expressing the Ca\(_{\text{v}}\)3.2 T-type Ca\(^{2+}\) channel produced higher basal [Ca\(^{2+}\)], and displayed an augmented proliferative response. [Ca\(^{2+}\)], and proliferation were both reduced by T-type Ca\(^{2+}\) channel inhibition, CO exposure, and HO-1 induction. T-type Ca\(^{2+}\) channel inhibition and HO-1 induction reduced [Ca\(^{2+}\)], and proliferation in the rat aortic VSMC line, A7r5. Exogenous CO exposure decreased [Ca\(^{2+}\)], in A7r5 cells, but conferred insignificant anti-proliferative effects, which correlated to a relatively low expression of the T-type Ca\(^{2+}\) channel. T-type Ca\(^{2+}\) channel inhibition, CO exposure, and HO-1 induction all have anti-proliferative effects in human VSMCs, yet simultaneous HO-1 induction and T-type Ca\(^{2+}\) channel inhibition do not cause additive inhibitory effects on proliferation.

These data provide evidence that CO is anti-proliferative, and that CO potentially acts via the T-type Ca\(^{2+}\) channel. This pathway could be a novel therapeutic target for vascular disorders involving excessive smooth muscle cell proliferation.
Table of Contents

Acknowledgements.................................................................................................................. ii
Abstract ........................................................................................................................................ iii
Table of Contents ........................................................................................................................ iv
Tables ............................................................................................................................................ ix
Figures .......................................................................................................................................... x
Abbreviations .............................................................................................................................. xv
CHAPTER 1 ................................................................................................................................... 1
  Introduction .................................................................................................................................. 1
    1.1 Disorders of Vascular Remodelling ...................................................................................... 1
      Atherosclerosis ......................................................................................................................... 1
      Hypertension ............................................................................................................................ 2
      Restenosis ................................................................................................................................ 3
    1.2 The response to vascular injury ........................................................................................... 4
      1.2.1 The role of the endothelium ......................................................................................... 4
      1.2.2 Vascular smooth muscle cells and phenotypic switching ........................................... 5
      1.2.3 Modulation of Ca^{2+} signalling during the phenotypic switch ................................ 7
    1.3 T-type Ca^{2+} channels ......................................................................................................... 12
      1.3.1 Properties of T-type Ca^{2+} channels .......................................................................... 12
      1.3.2 Modulation of T-type Ca^{2+} channels ....................................................................... 15
      1.3.3 Physiological Functions of T-type Ca^{2+} channels .................................................. 17
        Oxygen sensing ...................................................................................................................... 17
        Cardiac pacemaker potential ............................................................................................... 18
        Smooth muscle cell contraction and relaxation ................................................................. 18
        Proliferation and the cell cycle ............................................................................................ 19
    1.4 Heme oxygenase 1 .............................................................................................................. 22
      1.4.1 Inducers of HO-1 ......................................................................................................... 24
      1.4.2 Effects of HO-1 induction ............................................................................................ 27
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proliferation and Apoptosis</td>
<td>27</td>
</tr>
<tr>
<td>Inflammation and oxidation</td>
<td>30</td>
</tr>
<tr>
<td>Vasodilation</td>
<td>31</td>
</tr>
<tr>
<td>1.4.3 HO-1 and NO</td>
<td>31</td>
</tr>
<tr>
<td>1.4.4 Therapeutic potential of HO-1</td>
<td>32</td>
</tr>
<tr>
<td>1.5 Carbon Monoxide</td>
<td>33</td>
</tr>
<tr>
<td>1.5.1 Cytoprotective effects of CO</td>
<td>34</td>
</tr>
<tr>
<td>1.5.2 Ion channels as targets of CO</td>
<td>37</td>
</tr>
<tr>
<td>1.5.3 Therapeutic potential of CO</td>
<td>37</td>
</tr>
<tr>
<td>1.6 Aims of the present study</td>
<td>39</td>
</tr>
<tr>
<td>CHAPTER 2</td>
<td>41</td>
</tr>
<tr>
<td>Methods and Materials</td>
<td>41</td>
</tr>
<tr>
<td>2.1 Cell Isolation and Culture</td>
<td>41</td>
</tr>
<tr>
<td>2.1.1 WT HEK293 and HEK293/Ca,v3.2 Cells</td>
<td>41</td>
</tr>
<tr>
<td>2.1.2 A7r5 Cells</td>
<td>42</td>
</tr>
<tr>
<td>2.1.3 Human Coronary Artery Smooth Muscle Cells (HCASMC)</td>
<td>42</td>
</tr>
<tr>
<td>2.1.4 Human Saphenous Vein Smooth Muscle Cells (HSVSMC)</td>
<td>42</td>
</tr>
<tr>
<td>2.2 Proliferation Assay</td>
<td>43</td>
</tr>
<tr>
<td>2.2.1 Proliferation Assay Protocol</td>
<td>43</td>
</tr>
<tr>
<td>2.2.2 Determination of Proliferation Assay Length</td>
<td>44</td>
</tr>
<tr>
<td>2.3 Sodium-Dodecyl Sulphate Polyacrylamide Gel Electrophoresis</td>
<td>44</td>
</tr>
<tr>
<td>2.3.1 Cell Lysis and Protein Extraction of samples</td>
<td>44</td>
</tr>
<tr>
<td>2.3.2 Membrane Enrichment of HSVSMC samples</td>
<td>45</td>
</tr>
<tr>
<td>2.3.3 Immunoprecipitation</td>
<td>45</td>
</tr>
<tr>
<td>2.4 Bicinchoninic acid protein assay</td>
<td>46</td>
</tr>
</tbody>
</table>
2.5 Gel Electrophoresis ................................................................. 46
2.6 Western Blotting ................................................................. 48
  2.6.1 Electrophoretic Transfer .................................................. 48
  2.6.2 Immunodetection .......................................................... 48
2.7 Immunocytochemistry ......................................................... 50
  2.7.1 HO-1 ............................................................................. 50
  2.7.2 Cav3.2 and Ca_{v}3.1 T-type Ca^{2+} channels .................... 51
  2.7.3 Cell Characterisation ...................................................... 51
2.8 Detection of Caspase-3/7 Activation via CellEvent™ ............... 52
2.9 Measurement and analysis of [Ca^{2+}] ................................... 52
  2.9.1 Measurement of [Ca^{2+}] by microfluorimetry .................... 52
  2.9.2 Analysis of microfluorimetry traces from A7r5 cells .......... 56
  2.9.3 Analysis of microfluorimetry traces from HEK293 cells ...... 57
2.10 Real-Time Polymerase Chain Reaction (RT-PCR) .................. 57
  2.10.1 RNA generation .......................................................... 57
  2.10.2 cDNA generation ......................................................... 60
  2.10.3 RT-PCR ...................................................................... 61
2.11 Stable Transfection of A7r5 cells with pcDNAhHO-1 ............... 61
2.12 Cell Transfection with HO-1-targeting siRNA ....................... 62
  2.12.1 Transfection Protocol for a 6 well plate ......................... 62
  2.12.2 First transfection – determination of optimal HO-1-targeting siRNA .... 64
  2.12.3 Second transfection – determination of the period of gene knock-down ... 64
  2.12.4 Proliferation assay post-transfection ............................ 64
2.13 Cell Transfection with Ca_{v}3.1-targeting siRNA .................... 64
  2.13.1 First transfection – determination of optimal Ca_{v}3.1-targeting siRNA concentration ................................................................. 65
  2.13.2 Second transfection – determination of the period of gene knock-down .... 66
2.14 Drugs ................................................................................. 66
2.15 Statistical Analysis .............................................................. 67
The effect of T-type Ca\textsuperscript{2+} channel inhibition, HO-1 induction, and CO on human smooth muscle cell proliferation ................................................................. 170

6.1 Introduction ........................................................................................................ 170

6.2 Results ................................................................................................................ 171

6.2.1 Characterisation of HSVSMCs ................................................................... 171

6.2.2 The effect of T-type Ca\textsuperscript{2+} channel inhibition on HSVSMC and HCASMC proliferation ................................................................................................. 171

6.2.3 The effect of CO on HSVSMC and HCASMC proliferation .................... 179

6.2.4 The effect of HO-1 modulation on HSVSMC and HCASMC proliferation ... 179

6.3 Discussion .......................................................................................................... 189

CHAPTER 7 .............................................................................................................. 197

Conclusions ............................................................................................................. 197

7.1 Principle Findings .............................................................................................. 197

HEK293/Ca\textsubscript{v}3.2 cells ..................................................................................... 197

A7r5 cells .................................................................................................................. 197

Human VSMCs ........................................................................................................ 198

7.2 Summary and clinical relevance ...................................................................... 198

7.3 Further Work ..................................................................................................... 199
Tables

Table 2.1 Composition of sample buffers used for gel electrophoresis 47
Table 2.2 Composition of electrophoretic gels 47
Table 2.3 Primary and secondary antibodies used in western blotting and immunocytochemistry 49
Table 2.4 Primary and secondary antibodies used in immunocytochemistry for cell characterisation 51
Table 2.5 Composition of 1L buffers used in Ca\(^{2+}\) microfluorimetry 55
Table 2.6 Composition of iScript reaction solution 60
Table 2.7 Composition of RT-PCR reaction mix 61
Table 2.8 RT-PCR primer details 61
Table 2.9 Transfection volumes per well of each experimental group using 100nM siRNA 63
Table 2.10 Transfection volumes per well of each experimental group using 50nM siRNA 63
Table 2.11 Transfection volumes per well of each experimental group using 25nM siRNA 63
Table 2.12 Transfection volumes per well of each experimental group using 100nM siRNA 64
Table 2.13 Volumes for 50nM siRNA transfection for 1 well of each experimental group 65
Table 2.14 Volumes for 25nM siRNA transfection for 1 well of each experimental group 65
Table 2.15 Volumes for 10nM siRNA transfection for 1 well of each experimental group 66
Table 2.16 Volumes for 50nM siRNA transfection for 1 well of each experimental group 66
Table 2.17 Drugs used in experiments 67
# Figures

## Chapter 1

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 1.1</td>
<td>Ca(^{2+}) entry pathways in de-differentiated VSMCs</td>
<td>11</td>
</tr>
<tr>
<td>Figure 1.2</td>
<td>Window currents of T-type and L-type Ca(^{2+}) channels</td>
<td>14</td>
</tr>
<tr>
<td>Figure 1.3</td>
<td>Transmembrane structure of the T-type Ca(^{2+}) channel (\alpha_1) subunit</td>
<td>16</td>
</tr>
<tr>
<td>Figure 1.4</td>
<td>Crystal Structure of human HO-1</td>
<td>23</td>
</tr>
<tr>
<td>Figure 1.5</td>
<td>The HO-1 Pathway</td>
<td>25</td>
</tr>
<tr>
<td>Figure 1.6</td>
<td>Pathways mediating the cytoprotective effects of CO in VSMC</td>
<td>38</td>
</tr>
</tbody>
</table>

## Chapter 2

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 2.1</td>
<td>Fluorescence excitation spectra of Fura 2-AM in solutions containing 0-39.8µM free Ca(^{2+})</td>
<td>54</td>
</tr>
<tr>
<td>Figure 2.2</td>
<td>Details of how A7r5 traces were analysed</td>
<td>58</td>
</tr>
<tr>
<td>Figure 2.3</td>
<td>Illustration of the 200s integral calculated for all A7r5 cell traces in response to 80mM K(^+) buffer</td>
<td>59</td>
</tr>
<tr>
<td>Figure 2.4</td>
<td>Details of how HEK293 traces were analysed</td>
<td>59</td>
</tr>
</tbody>
</table>

## Chapter 3

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 3.1</td>
<td>Identification of the Ca(_{v}3.2) T-type Ca(^{2+}) channel in HEK293 cells</td>
<td>71</td>
</tr>
<tr>
<td>Figure 3.2</td>
<td>HEK293/Ca(_{v}3.2) cells have elevated basal ([\text{Ca}^{2+}]_i) levels</td>
<td>73</td>
</tr>
<tr>
<td>Figure 3.3</td>
<td>Augmented proliferation of HEK293/Ca(_{v}3.2) cells</td>
<td>74</td>
</tr>
<tr>
<td>Figure 3.4</td>
<td>Treatment with 3µM mibefradil reduces ([\text{Ca}^{2+}]<em>i) in HEK293/Ca(</em>{v}3.2) cells</td>
<td>75</td>
</tr>
<tr>
<td>Figure 3.5</td>
<td>Mibefradil inhibits proliferation of HEK293/Ca(_{v}3.2) cells</td>
<td>77</td>
</tr>
<tr>
<td>Figure 3.6</td>
<td>Treatment with 3µM NNC55-0396 reduces ([\text{Ca}^{2+}]<em>i) in HEK293/Ca(</em>{v}3.2) cells</td>
<td>78</td>
</tr>
</tbody>
</table>
Figure 3.7 Treatment with 30µM Ni^{2+} reduces [Ca^{2+}]_{i} in HEK293/Ca_v.3.2 cells

Figure 3.8 The effect of CORM-3 on [Ca^{2+}]_{i} and proliferation

Figure 3.9 The effect of 3µM iCORM-3 on [Ca^{2+}]_{i}

Figure 3.10 Identification of HO-1 induction in HEK293 cells

Figure 3.11 CoPPIX induces HO-1 protein expression in HEK293/Ca_v.3.2 cells

Figure 3.12 CoPPIX induces HO-1 protein expression in WT HEK293 cells

Figure 3.13 Treatment with CoPPIX reduces [Ca^{2+}]_{i} in HEK293/Ca_v.3.2 cells

Figure 3.14 HO-1 induction by CoPPIX inhibits cell proliferation

Chapter 4

Figure 4.1 Characterisation of A7r5 cells

Figure 4.2 T-type Ca^{2+} channel expression in A7r5 cells

Figure 4.3 Expression of the Ca_v.3.1 T-type Ca^{2+} channels in A7r5 cells

Figure 4.4 Expression of the Ca_v.3.2 T-type Ca^{2+} channel in A7r5 cells

Figure 4.5 20mM K^{+} buffer causes Ca^{2+} oscillations and an increase in [Ca^{2+}]_{i}

Figure 4.6 The response of [Ca^{2+}]_{i} on exposure to Ca^{2+}-free extracellular buffer

Figure 4.7 80mM K^{+} buffer causes a rapid increase in [Ca^{2+}]_{i}

Figure 4.8 3µM mibefradil inhibits [Ca^{2+}]_{i} and Ca^{2+} oscillations

Figure 4.9 Response to 80mM K^{+} buffer containing 3µM mibefradil

Figure 4.10 Inhibitory effects of Ni^{2+} on Ca_v.3.1 channels

Figure 4.11 30µM Ni^{2+} inhibits [Ca^{2+}]_{i} but not Ca^{2+} oscillations

Figure 4.12 Response to 80mM K^{+} buffer containing 30µM Ni^{2+}

Figure 4.13 2µM nifedipine inhibits [Ca^{2+}]_{i} and Ca^{2+} oscillations
Figure 4.14  Response to 80mM K\(^+\) buffer containing 2\(\mu\)M nifedipine

Figure 4.15  Simultaneous addition of 2\(\mu\)M nifedipine and 3\(\mu\)M mibebradil inhibits [Ca\(^{2+}\)]\(_i\) and Ca\(^{2+}\) oscillations

Figure 4.16  Response to 80mM K\(^+\) buffer containing 2\(\mu\)M nifedipine and 3\(\mu\)M mibebradil

Figure 4.17  Simultaneous addition of 2\(\mu\)M nifedipine and 30\(\mu\)M Ni\(^{2+}\) inhibits [Ca\(^{2+}\)]\(_i\) and Ca\(^{2+}\) oscillations

Figure 4.18  Mibebradil inhibits A7r5 cell proliferation

Figure 4.19  The effect of mibebradil on caspase-3/7 activation

Figure 4.20  Low Ni\(^{2+}\) concentrations do not inhibit A7r5 cell proliferation

Figure 4.21  The effect of nifedipine on A7r5 cell proliferation

Figure 4.22  The effect of high Ni\(^{2+}\) concentrations and 2\(\mu\)M nifedipine on A7r5 proliferation

Figure 4.23  Preliminary assessment of Ca\(_{\alpha,3.1}\)-targeting siRNA at 24h and 48h

Figure 4.24  Assessment of 25nM Ca\(_{\alpha,3.1}\)-targeting siRNA over a 96h time-course

Figure 4.25  The effect of 25nM Ca\(_{\alpha,3.1}\)-targeting siRNA on A7r5 proliferation over a 96h time-course

Figure 4.26  The effect of 50nM Ca\(_{\alpha,3.1}\)-targeting siRNA on A7r5 proliferation over a 96h time-course

Figure 4.27  The effect of 50nM Ca\(_{\alpha,3.1}\)-targeting siRNA on A7r5 proliferation over a 72h time-course

Chapter 5

Figure 5.1  The effect of 10\(\mu\)M CORM-3, iCORM-3 and 2\(\mu\)M DTT on [Ca\(^{2+}\)]\(_i\) and Ca\(^{2+}\) oscillations

Figure 5.2  DTT does not significantly prevent the effects of CORM-3
Figure 5.3  The change in $[\text{Ca}^{2+}]_i$ in response to 80mM K$^+$ buffer containing 10µM CORM-3

Figure 5.4  CORM-3 has no effect on A7r5 proliferation

Figure 5.5  Co-application of CORM-3 and mibefradil inhibits A7r5 proliferation

Figure 5.6  CORM-3 and iCORM-3 do not induce caspase-3/7 activation

Figure 5.7  Simultaneous addition of 10µM CORM-3 and 2µM nifedipine inhibits $[\text{Ca}^{2+}]_i$ and $\text{Ca}^{2+}$ oscillations

Figure 5.8  CORM-3 inhibits A7r5 proliferation in combination with nifedipine

Figure 5.9  HO-1 induction by CoPPIX and hemin

Figure 5.10  The effect of 10µM CoPPIX on $[\text{Ca}^{2+}]_i$ and $\text{Ca}^{2+}$ oscillations

Figure 5.11  A7r5 $[\text{Ca}^{2+}]_i$ and $\text{Ca}^{2+}$ oscillations are inhibited by simultaneous CoPPIX and nifedipine treatment

Figure 5.12  CoPPIX induces HO-1 protein expression in A7r5 cells

Figure 5.13  HO-1 induction by CoPPIX declines over a 3 day period

Figure 5.14  HO-1 induction by CoPPIX inhibits A7r5 cell proliferation in a concentration-dependent manner

Figure 5.15  CoPPIX does not induce caspase-3/7 activation

Figure 5.16  Hemin induces HO-1 protein expression in A7r5 cells

Figure 5.17  HO-1 induction by hemin declines over a 3 day period

Figure 5.18  The effect of hemin on A7r5 cell proliferation

Figure 5.19  HO-1 expression by A7r5/hHO-1 cells

Figure 5.20  $[\text{Ca}^{2+}]_i$ and $\text{Ca}^{2+}$ oscillations in A7r5 vs A7r5/hHO-1 cells

Figure 5.21  Stable over-expression of HO-1 inhibits A7r5 cell proliferation

Figure 5.22  The effect of QC-15 on HO-1 induction by CoPPIX

Figure 5.23  The effect of QC-15 on A7r5 cell proliferation
Chapter 6

Figure 6.1 Characterisation of HSVSMCs 172
Figure 6.2 Expression of Ca\textsubscript{3.1} and Ca\textsubscript{3.2} in HSVSMCs 173
Figure 6.3 Expression of the Ca\textsubscript{3.1} T-type Ca\textsuperscript{2+} channel in HSVSMCs 174
Figure 6.4 Expression of the Ca\textsubscript{3.2} T-type Ca\textsuperscript{2+} channel in HSVSMCs 175
Figure 6.5 Growth characteristics of HSVSMCs 176
Figure 6.6 Mibefradil inhibits HSVSMC proliferation 177
Figure 6.7 Mibefradil inhibits HCASMC proliferation 178
Figure 6.8 CORM-3 inhibits HSVSMC proliferation 180
Figure 6.9 CORM-3 inhibits HCASMC proliferation 181
Figure 6.10 HO-1 induction in HSVSMCs 182
Figure 6.11 CoPPIX induces HO-1 protein expression in HSVSMCs 183
Figure 6.12 CoPPIX inhibits HSVSMC proliferation 185
Figure 6.13 Co-application of CoPPIX and mibefradil inhibits HSVSMC proliferation 186
Figure 6.14 CoPPIX inhibits HCASMC proliferation 187
Figure 6.15 Optimisation of HO-1-targeting siRNA in HSVSMCs 188
Figure 6.16 The effect of HO-1-targeting siRNA in HSVSMCs 190
## Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A7r5</td>
<td>Rat aortic smooth muscle cell line</td>
</tr>
<tr>
<td>AM</td>
<td>Acetoxymethyl</td>
</tr>
<tr>
<td>β2M</td>
<td>β2-Microglobulin</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine Serum Albumin</td>
</tr>
<tr>
<td>CABG</td>
<td>Coronary Artery Bypass Graft</td>
</tr>
<tr>
<td>CAD</td>
<td>Coronary Artery Disease</td>
</tr>
<tr>
<td>CaMKII</td>
<td>Ca(^{2+})/Calmodulin Protein Kinase II</td>
</tr>
<tr>
<td>COHb</td>
<td>Carboxyhemoglobin</td>
</tr>
<tr>
<td>CCE</td>
<td>Capacitative Ca(^{2+}) Entry</td>
</tr>
<tr>
<td>CICR</td>
<td>Ca(^{2+})-Induced Ca(^{2+})-Release</td>
</tr>
<tr>
<td>CO</td>
<td>Carbon Monoxide</td>
</tr>
<tr>
<td>CORM</td>
<td>Carbon Monoxide Releasing Molecule</td>
</tr>
<tr>
<td>(I_{CRAC})</td>
<td>Ca(^{2+}) release activated Ca(^{2+}) current</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s Minimum Essential Medium</td>
</tr>
<tr>
<td>DTT</td>
<td>Dithiothreitol</td>
</tr>
<tr>
<td>EC</td>
<td>Endothelial Cells</td>
</tr>
<tr>
<td>ECL</td>
<td>Enhanced Chemiluminescence</td>
</tr>
<tr>
<td>eNOS</td>
<td>Endothelial Nitric Oxide Synthase</td>
</tr>
<tr>
<td>ERK1/2</td>
<td>Extracellular Signal-Regulated Kinase 1/2</td>
</tr>
<tr>
<td>FBS</td>
<td>Foetal Bovine Serum</td>
</tr>
<tr>
<td>FCS</td>
<td>Foetal Calf Serum</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Glyceraldehyde Phosphate Dehydrogenase</td>
</tr>
<tr>
<td>GPCR</td>
<td>G Protein-Coupled Receptor</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>HCASMC</td>
<td>Human Coronary Artery Smooth Muscle Cells</td>
</tr>
<tr>
<td>HEK</td>
<td>Human Embryonic Kidney Cells</td>
</tr>
<tr>
<td>HIF</td>
<td>Hypoxia Inducible Factor</td>
</tr>
<tr>
<td>HMOX1</td>
<td>Heme Oxygenase 1 gene</td>
</tr>
<tr>
<td>HO-1/HO-2</td>
<td>Heme Oxygenase 1/2</td>
</tr>
<tr>
<td>HPRT1</td>
<td>Hypoxanthine Phosphoribosyltransferase 1</td>
</tr>
<tr>
<td>HRP</td>
<td>Horseradish Peroxidise</td>
</tr>
<tr>
<td>HSVSMC</td>
<td>Human Saphenous Vein Smooth Muscle Cells</td>
</tr>
<tr>
<td>iCORM-3</td>
<td>Inactivated CORM-3</td>
</tr>
<tr>
<td>IP₃R</td>
<td>Inositol Trisphosphate</td>
</tr>
<tr>
<td>iNOS</td>
<td>Inducible Nitric Oxide Synthase</td>
</tr>
<tr>
<td>LDL</td>
<td>Low Density Lipoprotein</td>
</tr>
<tr>
<td>MAPK</td>
<td>Mitogen Activated Protein Kinase</td>
</tr>
<tr>
<td>MEM</td>
<td>Minimum Essential Medium</td>
</tr>
<tr>
<td>MMP</td>
<td>Matrix Metalloproteinase</td>
</tr>
<tr>
<td>mPER</td>
<td>Mammalian Protein Extraction Reagent</td>
</tr>
<tr>
<td>mTOR</td>
<td>Mammalian Target of Rapamycin</td>
</tr>
<tr>
<td>NADPH</td>
<td>Nicotinamide Adenine Dinucleotide Phosphate</td>
</tr>
<tr>
<td>NFAT</td>
<td>Nuclear factor of activated T-cells</td>
</tr>
<tr>
<td>NGS</td>
<td>Normal goat serum</td>
</tr>
<tr>
<td>NO</td>
<td>Nitric Oxide</td>
</tr>
<tr>
<td>NOS</td>
<td>Nitric Oxide Synthase</td>
</tr>
<tr>
<td>oxLDL</td>
<td>oxidised-Low Density Lipoprotein</td>
</tr>
<tr>
<td>PDGF</td>
<td>Platelet Derived Growth Factor</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate Buffered Saline</td>
</tr>
<tr>
<td>PIP$_2$</td>
<td>Phosphatidylinositol 4,5-bisphosphate</td>
</tr>
<tr>
<td>PKA</td>
<td>Protein Kinase A</td>
</tr>
<tr>
<td>PKC</td>
<td>Protein Kinase C</td>
</tr>
<tr>
<td>PLC</td>
<td>Phospholipase C</td>
</tr>
<tr>
<td>PMCA</td>
<td>Plasma Membrane Ca$^{2+}$ ATPase</td>
</tr>
<tr>
<td>PPAR</td>
<td>Peroxisome Proliferator-Activated Receptor</td>
</tr>
<tr>
<td>RMP</td>
<td>Resting Membrane Potential</td>
</tr>
<tr>
<td>ROC</td>
<td>Receptor-Operated Channel</td>
</tr>
<tr>
<td>ROS</td>
<td>Reactive Oxygen Species</td>
</tr>
<tr>
<td>RT</td>
<td>Room Temperature</td>
</tr>
<tr>
<td>RTK</td>
<td>Receptor Tyrosine Kinase</td>
</tr>
<tr>
<td>RT-PCR</td>
<td>Real Time Polymerase Chain Reaction</td>
</tr>
<tr>
<td>r.u.</td>
<td>ratio units</td>
</tr>
<tr>
<td>RyR</td>
<td>Ryanodine Receptor</td>
</tr>
<tr>
<td>SERCA</td>
<td>Sarco/Endoplasmic Reticulum ATPase</td>
</tr>
<tr>
<td>sGC</td>
<td>Soluble Guanylyl Cyclase</td>
</tr>
<tr>
<td>SHR</td>
<td>Spontaneously Hypertensive Rat</td>
</tr>
<tr>
<td>shRNA</td>
<td>short hairpin RNA</td>
</tr>
<tr>
<td>SnPP</td>
<td>Tin Protoporphyrin</td>
</tr>
<tr>
<td>SOC</td>
<td>Store Operated Channel</td>
</tr>
<tr>
<td>SR</td>
<td>Sarcoplasmic Reticulum</td>
</tr>
<tr>
<td>TBS</td>
<td>Tris Buffered Saline</td>
</tr>
<tr>
<td>TBST</td>
<td>TBS Tween</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>TGF-β</td>
<td>Transforming Growth Factor-β</td>
</tr>
<tr>
<td>TRPC</td>
<td>Transient Receptor Potential Canonical channel</td>
</tr>
<tr>
<td>VSMC</td>
<td>Vascular Smooth Muscle Cells</td>
</tr>
<tr>
<td>WKY</td>
<td>Wistar Kyoto rat</td>
</tr>
<tr>
<td>WT</td>
<td>Wildtype</td>
</tr>
<tr>
<td>ZnPP</td>
<td>Zinc Protoporphyrin</td>
</tr>
</tbody>
</table>
CHAPTER 1

Introduction

This thesis reports the results of a series of studies designed to investigate whether the vascular smooth muscle T-type Ca\(^{2+}\) channel is an anti-proliferative target for heme oxygenase-1 (HO-1). The prominent features of cardiovascular disorders will be reviewed, including the roles of both vascular smooth muscle cells (VSMCs) and endothelial cells (ECs), in addition to the changes that occur in cellular proteins and Ca\(^{2+}\) homeostasis. The relationship of the T-type Ca\(^{2+}\) channel to cardiovascular disorders will also be reviewed in detail, as will the stress response protein HO-1, and the associated by-product, carbon monoxide (CO).

1.1 Disorders of Vascular Remodelling
Cardiovascular disease accounts for 47% of all European deaths, equating to over 4 million deaths each year (British Heart Foundation, 2012, resource code HS2012EC, http://www.bhf.org.uk/publications/view-publication.aspx?ps=1002098). Coronary heart disease and stroke are the main forms of cardiovascular disease and the most common cause of death in western societies (Lusis, 2000). Vascular smooth muscle cell (VSMC) proliferation is a central feature of cardiovascular disorders, therefore the elucidation of therapeutic targets to limit this pathological proliferation is imperative. The major cardiovascular diseases in which VSMC proliferation is an important factor are considered further.

Atherosclerosis
Atherosclerosis is a progressive, chronic inflammatory disease of large arteries (Lusis, 2000). Lipid-rich sub-endothelial lesions consist of necrotic debris and VSMCs covered by a fibrotic cap (Lusis, 2000). This complex disease involves numerous cell types, the accumulation of extracellular matrix, and the action of proteases and inflammatory mediators (Owens et al., 2004). High circulating low density lipoprotein (LDL) levels are a primary factor in lesion formation, as they migrate into the sub-endothelial space where they are oxidised, forming oxidised LDL (oxLDL), and an inflammatory cascade ensues. Endothelial injury, in response to disturbed blood flow, for example, also
influences lesion formation and stimulates VSMC migration and proliferation (Lusis, 2000). Monocytes enter the sub-endothelial space where they differentiate into macrophages, and subsequently into foam cells as they imbibe lipids (Lusis, 2000). Activated macrophages release inflammatory mediators and growth factors that stimulate VSMC migration and proliferation. VSMCs secrete extracellular matrix which contributes to vessel occlusion (Rzucidlo et al., 2007). In response to oxLDL, synthetic VSMCs form a fibrous cap which overlays the atherosclerotic plaque. Matrix metalloproteinases (MMPs) are endopeptidases produced by VSMCs and macrophages. MMPs are involved in extracellular matrix degradation and remodelling, which can lead to plaque instability (Galis et al., 1994). Extracellular matrix proteins are degraded prior to VSMC migration (Galis et al., 1994), and elevated MMP levels have been linked to neointimal hyperplasia (Porter et al., 1999). Simvastatin has been shown to reduce neointimal hyperplasia in organ-cultured human VSMCs, in addition to limiting MMP activity and VSMC proliferation (Porter et al., 2002). Plaque rupture and subsequent thrombosis can lead to stroke or myocardial infarction (Lusis, 2000), therefore the inhibition of excessive VSMC proliferation may have beneficial effects on vessel morbidity by limiting the progression of atherosclerosis.

**Hypertension**

Hypertension results from increased vascular resistance and causes structural changes within the vessel wall. This process is termed eutrophic remodelling and involves narrowing of the vessel lumen via increased vessel wall thickness (Sonoyama et al., 2007). Hypertrophic remodelling can ensue upon increased wall stress, which also modulates collagen distribution, producing a less compliant vessel wall. This adaptive response to increased vessel wall stress involves the growth of VSMCs (Owens, 1989; Mulvany, 1993). Hypertension causes increased contractility, increased VSMC proliferation and vascular remodelling. Both systemic and pulmonary hypertension are linked to VSMC proliferation and altered Ca²⁺ handling (Firth et al., 2007). Up-regulation of Transient Receptor Potential Canonical (TRPC) channels has been associated with increased Ca²⁺ influx and the development of hypertension (Firth et al., 2007). Using cerebral arterial smooth muscle from a rat model of salt-sensitive hypertension, higher basal [Ca²⁺], was found in addition to a more depolarised resting membrane potential (Wellman et al., 2001). Reduced function of Kv channels together with an increase in [Ca²⁺]; via voltage-dependent Ca²⁺ channel activity stimulated activation of the cAMP response element binding protein transcription factor and the immediate early gene c-fos, thereby linking altered Ca²⁺ handling to gene expression in
hypertension (Wellman et al., 2001). Furthermore, the transcription factor c-fos has been identified as an important signalling component in pathological VSMC proliferation (Sylvester et al., 1998), which is linked to cyclin A transcription and cell cycle progression (Wei et al., 1997).

T-type Ca\(^{2+}\) channels have been linked to hypertension. The inhibition of both L- and T-type Ca\(^{2+}\) channels was shown to confer anti-hypertensive effects in systemic and renal circulation (Nakamura et al., 1999). Indeed, both L-type and T-type Ca\(^{2+}\) channels are expressed in afferent vessels, whereas efferent vessels appear to express T-type Ca\(^{2+}\) channels only, as reviewed by Cribbs (2006). Blockade of T-type Ca\(^{2+}\) channels was demonstrated to cause vasodilation of both afferent and efferent arterioles of Sprague-Dawley rats via in vitro perfusion (Feng et al., 2004). Furthermore, T-type Ca\(^{2+}\) channel inhibition has been linked to positive effects on the renin-angiotensin-aldosterone system, VSMC proliferation, and extracellular matrix deposition (Buhler, 1997). Given that adequate [Ca\(^{2+}\)] levels are required for the progression of the cell cycle (Ciapa et al., 1994), the increased Ca\(^{2+}\) influx via voltage-dependent Ca\(^{2+}\) channels may facilitate the enhanced gene expression, VSMC replication, and extracellular matrix remodelling of proliferative disorders such as hypertension.

**Restenosis**

Intimal hyperplasia occurs in response to vessel wall injury and endothelial damage as a result of stenting (Rzucidlo et al., 2007). Excessive amounts of extracellular matrix are produced by proliferating VSMCs, which causes hyperplastic lesions and restenosis (Rzucidlo et al., 2007). VSMC proliferation in response to stenting appears as an early event immediately post-stent insertion to repair the damaged endothelium, but this process can also continue and subsequently cause restenosis in order to shield the stent from thrombogenic blood constituents (Curcio et al., 2011). By blocking the mitogen-activated protein kinase (MAPK) and cAMP- protein kinase A (PKA) cell signalling pathways involved in VSMCs, studies have shown that the inhibition of VSMC proliferation in order to limit restenosis is a promising therapeutic strategy, as reviewed by Curcio et al. (2011). Indeed, the exposure of the compromised vessel to anti-proliferative compounds via drug-eluting stents initially demonstrated advantageous effects on intimal hyperplasia (Curcio et al., 2011). Rapamycin inhibits mTOR (mammalian target of rapamycin) which mediates environmental cues and, in-turn, regulates cell proliferation (Sarbassov et al., 2005). This immunosuppressant has
been shown to inhibit VSMC migration and proliferation \textit{in vitro} and \textit{in vivo} (Marx et al., 1995; Poon et al., 1996), and promote VSMC differentiation (Martin et al., 2004). Additionally, rapamycin drug-eluting stents have been shown to limit restenosis (Eisenberg & Konnyu, 2006). However, follow-up studies demonstrated the need for both anti-proliferative and anti-inflammatory drug-eluting stents.

Evidently numerous factors or interventions can cause vessel injury. The disruption of vascular integrity begins with damage to the endothelium, vascular remodelling then follows which involves VSMC proliferation, apoptosis, and the production of extracellular matrix proteins such as collagen, elastin and fibronectin (McCarthy & Bennett, 2000). Apoptosis of VSMCs can play a dual role in vascular remodelling by limiting intimal hyperplasia and reducing vessel occlusion, yet conversely VSMC apoptosis can contribute to atherosclerotic plaque rupture and thrombosis (McCarthy & Bennett, 2000). Vascular remodelling has been described as both the cause and consequence of ensuing pathology, as the inherent plasticity of VSMCs is a predisposing factor for proliferative disorders (Owens et al., 2004). The roles of the endothelium and the plasticity of VSMC in vascular remodelling are discussed further below.

1.2 The response to vascular injury

1.2.1 The role of the endothelium

Endothelial cells (ECs) form a continuous non-thrombogenic layer that mediates metabolic exchange through the arterial wall. A healthy endothelium co-ordinates vascular tone by the secretion of vasoactive agents, and plays a role in coagulation and inflammation (Widlansky et al., 2003). However, endothelial injury increases the risk of a cardiovascular event, as reviewed by Widlansky et al. (2003). Injury can occur as a result of denudation, inflammation, oxidative stress, hyperglycaemia or elevated levels of free fatty acids (Atochin & Huang, 2010).

ECs are an important source of nitric oxide (NO) which acts as a positive regulator of vascular function (Atochin & Huang, 2010). NO is principally a vasodilator of VSMC, although this signalling molecule also limits VSMC proliferation and inhibits platelet aggregation. A reduction in the bioavailability of NO can induce endothelial dysfunction
(Higashi et al., 2009). Oxidative stress is a prominent feature in the pathogenesis of cardiovascular diseases such as hypertension, dyslipidemia, diabetes mellitus, atherosclerosis, and myocardial infarction. Reactive oxygen species (ROS) arise from numerous sources including nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, xanthine oxidase, uncoupled endothelial nitric oxide synthase (eNOS), cyclooxygenase, and the mitochondrial electron transport chain (Higashi et al., 2009). ROS can inactivate NO by forming toxic peroxynitrite, thereby inducing endothelial dysfunction (Higashi et al., 2009). ROS can be produced in VSMCs, ECs, and mononuclear cells, and the associated effects include lipid and protein oxidation, increased $[\text{Ca}^{2+}]_i$ load, and DNA fragmentation (Higashi et al., 2009). Upon injury to the endothelium, EC located at the periphery of a wound are able to migrate and proliferate, whilst also remaining attached to neighbouring ECs. However, ECs located at sites distal to the wound are unable to participate in injury repair (Ross, 1981), and so the reparative capacity of the endothelium is limited. ECs are able to influence VSMC growth and migration by the secretion of growth factors, and it is this response by VSMCs that is central, not only to repair after injury, but to proliferative disorders of the vasculature.

### 1.2.2 Vascular smooth muscle cells and phenotypic switching

VSMCs are situated in the medial layer of the blood vessel wall, and are responsible for maintaining basal vascular tone. They respond to chemical, mechanical, and electrical signals, and thereby regulate systemic blood pressure (Cribbs, 2006). VSMCs are highly proliferative during vasculogenesis and development, before differentiating into contractile VSMCs in mature vessels (Owens et al., 2004). In healthy blood vessels VSMCs contain cytoskeletal proteins and ion channels specific to their contractile function, and exhibit low proliferative activity (Rzucidlo et al., 2007). Mature, contractile VSMCs retain the ability to de-differentiate in response to environmental cues in order to adapt to cellular stresses (Owens, 1995). This response to vessel injury is central to the repair and restoration of vascular function, yet excessive proliferation is associated with cardiovascular disorders such as restenosis, atherosclerosis and hypertension (House et al., 2008).

During the early stages of primary culture, VSMCs can be maintained in the contractile state by seeding at a high cell density, or by supplying endothelial growth factors (Ross, 1981). As VSMCs lose myosin and the ability to contract, they are able to
respond to mitogens and subsequently switch to a synthetic state (Ross, 1981). Synthetic VSMCs play a prominent role in the response to injury, according to the hypothesis proposed by Ross (1981); injury to the endothelial lining of blood vessels as a result of mechanical, chemical or immunological insult leads to the activation of platelets and monocytes. The subsequent release of growth factors and chemoattractant molecules, such as platelet derived growth factor (PDGF), stimulate medial VSMCs to migrate into the intima where they proliferate. Indeed, endothelial injury is the underlying factor that recruits VSMCs to neointima formation (Schwartz et al., 1986). Upon repair of the endothelium, VSMCs of the neointima switch back to a contractile state and exhibit prominent myofilaments, with a concurrent loss of synthetic organelles (Clowes et al., 1983). Differentiated VSMCs of the adult aorta predominantly express smooth muscle α-actin, which, in addition to smooth muscle myosin heavy chain, is a marker of contractile VSMCs (Kocher et al., 1985). The expression of these proteins decreases upon de-differentiation along with a simultaneous increase in abundance of the Golgi network and the endoplasmic reticulum, demonstrating two distinct phenotypes (Chamley-Campbell et al., 1981). In vitro studies have shown that VSMCs plated at a high density can revert back to a contractile state upon confluence, although VSMCs plated at a low density remain in a synthetic state (Chamley-Campbell et al., 1981). Using a rabbit model of aortic balloon injury, Louis et al. (2006) demonstrated that contractile VSMC markers declined and de-differentiation markers appeared at 2 days post injury. These changes appeared in all medial VSMCs, whereas inflammatory markers were isolated to VSMCs near to the site of injury (Louis et al., 2006). This implies that VSMCs are activated and de-differentiate in a timely manner in response to endothelial injury.

The phenotype of VSMC is also modulated by growth factors. ECs have been demonstrated to maintain VSMCs in a differentiated state in vitro, and co-culture of VSMCs with ECs limited activation of transforming growth factor-β1 (TGF-β1), thereby preventing VSMC growth (Powell et al., 1996). TGF-β was shown to mediate VSMC differentiation in culture conditions by increasing smooth muscle α-actin and smooth muscle myosin heavy chain (Owens et al., 1988). Conversely, in balloon injury models, TGF-β has been shown to increase neointima formation, matrix deposition and VSMC proliferation (Schulick et al., 1998). PDGF release from platelets was also demonstrated to be a requirement for VSMC proliferation after balloon injury (Ross, 1981). PDGF appears to mediate the down-regulation of contractile VSMC markers in vitro (Blank & Owens, 1990), and mediate VSMC migration and proliferation in vivo.
(Ferns et al., 1991). The down-regulation of VSMC markers reported by Blank and Owens (1990) in response to PDGF treatment was associated with only a temporary increase in VSMC growth, and the VSMC markers remained down-regulated during PDGF stimulation, leading the authors to conclude that the effects on VSMC markers are not secondary to proliferation. Consistent with this finding, a previous study also demonstrated that cell cycle withdrawal is not a pre-requisite for the up-regulation of contractile proteins in confluent VSMCs (Blank et al., 1988). The transition between the contractile and synthetic states of VSMCs appears complex, and the resulting changes occur in response to both environmental stimuli and active control (Owens et al., 2004). Another key feature of the phenotypic switch of VSMCs, which is central to the studies reported in this thesis, is the modulation of calcium signalling.

1.2.3 Modulation of Ca\(^{2+}\) signalling during the phenotypic switch

Ca\(^{2+}\) is an important second messenger that mediates VSMC contraction, migration, proliferation and gene expression. VSMC contraction is slow and sustained, and occurs in response to membrane depolarisation, or by the binding of contractile agonists, which produces an increase in cytoplasmic Ca\(^{2+}\) (House et al., 2008). Cytoplasmic Ca\(^{2+}\) activates Ca\(^{2+}\)/calmodulin-dependent myosin light chain kinase; myosin light chain is subsequently phosphorylated and interacts with actin myofilaments (Webb, 2003). Cytoplasmic Ca\(^{2+}\) is increased further by Ca\(^{2+}\)-induced Ca\(^{2+}\)-release (CICR) via ryanodine receptor (RyR) activation leading to Ca\(^{2+}\) release from the sarcoplasmic reticulum (SR), and receptor-operated channel (ROC) activation at the plasma membrane leading to further Ca\(^{2+}\) influx (Webb, 2003). VSMC relaxation occurs via Ca\(^{2+}\) extrusion from the cytoplasm and an increase in myosin light chain phosphatase activity. Cytoplasmic Ca\(^{2+}\) is decreased via Ca\(^{2+}\) extrusion by both the plasma membrane Ca\(^{2+}\) ATP-ase (PMCA) and the Na\(^+\)/Ca\(^{2+}\) exchanger, and reuptake by the sarco/endoplasmic reticulum ATPase (SERCA). In addition, L-type Ca\(^{2+}\) channels and ROC are inactivated (Webb, 2003). Cell proliferation depends on a sustained and adequate [Ca\(^{2+}\)]\(_i\) level which is sourced from intracellular stores and extracellular milieu (Kao et al., 1990; Sheng et al., 1990; Chao et al., 1992; Negulescu et al., 1994; Pratt et al., 2002). Numerous Ca\(^{2+}\) signalling pathways are modulated during the phenotypic switch of VSMCs in order to provide adequate [Ca\(^{2+}\)]\(_i\) levels, and these are outlined below.
Voltage-dependent L-type Ca\(^{2+}\) channels are characterised by their high voltage-activated currents, large single channel conductance, and slow voltage dependent inactivation (Catterall, 2000). L-type Ca\(^{2+}\) channels provide the dominant route of Ca\(^{2+}\) entry in muscle cells, and are highly expressed in contractile VSMCs (Catterall, 2000). These channels are essential for controlling blood pressure, and L-type antagonists are commonly used anti-hypertensive agents (Cribbs, 2006). Using rat aortic VSMCs, L-type Ca\(^{2+}\) channel expression was shown to decrease during de-differentiation, which correlated with a lower expression of the contractile VSMC markers, α-actin and myosin heavy chain, in addition to smaller L-type Ca\(^{2+}\) currents (Gollasch et al., 1998). The mechanisms underlying L-type Ca\(^{2+}\) channel suppression involve mitogenic transcriptional down-regulation, and MAPK-mediated post-transcriptional down-regulation (Ihara et al., 2002). This study used primary rat aortic VSMCs and demonstrated that L-type Ca\(^{2+}\) channels were re-expressed by contact inhibition of the cells. Conversely, voltage-dependent T-type Ca\(^{2+}\) channels have been shown to be up-regulated during VSMC de-differentiation, and therefore may have a role in augmenting a proliferative response (Kuga et al., 1996; Vallot et al., 2000). T-type Ca\(^{2+}\) channels convey small single channel conductance, are inactivated rapidly, and are characterised by activation at more negative membrane potentials than L-type Ca\(^{2+}\) channels (Cribbs, 2006). Consequently there is a strong case for the role of T-type Ca\(^{2+}\) channels in VSMC proliferation given that de-differentiated VSMCs have a more negative resting membrane potential (RMP), (McDonald et al., 1994; Gollasch et al., 1998). The role of the T-type Ca\(^{2+}\) channel, which is a major focus of this thesis, will be discussed in section 1.3.

TRPC channels have also been shown to be up-regulated in proliferative VSMCs. TRPC channels are non-selective cation channels, inactivated by membrane depolarisation, and are often active at RMP allowing Ca\(^{2+}\) influx at negative membrane potentials (Nilius et al., 2007). Furthermore, TRPC channels have been demonstrated to constitute store operated channels (SOCs) and ROCs, and therefore mediate capacitative Ca\(^{2+}\) entry (CCE) (Golovina, 1999; Nilius et al., 2007; House et al., 2008). SOCs are activated by Ca\(^{2+}\) store depletion and function to sustain Ca\(^{2+}\) influx. Therefore, SOCs have been indicated to play a role in proliferation and gene expression (Albert & Large, 2003). ROCs mediate Ca\(^{2+}\) influx in response to agonist activation, although both SOCs and ROCs function downstream of phospholipase C (PLC) (Gonzalez-Cobos & Trebak, 2010). TRPC1 and TRPC6 appear to have
important roles in VSMCs as they are expressed throughout the vasculature (Firth et al., 2007);

**TRPC1**

This TRPC channel has been correlated with SOC activity in both human and rat pulmonary artery VSMCs (Remillard & Yuan, 2006). TRPC1 is involved in VSMC contraction and proliferation in numerous vascular beds and species by mediating store-operated Ca\(^{2+}\) entry (Gonzalez-Cobos & Trebak, 2010). The Ca\(^{2+}\) release activated Ca\(^{2+}\) current (\(I_{\text{CRAC}}\)) provided by SOCs has been linked to the migratory and proliferative capacity of VSMCs, and TRPC channels appear to have a significant role in the phenotypic switch (Golovina, 1999;Bergdahl et al., 2005;Potier et al., 2009). De-differentiated human pulmonary artery VSMCs were shown to have higher basal [Ca\(^{2+}\)]\(_i\) and increased TRPC1 mRNA, suggesting that TRPC channels are involved in sustaining adequate [Ca\(^{2+}\)]\(_i\) for cell proliferation (Golovina, 1999;Golovina et al., 2001). Store-operated Ca\(^{2+}\) entry via TRPC1 also contributes to the maintenance of [Ca\(^{2+}\)]\(_i\) for neointimal hyperplasia in human organ culture (Kumar et al., 2006), and in hypertension (Firth et al., 2007).

**TRPC3/6/7**

This subfamily are activated by diacylglycerol in a protein kinase C (PKC)-dependent manner and are therefore considered to form ROCs (Gonzalez-Cobos & Trebak, 2010). Up-regulation of TRPC6 expression correlates with greater Ca\(^{2+}\) entry upon store depletion, and CCE via TRPC6 is enhanced during proliferative phases of VSMCs, as reviewed by Gonzalez-Cobos and Trebak (2010). TRPC6 expression was shown to be higher in mesenteric arterioles of salt-hypertensive rats, and high levels of TRPC6 were demonstrated in rat pulmonary artery VSMCs in a model of hypoxic pulmonary hypertension, implying this channel plays a role in vascular remodelling of hypertension, as reviewed by Gonzalez-Cobos and Trebak (2010).

**K\(_{\text{Ca}}\) channels** are K\(^+\) channels activated in response to increases in [Ca\(^{2+}\)]\(_i\) which occur as a result of cell depolarisation, and serve to induce hyperpolarisation (House et al., 2008). K\(_{\text{Ca}}\)1.1 expression is characteristic of differentiated VSMCs, and limits Ca\(^{2+}\) influx via L-type Ca\(^{2+}\) channels by cell hyperpolarisation. This channel displays voltage-dependent activation, which also occurs in response to high [Ca\(^{2+}\)]\(_i\) (Neylon et al., 1999;Wei et al., 2005). K\(_{\text{Ca}}\)3.1 channels are expressed in de-differentiated VSMCs, are voltage insensitive, and are activated in response to low levels of [Ca\(^{2+}\)]\(_i\) (Wei et al., 2005). Down-regulation of K\(_{\text{Ca}}\)1.1, along with the concomitant increase in K\(_{\text{Ca}}\)3.1
channel expression is apparent in cultured VSMCs, and in VSMCs in vivo post balloon injury (Neylon et al., 1999; Kohler et al., 2003; Ledoux et al., 2006). These altered expression levels increase the driving force for Ca\(^{2+}\) influx, therefore maintaining [Ca\(^{2+}\)]\(_i\) for proliferation. The major Ca\(^{2+}\) entry pathways in de-differentiated VSMCs are illustrated in Figure 1.1.

Ca\(^{2+}\)-release channels and re-uptake pumps are also modulated during the phenotypic switch. The ryanodine receptor, RyR3, on the SR is down-regulated in de-differentiated VSMCs, which hampers CICR that is important for VSMC contraction (House et al., 2008). More recently, RyR agonists were shown to induce Ca\(^{2+}\) release in freshly dissociated rat aortic VSMCs, whereas Ca\(^{2+}\) release was not stimulated in cultured cells (Kim et al., 2011a). Inositol trisphosphate receptor (IP\(_3\)R) down-regulation is another feature of the phenotypic switch, and is apparent in VSMCs exposed to oxLDL, and in VSMCs of animal models of diabetes (Narayanan et al., 2012). SERCA2a is down-regulated in de-differentiated VSMCs, but re-expressed when cells reach confluence, indicating the importance of sustaining [Ca\(^{2+}\)]\(_i\), in proliferating cells (Lipskaia et al., 2009). Indeed, gene transfer of SERCA2a limited neointima formation in the injured rat carotid artery, and VSMCs demonstrated cell cycle arrest at G\(_1\) (Lipskaia et al., 2005). The inhibition of VSMC proliferation in response to SERCA2a up-regulation was mediated by inactivation of calcineurin and nuclear factor of activated T-cells (NFAT). This study also demonstrated a marked decrease in the amplitude and the propagation of IP\(_3\) stimulated Ca\(^{2+}\) signals. However, contrasting data have been generated regarding the effects of PMCA modulation on cell proliferation, indicating that spatial Ca\(^{2+}\) arrangements and microdomains may play a role in the physiological response of the VSMC, as reviewed by (House et al., 2008).

NFAT is a Ca\(^{2+}\) dependent transcription factor involved in the proliferative response of VSMCs (Hill-Eubanks et al., 2003). Sustained increases of [Ca\(^{2+}\)]\(_i\), activate calcineurin which dephosphorylates NFAT, promoting activation and nuclear translocation (Hill-Eubanks et al., 2003). The calcineurin/NFAT pathway is implicated as the major VSMC transcription pathway, and sustained rises in [Ca\(^{2+}\)]\(_i\) have been associated with NFAT stimulation and subsequent VSMC proliferation and remodelling (Lipskaia et al., 2009). Balloon injury of the carotid artery stimulated NFAT expression, and pharmacological inhibition of NFAT limited neointimal hyperplasia (Liu et al., 2005). The vasoactive agonists, angiotensin II (Gomez et al., 2002), PDGF (Liu et al., 2004), and LDL
Figure 1.1 Ca\textsuperscript{2+} entry pathways in de-differentiated VSMCs

[Ca\textsuperscript{2+}]\textsubscript{i} is sustained in de-differentiated VSMCs for gene expression and proliferation by modulation of numerous ion channels. TRPC channels in the form of both SOC and ROC channels are up-regulated. These channels are active at RMP and can be stimulated by G protein-coupled receptor (GPCR) or Receptor Tyrosine Kinase (RTK)-mediated production of PLC. T-type Ca\textsuperscript{2+} channels are also up-regulated, which are active at negative membrane potentials, and allow Ca\textsuperscript{2+} influx via their window current at RMP. Increased K\textsuperscript{+} efflux via K\textsubscript{Ca}3.1 channels leads to hyperpolarisation and a greater driving force for Ca\textsuperscript{2+} entry. PIP\textsubscript{2} = phosphatidylinositol 4,5-bisphosphate. Image adapted from Remillard & Yuan (2006).
(Lipskaia et al., 2003), all stimulate NFAT activation and subsequent VSMC proliferation. Different splice variants of Ca\textsuperscript{2+}/calmodulin protein kinase II (CaMKII) mediate Ca\textsuperscript{2+} signalling in the differentiated and de-differentiated VSMC phenotypes; CaMKII\textgamma is prominently expressed in differentiated VSMCs, whereas CaMKII\textdelta\textsubscript{2} is prominently expressed in de-differentiated VSMCs (House et al., 2007). The altered expression of the splice variant occurred within 30 hours of rat aortic VSMC culture, and CaMKII\textdelta\textsubscript{2} suppression halted cell cycle progression. Comparable results were seen in vivo after balloon angioplasty; CaMKII\textgamma was the dominant variant in medial VSMCs, and CaMKII\textdelta\textsubscript{2} was expressed in neointimal VSMCs (House & Singer, 2008).

Evidently a wide variety of modulations in Ca\textsuperscript{2+} handling occur during the phenotypic switch of VSMCs. Modulation of voltage-dependent Ca\textsuperscript{2+} channels, K\textsubscript{Ca}3.1, and SOCs mediate an increase in \([\text{Ca}^{2+}]_{\text{i}}\), which is required for cell proliferation and cell cycle checkpoints (Golovina, 1999; House et al., 2008). The processes mediating the phenotypic switch appear highly complex and involve numerous pathways. It is likely that the duration and amplitude of the Ca\textsuperscript{2+} signals determines the physiological response of the VSMCs (Munaron et al., 2004). Moreover, a recent report implies that nanojunctions between the plasma membrane and the SR are responsible for deciphering local Ca\textsuperscript{2+} signals to produce specific functional responses such as contraction, relaxation, or proliferation (van et al., 2013). Therapeutic targeting of the pathways involved in maintaining \([\text{Ca}^{2+}]_{\text{i}}\), for proliferation and gene expression may assist the treatment of disorders involving vascular remodelling. This thesis focuses on one particular Ca\textsuperscript{2+} entry pathway, the T-type Ca\textsuperscript{2+} channel. As described previously, the up-regulation of T-type Ca\textsuperscript{2+} channels appears to be a prominent feature in the phenotypic switch of VSMCs. Therefore, this channel may provide a potential therapeutic target within cardiovascular disease.

1.3 T-type Ca\textsuperscript{2+} channels

1.3.1 Properties of T-type Ca\textsuperscript{2+} channels

T-type Ca\textsuperscript{2+} channels are activated upon membrane depolarisation and provide a route for Ca\textsuperscript{2+} influx, which is fundamentally linked to numerous cellular physiological effects (Catterall et al., 2005). There are three T-type Ca\textsuperscript{2+} channel subtypes; Ca\textsubscript{v}3.1, Ca\textsubscript{v}3.2, and Ca\textsubscript{v}3.3, and they are expressed in a range of cell types. All three subtypes are found in neuronal cell bodies and dendrites, and Ca\textsubscript{v}3.1 and Ca\textsubscript{v}3.2 are also found in
cardiac and smooth muscle, with Ca,3.2 displaying the widest expression level (Catterall et al., 2005). T-type Ca\(^{2+}\) channels are termed low-voltage activated as they open in response to weak depolarisations at low voltages. They play a role in intracellular Ca\(^{2+}\) oscillations, repetitive firing and pacemaker potentials (Perez-Reyes, 2003). T-type Ca\(^{2+}\) currents have the following characteristics:

- Transient currents due to fast inactivation at strong depolarisations
- Tiny single channel conductance (in comparison to L-types Ca\(^{2+}\) channels)
- Slow channel deactivation (closing), producing tail currents
- Voltage dependence of steady state inactivation overlaps significantly with voltage dependence of activation, giving rise to a window current

T-type Ca\(^{2+}\) channel activity has been studied in numerous cell types including neurons, cardiomyocytes and fibroblasts, which has subsequently allowed the transitions between open and closed states to be defined, as reviewed by Perez-Reyes (2003). Upon depolarisation, T-type Ca\(^{2+}\) channels exhibit burst firing by opening and closing rapidly, then they begin to inactivate as membrane depolarisation continues. The channels may be inactive for some time before recovering to a deactivated state. This model contains further complexity as T-type Ca\(^{2+}\) channels are also capable of deactivating immediately from their open state, without inactivation, and different subtypes display different kinetics. An important feature of T-type Ca\(^{2+}\) channels is the associated window current that is active at physiologically relevant membrane potentials. This window current is produced under basal conditions and is due to the overlap of activation and inactivation curves (Perez-Reyes, 2003), as illustrated in Figure 1.2. Consequently, Ca\(^{2+}\) is constantly able to enter the cell via a proportion of T-type Ca\(^{2+}\) channels that are active and not fully inactivated, therefore influencing [Ca\(^{2+}\)]\(_i\) levels at RMP (Capiod, 2011). Indeed, the over-expression of T-type Ca\(^{2+}\) channels was shown to increase basal [Ca\(^{2+}\)], which could be reduced by the T-type antagonists, mibefradil and Ni\(^{2+}\) (Chemin et al., 2000). In numerous cell types the window current is active at -65 to -40mV, which acts as a driving force for Ca\(^{2+}\) entry (Lory et al., 2006), and has been demonstrated to be an important contributor to vascular tone in mesenteric and renal arterioles (Bijlenga et al., 2000). L-type Ca\(^{2+}\) channels also display a window current, although it is not active at RMP (Capiod, 2011).

Voltage-dependent Ca\(^{2+}\) channels are composed of up to five subunits. The auxiliary β-subunit is essential for L-type Ca\(^{2+}\) channel expression at the cell membrane, in
Figure 1.2 Window currents of T-type and L-type Ca\textsuperscript{2+} channels

The window currents of voltage-gated Ca\textsuperscript{2+} channels are a result of the overlap between the activation and inactivation curves at steady state. The window current of T-type Ca\textsuperscript{2+} channels has an important role in Ca\textsuperscript{2+} homeostasis. Ca\textsuperscript{2+} is able to flow continuously into the cell via T-type Ca\textsuperscript{2+} channels that are partially active, thereby contributing to sustained [Ca\textsuperscript{2+}], at RMP. The L-type Ca\textsuperscript{2+} channel window current is active at more depolarised membrane potentials, and therefore, does not contribute to Ca\textsuperscript{2+} homeostasis at RMP. Image taken from Capiod (2011).
addition to the voltage dependence of the channel (Perez-Reyes, 2003). However, it appears T-type Ca\textsuperscript{2+} channels are capable of functioning without auxiliary subunits, as recombinant channels have comparable electrophysiological properties to native T-type currents (Perez-Reyes, 2003). Despite this, co-expression with the α2-δ auxiliary subunit was shown to increase membrane expression of the channel (Dolphin et al., 1999). The α\textsubscript{1} subunit acts as the conduction pore and has four domains, each with six transmembrane segments, and confers voltage sensitivity, in addition to gating apparatus (Catterall et al., 2005). Figure 1.3 illustrates the structure of the T-type Ca\textsuperscript{2+} channel α\textsubscript{1} subunit. The cloning of rat and human isoforms of the T-type Ca\textsuperscript{2+} channels by the Perez-Reyes group (Perez-Reyes et al., 1998), has allowed for the over-expression of recombinant channels in various cell models in order to assess further the properties of these currents (Perez-Reyes, 1998). Indeed, the stable over-expression of Ca\textsubscript{v}3.1 or Ca\textsubscript{v}3.2 in HEK293 cells was shown to augment a proliferative response, with more cells in the S phase of the cell cycle (Wang et al., 2002a; Wang et al., 2002b; Gray et al., 2004). Indeed, Gray et al. (2004) demonstrated that a direct, non-linear relationship existed between Ca\textsuperscript{2+} entry and HEK293/Ca\textsubscript{v}3.2 cell proliferation.

1.3.2 Modulation of T-type Ca\textsuperscript{2+} channels

Mibefradil was introduced as an anti-hypertensive agent in 1997, but withdrawn the following year due to adverse interactions with β-blockers (Mullins et al., 1998). However, the drug has subsequently been used as an experimental tool to inhibit T-type Ca\textsuperscript{2+} channels. First described as Ro 40-5967; a selective T-type Ca\textsuperscript{2+} channel antagonist found to inhibit T-type Ca\textsuperscript{2+} currents after dihydropyridine abolition of L-type Ca\textsuperscript{2+} currents in rat VSMCs (Mishra & Hermsmeyer, 1994). Subsequent investigations have described the actions of mibefradil to be less specific. Mibefradil can inhibit Ca\textsuperscript{2+} activated Cl\textsuperscript{−} channels with a K\textsubscript{i} of 4.7µM (Nilius et al., 1997), voltage gated Na\textsuperscript{+} channels with an IC\textsubscript{50} of 0.98µM (Strege et al., 2005), and L-type Ca\textsuperscript{2+} channels with an IC\textsubscript{50} of 13µM (Martin et al., 2000). Although, the concentration required to inhibit L-Type Ca\textsuperscript{2+} channels has been stated to be at least 10-fold higher than that for T-type Ca\textsuperscript{2+} channels (Bezprozvanny & Tsien, 1995; Martin et al., 2000). Ni\textsuperscript{2+} has also been demonstrated as a selective T-type channel inhibitor, with varying affinities for the different channel subtypes, and the Ca\textsubscript{v}3.2 subtype exhibiting the highest sensitivity (Lee et al., 1999).
The α₁ subunits of voltage-gated Ca²⁺ channels comprise of four homologous domains (I to IV), each with six transmembrane spanning helices (S1 to S6). The S4 helix of each domain contains positive amino acids, which constitutes the voltage sensor of the channel. The II-III linker is the site of action by numerous pathways, including PKA, PKC, Rho kinase, and CaMKII. The extracellular His191 residue is the site of redox modulation by Zn²⁺, ascorbate, and L-cysteine. Image taken from Iftinca and Zamponi (2009).
T-type Ca\textsuperscript{2+} channels contain numerous phosphorylation consensus sites for modulation by protein kinases (Iftinca & Zamponi, 2009). Serine/threonine kinases (PKA and PKC), calmodulin dependent kinases and RTKs have all been shown to modulate T-type Ca\textsuperscript{2+} channel activity, and the II-III loop of Ca\textsubscript{v}3 channels appears to be an important site of regulation, as reviewed by Iftinca and Zamponi (2009). Numerous hormones have been demonstrated to inhibit or stimulate T-type Ca\textsuperscript{2+} currents in neurons (Perez-Reyes, 2003). Endothelin has been shown to stimulate smooth muscle and cardiac muscle T-type Ca\textsuperscript{2+} currents (Perez-Reyes, 2003). Lysophosphatidic acid inhibits T-types Ca\textsuperscript{2+} channels via Rho kinase activation, and Rho kinase inhibitors have been shown to limit seizures, suggesting a role for this pathway in epilepsy (Iftinca & Zamponi, 2009). The reducing agent L-cysteine can increase T-type Ca\textsuperscript{2+} currents in nociceptive and thalamic neurons, and the oxidising agent ascorbate inhibited Ca\textsubscript{v}3.2 Ca\textsuperscript{2+} channels (Huc et al., 2009). This redox modulation of Ca\textsubscript{v}3.2 Ca\textsuperscript{2+} channels was mediated via the extracellular His191 residue. Zn\textsuperscript{2+} selectively blocks Ca\textsubscript{v}3.2 channels, but in contrast can slow the deactivation kinetics of Ca\textsubscript{v}3.3 (Huc et al., 2009). Considering the wide range of endogenous and exogenous modulators of Type Ca\textsuperscript{2+} channels, there is scope for therapeutic intervention of the numerous functions that these channels are involved in, and these functions are discussed in detail below.

### 1.3.3 Physiological Functions of T-type Ca\textsuperscript{2+} channels

T-type Ca\textsuperscript{2+} channels are prevalent throughout the body including VSMCs, the heart, nerves, sperm, and endocrine organs. In these tissues the channels are involved in proliferation, gene expression, VSMC contraction, vascular tone, fertilisation, hormone secretion, neuronal firing, nociception, cancer growth, and epilepsy (Perez-Reyes, 2003). These channels enhance membrane depolarisation in excitable cells and mediate Ca\textsuperscript{2+} influx in non-excitable cells (Nilius et al., 2006).

**Oxygen sensing**

Hypoxia has been shown to enhance T-type Ca\textsuperscript{2+} channel gene expression via a hypoxia inducible factor (HIF) -dependent signalling pathway (del Toro et al., 2003). T-type Ca\textsuperscript{2+} channel mRNA, in addition to Ca\textsuperscript{2+} currents, were increased in response to hypoxia in rat pheochromocytoma (PC12) cells (del Toro et al., 2003). This enhanced T-type activity occurred via HIF, which is reinforced by the presence of hypoxia responsive elements in the Ca\textsubscript{v}3.2 gene, and demonstrates the importance of the T-
type Ca\textsuperscript{2+} channel as regulator of the hypoxic response (del Toro et al., 2003). Exposure of human VSMCs to hypoxia attenuated depolarisation-stimulated Ca\textsuperscript{2+} entry via voltage-gated Ca\textsuperscript{2+} channels, although T-type Ca\textsuperscript{2+} channels appeared to play a more prominent role than L-type Ca\textsuperscript{2+} channels (Aley et al., 2008). This response was apparent in VSMCs from internal mammary artery, but not saphenous vein, implying that hypoxic remodelling is dependent on the vascular bed. T-type Ca\textsuperscript{2+} channels have also been shown to be re-expressed in the heart in response to hypoxia (Pluteanu & Cribbs, 2009). Ventricular myocytes demonstrated a reduction in T-type current density, and Ca\textsubscript{v}3.1, but not Ca\textsubscript{v}3.2, mRNA was reduced via HIF-1\textalpha during a hypoxic insult. These data show that T-type Ca\textsuperscript{2+} channels selectively undergo redox modulation (Pluteanu & Cribbs, 2009).

**Cardiac pacemaker potential**
In health, T-type Ca\textsuperscript{2+} channels are prominent in the conduction system of the heart where they contribute to pacemaker potential (Perez-Reyes, 2003). T-type Ca\textsuperscript{2+} channels are expressed in embryonic hearts; this expression decreases after birth, but can increase again under pathological conditions (Perez-Reyes, 2003). One example is cardiac hypertrophy, as this condition involves reversion to the foetal gene program. Pressure overload-induced hypertrophy was attenuated in Ca\textsubscript{v}3.2\textsuperscript{−/−} mice, but not Ca\textsubscript{v}3.1\textsuperscript{−/−} mice, implying that Ca\textsuperscript{2+} entry via the Ca\textsubscript{v}3.2 T-type Ca\textsuperscript{2+} channel plays a role in this condition (Chiang et al., 2009).

**Smooth muscle cell contraction and relaxation**
T-type Ca\textsuperscript{2+} channels were reported to play a role in arterial vasoconstriction, as mibefradil treatment produced vasodilatory effects (Cribbs, 2006). These channels have been attributed to vasoconstrictor responses of renal microcirculation, more specifically efferent arteriole resistance, as reviewed by Cribbs (2006). Indeed, a role for T-type Ca\textsuperscript{2+} channels in microvascular tone has been demonstrated in both rats and humans (Ball et al., 2009). The Ca\textsubscript{v}3.1 T-type Ca\textsuperscript{2+} channel has been shown to play a role in vasoconstriction of rat mesenteric arterioles (Braunstein et al., 2009). Ca\textsubscript{v}3.1 was also found to be the most prominent subtype in A7r5 cells, a rat aortic VSMC line, and mibefradil abrogated arginine-vasopressin induced Ca\textsuperscript{2+} oscillations (Brueggemann et al., 2005). This group concluded that T-type Ca\textsuperscript{2+} channels are important for VSMC Ca\textsuperscript{2+} oscillations, but are not the sole contributors, as Ca\textsubscript{v}3.2 over-expression did not increase oscillation frequency. Ca\textsuperscript{2+} oscillations mediate pacemaker
activity, which manifests as vasomotion (Cribbs, 2006). Pacemaker potential as a result of T-type Ca\(^{2+}\) channel activity has been documented in pulmonary veins as reviewed by Cribbs (2006). Unexpectedly, the Ca\(_{\text{3.2}}\) T-type Ca\(^{2+}\) channel was demonstrated to be responsible for coronary artery relaxation, as Ca\(_{\text{3.2}^-}\) mice demonstrated constricted vessels (Chen et al., 2003). This group hypothesised that the Ca\(_{\text{3.2}}\) T-type Ca\(^{2+}\) channel could be functionally coupled to BK\(_{\text{ca}}\) channels in coronary artery VSMC. The presence of T-type Ca\(^{2+}\) channels in the endothelium still remains controversial, as reviewed by Kuo et al. (2011). The presence of these channels has not been documented in cultured ECs, yet their expression in small vessels has been suggested, where they may play a role in vasodilation (Kuo et al., 2011). From these data it appears that T-type Ca\(^{2+}\) channels play a prominent role in vasoconstriction of peripheral arterioles.

**Proliferation and the cell cycle**

**VSMCs**

T-type Ca\(^{2+}\) channels are often expressed alongside L-type Ca\(^{2+}\) channels, which in addition to their small conductance, makes for challenging current detection (Cribbs, 2006). It is likely that T-type Ca\(^{2+}\) channels contribute to \([\text{Ca}^{2+}]_i\) in VSMCs via the associated window current, which lies in the range of -65 to -40mV, as determined in numerous cell types (Janssen, 1997; Blanks et al., 2007; Lory et al., 2006; Capiod, 2011). The RMP of de-differentiated VSMCs is initiated at -60mV, implying that T-type Ca\(^{2+}\) channels can influence \([\text{Ca}^{2+}]_i\) via their window current (Perez-Reyes, 2003). Ca\(_{\text{3.1}}\) and Ca\(_{\text{3.2}}\) are the most prominent cardiovascular subtypes (Cribbs, 2006), and Ca\(_{\text{3.2}}\) is involved in VSMC contraction and proliferation (Catterall et al., 2005). T-type Ca\(^{2+}\) currents have been characterised in numerous smooth muscle cell tissues from a variety of species, including VSMCs, as reviewed by Perez-Reyes (2003).

The profile of T-type Ca\(^{2+}\) channel activity has been demonstrated to change across the period of culture of rat aortic VSMCs. At day 5 and 6 of culture, T-type Ca\(^{2+}\) channel currents were prominent. However, at day 15 of culture when the cells were confluent, T-type Ca\(^{2+}\) currents were reduced, and L-type Ca\(^{2+}\) currents were more prominent (Akaike et al., 1989). These findings were corroborated by Neveu et al. (1994). Rat aortic VSMCs displayed a progressive increase in T-type Ca\(^{2+}\) channel currents throughout culture, which decreased as the cells reached confluence. In contrast, L-
type Ca\textsuperscript{2+} currents decreased during the first few days of culture, remaining constant until the cells reached confluence. Furthermore, L-type Ca\textsuperscript{2+} currents increased upon growth arrest by serum-starvation, with the concomitant decrease of T-type Ca\textsuperscript{2+} currents (Neveu et al., 1994). Similarly, L-type Ca\textsuperscript{2+} channels were predominantly associated with freshly isolated VSMCs and confluent cultures, and T-type Ca\textsuperscript{2+} currents were apparent throughout proliferative phases (Richard et al., 1992). Furthermore, T-type Ca\textsuperscript{2+} currents were not detected in freshly isolated human coronary artery VSMCs, but they were found after 4 days in culture (Quignard et al., 1997). The U8A4 VSMC line can be maintained in the differentiated state, or stimulated to de-differentiate. Mibefradil was able to cause a dose-dependent inhibition of proliferation of de-differentiated U8A4 cells, with no effect of differentiated U8A4 cells (Louis et al., 2006). These data strongly link T-type Ca\textsuperscript{2+} channel up-regulation to the de-differentiated VSMC phenotype.

Consistent with a role for T-type Ca\textsuperscript{2+} channels in VSMC proliferation, mibefradil was shown to limit neointima formation after balloon injury in rat carotid arteries, and also inhibit rat VSMC proliferation in vitro (Schmitt et al., 1995). The role of the T-type Ca\textsuperscript{2+} channel was confirmed by the lack of effect of L-type Ca\textsuperscript{2+} channel blockers. A study of rat aortic VSMCs in primary culture demonstrated cell cycle dependent expression of T- and L-type Ca\textsuperscript{2+} channels (Kuga et al., 1996). T-type current density was shown to be greater in cells of the G\textsubscript{i} and S phases, therefore linking DNA replication and proliferation to T-type Ca\textsuperscript{2+} currents. Ca\textsubscript{v}3.1 was found to be the most prominent T-type Ca\textsuperscript{2+} channel subtype in human pulmonary artery VSMCs, and Ca\textsubscript{v}3.1-targeting siRNA limited cell proliferation (Rodman et al., 2005). Mibefradil also inhibited proliferation of these cells, which correlated with a higher proportion of cells in the G\textsubscript{0}/G\textsubscript{1} phase of the cell cycle, implying T-type Ca\textsuperscript{2+} channels play a central role in the proliferative response. Insulin-like growth factor-1 has a role in pathological VSMC proliferation. This growth factor increased Ca\textsubscript{v}3.1 mRNA in rat pulmonary artery VSMCs, and consequently enhanced cyclin D signalling (Pluteanu & Cribbs, 2011). Furthermore, the Ca\textsubscript{v}3.1, but not the Ca\textsubscript{v}3.2, T-type Ca\textsuperscript{2+} channel mediated VSMC proliferation and neointima formation in mice (Tzeng et al., 2012). Injury of carotid arteries produced neointima in Ca\textsubscript{v}3.2\textsuperscript{-/-} but not in Ca\textsubscript{v}3.1\textsuperscript{-/-} mice, and the proliferative response of VSMCs from Ca\textsubscript{v}3.1\textsuperscript{-/-} mice was suppressed. This group also demonstrated that Ca\textsubscript{v}3.1 knockdown hampered the progression of the S phase of the cell cycle, and indicated that the Ca\textsubscript{v}3.1 channel regulates VSMC proliferation by a calmodulin dependent pathway. Moreover, inhibition of Ca\textsubscript{v}3.1 by the more selective T-type Ca\textsuperscript{2+} channel
blocker, NNC55-0396, limited \([\text{Ca}^{2+}]\), in addition to cell proliferation, implying that this channel is essential to VSMC proliferation, and is a potential therapeutic target for vascular disorders.

Cancer

A sustained level of \([\text{Ca}^{2+}]\) is required for activation of calmodulin and downstream signals that stimulate cell cycle progression (Means, 1994). The \(G_1/S\) and the \(G_2/M\) cell cycle checkpoints are dependent on adequate \([\text{Ca}^{2+}]\) and calmodulin activity (Means, 1994). Highly proliferative cells, such as cancer cells, have increased \(\text{Ca}^{2+}\) requirements, and T-type \(\text{Ca}^{2+}\) channels have been shown to be up-regulated in many forms of cancer (Taylor et al., 2008). The window current associated with T-type \(\text{Ca}^{2+}\) channel expression is important for the maintenance of \([\text{Ca}^{2+}]\) in non-excitatory cancer cells (Taylor et al., 2008). T-type \(\text{Ca}^{2+}\) channels are expressed in many types of cancer including, but not limited to neuroblastoma, glioblastoma, and breast, prostate, and colorectal carcinoma. The T-type inhibitors mibefradil and NNC55-0396 have been shown to limit breast cancer growth, as reviewed by Taylor et al. (2008). Proliferation of both U87MG glioma cells and N1E-115 neuroblastoma cells was reduced in response to T-type \(\text{Ca}^{2+}\) channel inhibition by mibefradil, or via serum starvation (Panner et al., 2005). This study also demonstrated that over-expression of \(\text{Ca}_v3.2\) enhanced cell proliferation. The blockade of T-type \(\text{Ca}^{2+}\) channels by the endogenous angiogenesis inhibitor, endostatin, was demonstrated to have limiting effects on U87MG cell migration and proliferation (Zhang et al., 2012). These data establish a role for T-type \(\text{Ca}^{2+}\) channels in cancer progression. T-type \(\text{Ca}^{2+}\) channels have been linked to a CCE in non-excitatory cancer cells (Gray et al., 2004). This study demonstrated that prostate cancer, breast cancer, T cell leukemia, and neuroblastoma cell lines expressed \(\text{Ca}_v3.2\) T-type \(\text{Ca}^{2+}\) channels or the splice variant \(\alpha25\). These cell lines were sensitive to the novel compound, TH-1177, which blocked \(\text{Ca}^{2+}\) entry through T-type \(\text{Ca}^{2+}\) channels, as demonstrated in HEK/Ca3.2 cells, but not in cells lacking T-type \(\text{Ca}^{2+}\) channel expression. This inhibition of \(\text{Ca}^{2+}\) entry led to a decrease in cell proliferation, implicating a role for T-type \(\text{Ca}^{2+}\) channels in CCE. However, a role for T-type \(\text{Ca}^{2+}\) channels in CCE was excluded in a range of prostate cancer cell lines (Gackiere et al., 2006). Mibefradil was able to decrease CCE in prostate cancer cells over-expressing the \(\text{Ca}_v3.2\) T-type \(\text{Ca}^{2+}\) channel, yet this inhibition could not be reproduced with other T-type \(\text{Ca}^{2+}\) channel blockers, such as Ni\(^{2+}\). This group proposed that mibefradil is therefore able to inhibit SOC channels, which is another group of channels proposed to be essential for sustaining \([\text{Ca}^{2+}]\) in proliferating cells.
Mechanisms linking Ca\textsuperscript{2+} channels and Ca\textsuperscript{2+} influx to proliferation are complex and cell dependent. NFAT was shown to be highly sensitive to Ca\textsuperscript{2+} and can be activated by low Ca\textsuperscript{2+} levels accordingly (Dolmetsch et al., 1997). Furthermore, NFAT requires sustained [Ca\textsuperscript{2+}]\textsubscript{i} to remain in the nucleus. The amplitude and duration of Ca\textsuperscript{2+} signals contribute to differing Ca\textsuperscript{2+} sensitivities, and therefore, the specificity of Ca\textsuperscript{2+} waves or oscillations can selectively activate gene expression and proliferation (Dolmetsch et al., 1997). Nevertheless, T-type Ca\textsuperscript{2+} channels are evidently involved in the pathological proliferative response, and appear to play an important role in sustaining [Ca\textsuperscript{2+}]\textsubscript{i} levels required for cell cycle progression.

In addition to excess VSMC proliferation, cardiovascular disorders often feature hypoxia, oxLDL, ROS and inflammatory mediators, and all of which are capable of inducing the stress-response protein, HO-1. This enzyme is also studied in depth in this thesis, and is discussed in detail below.

1.4 Heme oxygenase 1
Heme oxygenase was discovered over 40 years ago as a microsomal enzyme responsible for the oxidative breakdown of heme (Tenhunen et al., 1969). Free heme has pro-oxidant properties, therefore the action of heme oxygenase provides cellular defence (Abraham & Kappas, 2008). HO-1 is a highly inducible form of the enzyme and up-regulation occurs in response to numerous cell stresses (Kim et al., 2011b). Found at basal levels in select tissues including the spleen and reticuloendothelial cells of the liver and bone marrow, HO-1 can be induced in all other cell types (Kim et al., 2011b). Figure 1.4 shows the crystal structure of human HO-1. Heme oxygenase 2 (HO-2) is a constitutively expressed form of the enzyme found mainly in the testes, the brain, and the vasculature (Kim et al., 2011b). The functions of HO-2 appear to include heme sequestration to maintain an intracellular heme pool, oxygen sensing, and basal levels of cytoprotection, as reviewed by Kim et al. (2011b). A third isoform of HO was detected, although this form is sparsely distributed, has low enzyme activity, and is a pseudogene of HO-2 which is not expressed in humans (Kim et al., 2011b). HO-1 is a membrane bound protein, principally localised to the endoplasmic reticulum, although studies have identified HO-1 in mitochondria, in the nucleus and within caveolae, as reviewed by Abraham and Kappas (2008). Plasma membrane caveolae localisation correlated with reduced HO-1 activity, yet these lipid rafts may provide a scaffold for
Figure 1.4 Crystal Structure of human HO-1

This image shows the secondary structure of the human HO-1 protein, together with a depiction of the heme substrate within the active site. Image taken from http://nist.rcsb.org/pdb/explore/images.do?structureId=1N45
the cytoprotective actions of this enzyme (Kim et al., 2004). One study outlined that translocation of HO-1 into the nucleus upon cleavage of the C-terminus augmented oxidant-responsive transcription factor activation, suggesting that the effects of HO-1 can be produced in various cell locales (Lin et al., 2007). HO-1 is highly conserved and expressed in many species (Ryter et al., 2006). The natural substrate of this enzyme, heme, can induce HO-1 expression and activity, and heme also acts a cofactor (Ryter et al., 2006). Upon induction, HO-1 degrades free heme oxidatively in a NADPH-dependent reaction to produce iron, biliverdin, and carbon monoxide (CO), and these by-products mediate the numerous cytoprotective effects of this enzyme (Ryter et al., 2006). Figure 1.5 illustrates the HO-1 pathway. Free iron has pro-oxidant properties, although increased production stimulates ferritin synthesis, which rapidly sequesters free iron, thereby promoting anti-oxidant effects. Indeed, ferritin confers protection against oxLDL in ECs, as reviewed by Abraham and Kappas (2008). Biliverdin is rapidly converted to bilirubin by biliverdin reductase, and both compounds are able to scavenge reactive oxygen species (ROS) (Durante, 2002). Endogenous bilirubin has anti-apoptotic effects in ECs, exogenous bilirubin limits oxidative stress-induced injury in vascular cells, and this compound has positive effects on leukocyte infiltration, as reviewed by Durante (2002). HO-1 derived bilirubin can inhibit NADPH oxidase, and was shown to limit ROS generation and proliferation of human airway smooth muscle cells via extracellular signal-regulated kinase 1/2 (ERK1/2) MAPK (Taille et al., 2003). Furthermore, serum bilirubin has been described as an independent, inverse risk factor for coronary artery disease (Ryter et al., 2006). Low serum bilirubin levels correlate with an increased incidence of peripheral vascular disease, whereas mild elevations have protective cardiovascular effects (Ryter et al., 2006). HO-1 activity is the major source of endogenous CO, and this signalling molecule is associated with a vast array of protective effects, which are discussed in detail later.

### 1.4.1 Inducers of HO-1

The majority of HO-1 inducers regulate the transcription of the HO-1 gene (HMOX1) in a cell specific manner (Gozzelino et al., 2010). Oxidative stress is an important regulator of HO-1 expression, and the promoter regions of the HMOX1 gene contain stress response elements (Gozzelino et al., 2010). HO-1 induction occurs in response to heme and protoporphyrins, heavy metals, ROS, hypoxia, hyperoxia, UVA radiation, NO gas and NO donors, resveratrol, curcumin, aspirin, statins, growth factors such as PDGF and TGF-β, inflammatory cytokines such as TNF-α and IL-1, anti-inflammatory cytokines, angiotensin II, oxLDL and endotoxin (Abraham & Kappas, 2008).
Figure 1.5 The HO-1 Pathway

HO-1 is induced in response to numerous cell stressors including, but not limited to, hypoxia, oxLDL, NO, ROS, inflammation and heme. HO-1 breaks down free heme oxidatively to produce iron, biliverdin, and CO. It is the by-product CO that mediates the majority of the cytoprotective effects associated with HO-1 activity.
recruitment of signalling pathways and subsequent transcription factors by this vast array of inducers appears to be cell type and species specific (Ryter et al., 2006). The MAPK signal transduction pathways are involved in HO-1 induction along with numerous transcription factors (Ryter et al., 2006). Nrf2 is involved in HO-1 induction, along with redox sensitive transcription factors NF-κβ and AP-1 (Ryter et al., 2006).

A vast amount of data regarding the protective effects of HO-1 has relied on the use of metalloporphyrins such as cobalt protoporphyrin IX (CoPPIX), which consists of a cobalt ion chelated by protoporphyrin IX (Kappas & Drummond, 1986). Administration of CoPPIX or cobalt chloride in rats caused an induction of hepatic HO-1 which lasted 48-72h (Maines & Kappas, 1975). Cobalt chloride and tin chloride are also HO-1 inducers, however tin protoporphyrin (SnPP) is a competitive HO-1 inhibitor (Kappas & Drummond, 1986). The heme pocket within the HO-1 molecule where heme binds is also the site at which the synthetic metalloporphyrins bind, thereby acting as competitive inhibitors (Maines, 1997). Zinc protoporphyrin (ZnPP) is a competitive inhibitor of HO-1 activity, but ZnPP is conversely able to induce HO-1 mRNA and protein levels (Maines & Trakshel, 1992; Yang et al., 2001). It appears that a region of DNA upstream of the murine HO-1 gene is the convergence point for the different signalling pathways from numerous HO-1 inducers, including hemin and CoPPIX (Alam et al., 1995). It has also been demonstrated in chick embryonic liver cells that the response element for HO-1 induction by heme and CoPPIX differs from that of stress inducers such as heavy metals (Shan et al., 2000; Shan et al., 2002). The signalling pathway in human liver cells involves down-regulation of Bach1 and up-regulation of Nrf2 transcription factors (Shan et al., 2006). Hypoxia has been demonstrated to induce HO-1 in rat tissues and in culture via the action of HIF-1α (Lee et al., 1997). Peroxisome Proliferator-Activated Receptors (PPAR) are also capable of up-regulating HO-1 expression. Upon ligand activation, PPARα and PPARγ have been shown to induce HO-1 expression in VSMCs and ECs (Kronke et al., 2007). Therefore, PPAR ligands, such as lipid-lowering fibrates, may also enhance cardiovascular integrity (Kronke et al., 2007). The cytoprotective effects of HO-1 have been examined in a wide range of tissues and diseases, but for the purpose of this project only those effects relating to disorders of the vasculature will be examined.
1.4.2 Effects of HO-1 induction

**Proliferation and Apoptosis**

PDGF was demonstrated to induce HO-1 mRNA and protein levels in rat aortic VSMCs, with a concomitant increase in CO and ROS production (Durante et al., 1999). A later study by this group once again demonstrated mitogen-induced HO-1 induction, yet they concluded that CO was able to inhibit VSMC proliferation via modulation of the cell cycle (Peyton et al., 2002). Exogenously applied gaseous CO was able to limit cell cycle progression by increasing the number of cells in the G₀/G₁ phase. Additionally, cyclin A expression was reduced, as was cyclin A-associated kinase activity and cyclin-dependent kinase 2 activity. Concerning cell cycle progression, differential effects of HO-1 induction have been demonstrated in VSMCs and ECs. In VSMCs HO-1 induction increased the proportion of cells in the G₀/G₁ phase, and decreased the proportion of cells in the S and G₂/M phases. The opposite effect was observed with HO-1 inhibition. In ECs HO-1 induction produced reciprocal effects, mediating a pro-proliferative response (Li et al., 2002). HO-1 induction and subsequent CO production occurred in response to balloon injury in rat carotid arteries, and CO limited neointimal hyperplasia via a cGMP dependent pathway (Togane et al., 2000). HO-1 expression within VSMCs of the intima correlated with the timely migration of medial VSMCs, further demonstrating a role for HO-1 in the repair of cardiovascular injury.

An extensive study involving numerous *in vitro* and *in vivo* methods demonstrated the pleiotropic and protective effects of HO-1 within the vasculature. Transfection of HO-1 in primary VSMCs reduced cell proliferation in a soluble guanylyl cyclase (sGC) and cGMP dependent pathway, which was associated with cell cycle arrest in the G₀/G₁ phase and up-regulation of the cyclin-dependent kinase inhibitor, p21 (Duckers et al., 2001). HO-1 gene transfer in pig arteries limited the development of intimal hyperplasia after angioplasty, and this correlated with the expression of cyclin-dependent kinase inhibitors p21 and p27, leading the authors to conclude that HO-1 functions upstream of these inhibitors to limit cell cycle progression (Duckers et al., 2001). Enhanced relaxation of these arteries was also apparent, and was mediated via a cGMP mechanism. The beneficial effects of HO-1 were also evidenced by experimentation with HO-1 gene knockout mice (*HMOX1⁻/⁻*). Wire injury of the femoral artery produced significant hyperplastic lesions, and VSMCs cultured from these mice proliferated to a greater extent than control VSMCs (Duckers et al., 2001). Consistent with the effects of proliferation, p21 was down-regulated and G₁/S phase progression occurred in
HMOX1−/− VSMCs. These data established the vasodilatory and anti-proliferative effects of HO-1 in VSMCs.

Metalloporphyrins also demonstrate how the cytoprotective effects of HO-1 are involved in numerous cardiovascular disorders. Hemin pre-treatment of rats subject to balloon injury of the carotid artery induced HO-1 in both the endothelial and medial vessel layers, and limited neointima formation (Tulis et al., 2001). Furthermore, neointimal hyperplasia was not affected by pre-treatment with the HO-1 inhibitor, SnPP, demonstrating that HO-1 protects against vascular remodelling (Tulis et al., 2001). The contrasting effects of hemin and SnPP were also demonstrated in vitro using rat aortic VSMCs. An increase in HO-1 expression and activity decreased the proliferative response, arresting cells in the G0/G1 phase of the cell cycle and increasing p21 expression (Chang et al., 2008). SnPP and HO-1 siRNA attenuated such effects. The levels of ROS were also reduced by HO-1 induction, demonstrating a role for HO-1 in proliferative and oxidative disorders of the vasculature (Chang et al., 2008). Zhang et al. (2002) also provided evidence that HO-1 is likely to confer antioxidant effects. Rat aortic VSMCs transfected with HO-1 exhibited increased HO-1 activity, decreased proliferation, and resistance to oxidative stress in the form of H2O2. ZnPP abolished these effects, implying that HO-1 could protect against cardiovascular disorders such as atherosclerosis (Zhang et al., 2002).

Restenosis is another proliferative disorder that could benefit from enhanced HO-1 activity. Hemin treatment of stented rabbit aorta and iliac arteries limited neointima formation without causing adverse effects on re-endothelialisation (Hyvelin et al., 2010). HO-1 induction reduced early adverse inflammatory, proliferative, and apoptotic events, thereby enhancing the integrity of a stented vessel (Hyvelin et al., 2010). HO-1 inhibition attenuated the associated protective responses, and the anti-proliferative effects appeared to be mediated via activation of cyclin-dependent kinase inhibitors and a reduction in RhoA expression (Hyvelin et al., 2010). Furthermore, the application of a CO donor, CORM-2, also limited intimal hyperplasia, implying that the beneficial effects associated with HO-1 induction are in fact mediated by the product CO (Hyvelin et al., 2010). HO-1 may play a role in limiting vascular damage during hypertension. It was found that basal HO-1 was higher in spontaneously hypertensive rats (SHR) than in wistar Kyoto rats (WKY) (Jeon et al., 2009). HO-1 gene transfer or induction by hemin inhibited VSMC proliferation to a greater extent in SHR, and this correlated to a
higher proportion of cells in the G₁ phase of the cell cycle, lower cyclin D expression, and higher p21 expression (Jeon et al., 2009).

Morita et al. have provided extensive data regarding the effects of HO-1 induction by hypoxia. HO-1 mRNA and activity were up-regulated in response to hypoxia in rat aortic and pulmonary VSMCs, producing CO which was shown to regulate cGMP (Morita et al., 1995). Hypoxia was not able to induce HO-1 in ECs, although the induction of HO-1 and CO in VSMCs limited proliferation of these cells, and exerted paracrine effects on ECs (Morita & Kourembanas, 1995). CO production increased levels of cGMP and inhibited the expression of growth factors. A later study corroborated these findings and proved that the reduction in rat aortic VSMC proliferation in response to hypoxia is due to CO (Morita et al., 1997). CO reduced E2F-1 and c-myc expression in a cGMP-dependent manner.

In contrast to the well documented anti-proliferative effects in VSMCs, HO-1 functions in a pro-proliferative manner in ECs and some tumours. Transfection of HO-1 into rabbit ECs resulted in an increase in HO-1 activity, cell proliferation, and angiogenesis (Deramaudt et al., 1998). Inhibition of HO-1 activity in a B-cell leukaemia/lymphoma 1 tumour down-regulated cyclin D1 expression and tumorigenesis (La et al., 2009). The pro-proliferative effects of HO-1 on tumorigenesis are tissue specific, as are the anti-apoptotic effects (Jozkowicz et al., 2007). However, HO-1 activity appears to enhance tumour viability by promoting angiogenesis and metastasis, in addition to limiting apoptosis, as reviewed by Jozkowicz et al. (2007). The DAOY medulloblastoma cell line was documented to have constitutive HO-1 expression, which was potentiated by hypoxia or metalloporphyrins, and augmented anti-apoptotic effects via a p38/MAPK-dependent pathway (Al-Owais et al., 2012). Exogenous application of the CO donor, CO releasing molecule-2 (CORM-2), reproduced these effects, implying that CO is the HO-1 by-product responsible for promoting cancer cell survival. Interestingly, the abolition of HO-1 expression improves the response to chemotherapy in pancreatic cancer cells, as reviewed by Abraham and Kappas (2008).

There are conflicting data regarding the effects of HO-1 and CO on apoptosis in vascular cells. Adenovirus-mediated HO-1 over-expression limited VSMC proliferation
and caused apoptosis (Liu et al., 2002b). Furthermore, these effects were mimicked by exogenous bilirubin and biliverdin, implying that the anti-oxidant properties of these by-products can stimulate apoptosis (Liu et al., 2002b). In contrast, HO-1 over-expression or exogenous CO confer anti-apoptotic effects in rat aortic VSMCs, which was dependent on the sGC/cGMP pathway (Liu et al., 2002a). However, HO-1 and CO appear to protect ECs from apoptosis, which may play an essential role in maintaining endothelial integrity. (Liu et al., 2002b; Liu et al., 2002a).

**Inflammation and oxidation**

HO-1 activity has been associated with anti-inflammatory effects in numerous *in vivo* and *in vitro* studies. The expression of this enzyme has been documented in VSMCs, ECs, and macrophages involved in an inflammatory response. However, expression is visibly lacking in adjoining, unaffected cells, as reviewed by Kim et al. (2011). A study involving aortic balloon injury of rabbits fed an atherogenic diet demonstrated a prominent inflammatory response together with thin fibrous caps of lesions (Li et al., 2011). Metalloporphyrin induction of HO-1 limited the development of atherosclerosis and plaque disruption by preventing lipid deposition and attenuating an inflammatory response. Plaque stability was maintained by a reduced level of apoptosis, a decreased expression of pro-inflammatory mediators such as MMP-9, IL-6 and TNF-α, and an increased expression of the anti-inflammatory cytokine IL-10 (Li et al., 2011). An increase in eNOS activity also appeared to play a protective role. HO-1<sup>−/−</sup> apoe<sup>−/−</sup> mice demonstrated advanced atherosclerotic lesions containing higher levels of lipids, macrophages and VSMCs (Yet et al., 2003). HO-1<sup>−/−</sup> mice underwent vein grafting which promoted neointimal hyperplasia, followed by neointimal cell death (Yet et al., 2003). The pleiotropic effects of HO-1 are evidently important in the progression of atherosclerosis.

HO-1 is induced by oxidative stress and alterations in the redox state of proteins such as glutathione, as reviewed by Ryter et al. (2006). Human pulmonary artery VSMCs were shown to express HO-1 upon an oxidative insult. The application of the CO donor, CORM-2, reduced cell proliferation, suggesting a protective role for the by-products of this enzyme in airway remodelling and pulmonary hypertension (Stanford et al., 2003). HO-1 induction in human airway VSMCs also limited oxidative stress and apoptosis via an Akt-dependent pathway leading to Nrf2 activation of the HO-1 promoter (Brunt et al., 2006).
**Vasodilation**

High flow laminar shear stress can induce HO-1 expression (Wagner et al., 1997). Indeed, this shear stress also leads to NO production and mitochondrial derived H$_2$O$_2$, which play a role in resistance artery remodelling (Freidja et al., 2011). HO-1 derived CO activates sGC with subsequent cGMP production and vasodilation, therefore contributing to adaptive vascular remodelling (Freidja et al., 2011). Moreover, NO is capable of inducing HO-1 in numerous vascular cells and the associated compensatory mechanisms are discussed below.

### 1.4.3 HO-1 and NO

Both NO and CO can promote vasodilation via the sGC/cGMP pathway. NO is an inducer of HO-1, and the HO-1/CO system can regulate NOS activity. High CO levels inhibit NOS and NO generation which leads to vasoconstriction, whereas low CO levels stimulate eNOS activity leading to vasodilation, as reviewed by Kim et al. (2011). NO bioavailability is critical to endothelial function and vascular homeostasis. Shear stress can up-regulate eNOS via NF-κβ leading to NO production in vascular cells (Pae et al., 2010). In addition to conferring vasodilatory effects, the generation of NO via eNOS has been shown to inhibit VSMC proliferation and platelet aggregation (Pae et al., 2010). Oxidative stress can cause eNOS uncoupling and subsequent HO-1 induction, which can compensate for a reduction in NO bioavailability, as reviewed by Pae et al. (2010). The interplay between the HO-1/CO and eNOS/NO systems serves to protect cells from physiological stress. In a rat model of carotid artery balloon injury the exposure to gaseous CO (250ppm) or to the CO donor, CORM-2, enhanced the proliferation of ECs *in vivo* and *in vitro* (Wegiel et al., 2010). The increased cell growth was associated with a higher proportion of cells in the S phase of the cell cycle and was mediated via RhoA with subsequent downstream phosphorylation of Akt and eNOS (Wegiel et al., 2010). These effects associated with CO appeared to be dependent on NO, as re-endothelialisation did not occur in eNOS$^{-/-}$ mice. In human ECs, HO-1 was induced in response to a NO donor, which limited NADPH oxidase activity, thereby promoting anti-oxidant effects (Jiang et al., 2006). Bilirubin also inhibited NADPH oxidase, therefore NO is able to regulate ROS production via HO-1 activity (Jiang et al., 2006).

Inducible NOS (iNOS) expression occurs in response to inflammatory cytokines and produces abundant amounts of NO over extended time periods, whereas eNOS
production of NO is transient (Durante, 2002). Furthermore, NO production via iNOS has the potential to produce both beneficial and adverse effects (Singh & Evans, 1997). iNOS plays an adverse role in oxidative stress, whereas a beneficial role has been documented in hypertension, as summarised by (Lee & Yen, 2009) However, iNOS expression has been demonstrated in intimal VSMCs after injury, and this expression was linked to increased VSMC proliferation (Chyu et al., 1999). The interaction between HO-1/CO and NO is complex and cell specific. There are feedback mechanisms that allow CO to compensate for a reduction in NO bioavailability, which is essential to vascular integrity.

1.4.4 Therapeutic potential of HO-1
Evidently from the data described above, HO-1 holds great potential as a therapeutic target for cardiovascular disorders. However, metalloporphyrins are unsuitable for clinical use due to associated side effects and structural similarity to heme, which can cause cytotoxicity, as reviewed by (Kinobe et al., 2008). However, there are numerous naturally occurring compounds that have the ability to induce HO-1, and therefore could confer cardiovascular benefits. Resveratrol is a polyphenolic component of red grapes that is associated with anti-oxidant properties, and has been shown to induce HO-1 in rat aortic VSMCs (Huang et al., 2005). Indeed, moderate consumption of red wine correlates with a reduced incidence of cardiovascular disease (Huang et al., 2005). Numerous studies have detailed the effects of the spice curcumin on HO-1 expression. Curcumin increased HO-1 mRNA and provided protection against oxidative stress when applied to bovine ECs (Motterlini et al., 2000). Proliferation of primary rat VSMCs and human airway VSMCs was inhibited by curcumin-induced HO-1 via up-regulation of p21 (Pae et al., 2007). This study demonstrated that curcumin induced HO-1 via Nrf2 translocation and anti-oxidant response element activation within the HO-1 promoter.

A range of drugs currently used to treat disorders of the vasculature have also been demonstrated to induce HO-1, including rapamycin and probucol. Aspirin can induce HO-1 in human ECs, the effects of which were associated with anti-inflammatory and anti-oxidative benefits, as reviewed by Abraham and Kappas (2008). The pleiotropic effects of statins also extend to HO-1 induction, as increased protein and mRNA levels have been produced in human ECs in vitro and in vivo in response to simvastatin and lovastatin, as reviewed by Abraham and Kappas (2008). The associated anti-
inflammatory and anti-oxidative effects were shown to be mediated by the p38/MAPK and the ERK1/2 MAPK pathways, implying that the MAPK pathways act co-operatively, as reviewed by Kim et al. (2011).

As HO-1 can be induced in all cells, targeting a HO-1 inducer to the correct tissue poses difficulties. To try and overcome this issue, HO-1 gene transfer has been investigated. Trials in animals have been successful, yet the major risks include an immune response and the development of cancer, as reviewed by Abraham and Kappas (2008). Delivery of the human HO-1 gene into rats generated protective effects within the vasculature, and the use of adenovirus-mediated gene transfer of HO-1 into liver cells of mice did not elicit immune or inflammatory responses (McCarter et al., 2003). These effects have been corroborated within a cardiac allograft of rats (Braudeau et al., 2004).

HMOX1 is an extremely sensitive gene which can be up-regulated by numerous factors that are associated with the cellular redox state. HO-1 activity has pleiotropic actions within the vasculature, and all three of the by-products confer cytoprotective effects. However, the majority of these effects appear to be mediated by CO.

1.5 Carbon Monoxide
CO is a renowned environmental toxin that causes tissue hypoxia at high levels by producing carboxyhemoglobin (COHb), (Wu & Wang, 2005). Chronic exposure modulates mitochondrial function promoting superoxide production and ensuing adverse effects including oxidative damage and apoptotic cell death (Ryter et al., 2006). Contrastingly, this gas is also a vital cell signalling molecule produced endogenously via HO-1 activity (Ryter et al., 2006). CO is a stable signalling molecule in comparison to NO, and the cellular targets of CO are hemoproteins such as hemoglobin, myoglobin, guanyl cyclase, cyclooxygenase, cytochrome P450, cytochrome c oxidase, iNOS, and NADPH oxidase (Otterbein et al., 2003a). Oxidative stress is an underlying factor of numerous cardiovascular disorders, and CO plays an important role in regulating ROS availability. CO can rapidly increase ROS production in the mitochondria by modulation of cytochrome c oxidase, as reviewed by Peers and Steele (2012). ROS production may subsequently regulate physiological functions by
interacting with ion channels, as discussed in section 1.5.2. Additionally, CO has been proposed to initiate an adaptive response which subsequently leads to a reduction in ROS and the restoration of cellular homeostasis via the inhibition of NADPH oxidase and HO-1 induction (Ruiz & Ameredes, 2012). This may involve the conditioning of cells via transcriptional up-regulation of genes to combat a subsequent oxidant mediated insult (Bilban et al., 2008). Moreover, CO induced ROS can confer cell-specific anti-inflammatory, anti-proliferative and anti-apoptotic effects, as reviewed by Bilban et al. (2008). The plethora of cytoprotective effects associated with CO in vascular cells appear to be mediated by the sGC/cGMP and p38/MAPK pathways, either in concert or independently, with additional effects on PI3K-Akt, PPARγ, and HIF-1α (Kim et al., 2006).

1.5.1 Cytoprotective effects of CO

Vasorelaxation

CO stimulates vasorelaxation in numerous vascular beds across numerous species via direct binding to sGC and increased levels of cGMP, or via stimulation of BK\textsubscript{Ca} channels, which leads to K\textsuperscript{+} efflux, membrane hyperpolarisation and subsequent closure of voltage-dependent Ca\textsuperscript{2+} channels, as reviewed by Bilban et al. (2008). CO has been proposed to bind to histidine residues within the channel, to the heme moiety associated with the channel, or to histidine/aspartate residues in the conductance regulator domain to augment this channel (Wilkinson & Kemp, 2011). Gaseous CO has been shown to dilate VSMCs of rat aortas (Lin & McGrath, 1988), and the CO donor, CORM-3, relaxed pre-contracted rat aortae (Foresti et al., 2008). The vasodilatory effects of the latter were associated with an increase in cGMP and were mediated in part by BK\textsubscript{Ca} channels. CO may be a viable therapeutic agent for pulmonary arterial hypertension, as gaseous CO restored pulmonary arterial pressures in a rodent model (Zuckerbraun et al., 2006). Acute exposure of low dose CO (250ppm) stimulated VSMC apoptosis and limited VSMC proliferation in hypertrophied vessels. These protective effects required eNOS, implying that a functional endothelium is critical to limiting vessel remodelling (Zuckerbraun et al., 2006). The vasodilatory responses to hypoxia appear to be tissue specific; systemic vessels dilate, but pulmonary vessels constrict, as reviewed by Wu and Wang (2005). Ventilation with CO abolishes this constriction of pulmonary vessels (Wu & Wang, 2005).
**Proliferation**

In airway VSMCs 250ppm CO conferred anti-proliferative effects by halting the cell cycle in the G0/G1 phase via an ERK1/2 MAPK-dependent pathway (Song et al., 2002). These effects also correlated with increased levels of p21 and a reduction of cyclin D1. The same pathway was proposed to be responsible for limiting proliferation of airway smooth muscle cells in response to the CO donor, CORM-2 (Taille et al., 2005). In this study, CO played a role in redox signalling by inhibiting NADPH oxidase cytochrome b activity, leading to mitochondrial ROS production and subsequent anti-proliferative effects. The idea that the mitochondrial electron transport chain could act as a CO sensor may underlie the mechanism of airway remodelling (Taille et al., 2005).

Transplant-associated atherosclerosis was limited in a rat model by exogenous CO (250ppm), which also inhibited leukocyte infiltration (Otterbein et al., 2003b). Additionally, intimal hyperplasia was limited by exogenous CO (250ppm) after balloon injury of the carotid artery (Otterbein et al., 2003b). This level of exogenous CO also increased the expression of p21, and the anti-proliferative effects of CO appeared to be mediated by a pathway involving both cGMP and p38/MAPK (Otterbein et al., 2003b). Caveolae may play a role in the anti-proliferative effects of exogenous CO, as up-regulation of the p38β/MAPK signalling pathway by CO increased the expression of caveolin-1 in fibroblasts and VSMCs (Kim et al., 2005). This cell cycle arrest was promoted by the up-regulation of p21 and the down-regulation of cyclin A, and also appeared to involve cGMP (Kim et al., 2005).

In a porcine model of balloon injury, pre-operatively and intra-operatively inhaled CO (250ppm) limited neointima formation (Raman et al., 2006). Interestingly, inhaled CO and iNOS gene transfer together conferred non-additive but enhanced effects on intimal hyperplasia. This evidences the co-operative effects of CO and NO, and it is possible that NO induced HO-1, which would further produce CO. The protective effects of 250ppm inhaled CO on intimal hyperplasia were also demonstrated within a porcine model of femoral artery grafting (Ramlawi et al., 2007). Levels of COHb did not reach toxicity in either of these studies, suggesting that gaseous CO could be a potential therapeutic agent. The anti-proliferative effects of CO were also reproduced with porcine VSMCs in vivo (Ramlawi et al., 2007).
**Inflammation**

Exogenous CO has demonstrated anti-inflammatory properties both *in vitro* and *in vivo*, the effects of which appear to be mediated by the p38/MAPK pathway (Otterbein *et al.*, 2000). Pro-inflammatory cytokines were down-regulated and anti-inflammatory cytokines were up-regulated in murine macrophages and M KK3−/− mice by gaseous CO (Otterbein *et al.*, 2000). The application of CORM-3, a CO donor, to human umbilical vein ECs suppressed the expression of the adhesion molecules, E-selectin and I-CAM (Song *et al.*, 2009). These data suggest that CO is able to promote an anti-inflammatory environment that could protect the vasculature and limit remodelling. However, when gaseous CO (500ppm) was inhaled by human volunteers for 1 hour prior to an endotoxin challenge, anti-inflammatory effects were absent (Mayr *et al.*, 2005a). These data contrast the beneficial anti-inflammatory and anti-proliferative effects demonstrated in rodent and murine models in response to 250ppm CO (Otterbein *et al.*, 2000; Otterbein *et al.*, 2003b). Species differences obviously factor into the response, as CO tissue levels will depend on the respiration rate of the subject (Mayr *et al.*, 2005b). However, the exposure of chronic obstructive pulmonary disease patients to 125ppm CO for 2 hours a day, for a period of 4 days, conferred moderate anti-inflammatory benefits (Bathoorn *et al.*, 2007). CO may therefore be a potential therapy for disorders involving remodelling of the airways and the vasculature.

**Thrombosis**

The inhibition of platelet aggregation by CO was demonstrated over 20 years ago, and is dependent on the cGMP pathway (Brune & Ullrich, 1987). These anti-thrombotic effects were also demonstrated by endogenous CO in rat aortic VSMCs (Wagner *et al.*, 1997). Induction of HO-1 by shear stress limited platelet aggregation via a cGMP-dependent mechanism, as HO-1 and not iNOS inhibitors abrogated the effects (Wagner *et al.*, 1997). The CO donor, CORM-3, inhibited platelet aggregation *in vitro*, *ex vivo*, and *in vivo*, although these effects were attributed to actions of both NO and CO, in a sGC/cGMP-dependent mechanism (Soni *et al.*, 2011). These anti-thrombotic effects of CO are likely to play a protective role after endothelial injury, during late stage atherosclerosis, and during organ grafting. Delivering the optimal concentration of CO in a timely and tissue specific manner may lead to beneficial effects, yet the cellular targets of CO are still being uncovered.
1.5.2 Ion channels as targets of CO

Our research group has demonstrated that CO can inhibit numerous ion channels. Both CO and CORM-2 inhibited L-type Ca\(^{2+}\) channel currents, and given these channels provide an important route for Ca\(^{2+}\) entry in VSMCs, this has important implications during situations of vascular stress, when CO production is enhanced via HO-1 induction (Scragg et al., 2008). CO was shown to increase mitochondrial ROS, which caused redox modulation of cysteine residues within the L-type Ca\(^{2+}\) channel in cardiac myocytes and HEK293 cells expressing the human Ca\(_{v}1.2\) subunit. Both gaseous CO and CORM-2, were shown to inhibit K\(_{v}2.1\) channels. CO inhibited native neuronal K\(_{v}2.1\) and HEK293 cells expressing recombinant K\(_{v}2.1\) by a protein kinase G dependent mechanism (Dallas et al., 2011). More recently, our group demonstrated that CO was able to block K\(_{v}2.1\) channels in a medulloblastoma cell line, which consequently plays a role in limiting apoptosis (Al-Owais et al., 2012). Subsequently, our group has made a novel discovery in the form of Ca\(_{v}3.2\) T-type Ca\(^{2+}\) current inhibition by CORM-2, and these currently unpublished findings opened avenues of investigation which led to this PhD project. Recent reviews discuss the findings that CO is also able to inhibit epithelial Na\(^{+}\) channels, whilst conversely augmenting BK\(_{Ca}\) channels, tandem P domain K\(^{+}\) channels, interstitial smooth muscle L-type Ca\(^{2+}\) channels, and the ATP gated P2X receptor (Peers, 2011; Wilkinson & Kemp, 2011; Peers & Steele, 2012). These ion channels may provide novel therapeutic targets for a wide range of disorders. Figure 1.6 illustrates the pathways involved in mediating the cytoprotective effects of CO in VSMCs, and given the various signalling pathways that are sensitive to CO, it seems likely that other ion channels will also be found to be regulated by CO.

1.5.3 Therapeutic potential of CO

The wide ranging cytoprotective effects attributed to CO allow this gasotransmitter to be regarded as an essential signalling molecule and a potential therapeutic agent. Concerning gaseous CO, the data thus far is equivocal, with the beneficial effects dependent on dose, length of exposure and the species under examination. However, the general consensus is that acute CO exposure confers positive effects, whereas chronic exposure is associated with adverse outcomes, as reviewed by Bilban et al. (2008). Indeed, the first Phase I clinical trial assessing the safety of inhaled CO in humans using the Covox DS CO delivery device has been completed (Motterlini & Otterbein, 2010). This study assessed acute CO exposure, 3mg/kg/hour for 1 hour a day for 10 days, and reported no cytotoxic COHb levels, as reviewed by Motterlini and
Figure 1.6 Pathways mediating the cytoprotective effects of CO in VSMC

CO acts at numerous cellular targets, shown in boxes in the diagram, to mediate cytoprotective effects. CO modulates numerous ion channels; BK$_{Ca}$ channels are augmented, K$_{v}$2.1 channels are inhibited, and T-type Ca$^{2+}$ channels have also been shown to be inhibited. CO interacts with cytochrome oxidase in the mitochondria and with NADPH oxidase to inhibit their activity, thereby modulating ROS production. NOS is either inhibited or up-regulated depending on the level of CO available, with subsequent effects on NO production, sGC activity and HO-1 induction. CO binds sGC and directly activates this second messenger leading to increased levels of cGMP. The p38/MAPK pathway also mediates a variety of cytoprotective effects associated with CO, potentially via interaction with the MAPK-mediated protein phosphatase 2C (Boczkowski et al., 2006). The ensuing physiological effects are displayed in red.
Otterbein (2010). Issues associated with the targeting of this gas to the correct tissue, such as respiration rates, levels of CO exhalation, and COHb conversion, may restrict the use as therapeutic agent to disorders involving pulmonary remodelling (Mayr et al., 2005b; Ruiz & Ameredes, 2012). However, the advent of CORMs may allow targeted CO delivery for specific disorders with a view to providing distinct physiological benefits. CORMs are transition metal carbonyls that release CO either in the presence of light (in the case of CORM-1), by a pH change (in the case of CORM-A1), or by ligand substitution (in the case of CORM-2 and CORM-3), and allow controlled delivery of low doses of CO (Foresti et al., 2008). CORM-1 and -2 were the first to be produced and are soluble in inorganic solvents. The treatment of VSMCs with CORM-2 did not affect cell viability, and had favourable vasodilatory and anti-hypertensive effects on isolated aortic tissue and on in vivo models respectively (Motterlini et al., 2002). Indeed, CORM-2 has been associated with numerous beneficial effects including reduced proliferation and inflammation, as described in the previous section. CORM-3 has a biological ligand incorporated into the molecular structure, resulting in a less toxic compound that is water soluble, and therefore more compatible with experiments involving live cells, (Motterlini et al., 2003). CORM-3 has demonstrated cardioprotective effects on cardiac cells and isolated hearts (Clark et al., 2003), and has been shown to dilate pre-contracted rat aortic rings (Foresti et al., 2004). The experimental use of CORMs has further validated the understanding that CO is a cytoprotective molecule at the correct concentration (Motterlini et al., 2003), and application of micromolar concentrations of CORM-3 are deemed to be comparable to the effects of endogenous CO (Foresti et al., 2004). CORMs are currently undergoing assessment in Phase III clinical trials (Motterlini & Otterbein, 2010), therefore it is possible that these molecules will provide safe and effective targeting of therapeutic levels of CO, as reviewed by Foresti et al. (2008), although tissue selectivity remains an issue to be resolved.

1.6 Aims of the present study
Numerous cardiovascular disorders involve excess proliferation of VSMCs, therefore limiting this adverse response may confer beneficial effects. HO-1 is up-regulated during disorders of vascular remodelling and is associated with cytoprotective effects. HO-1 induction is the major pathway of endogenous CO production, and this vital gasotransmitter is gaining a reputation as a possible therapeutic agent. Moreover, CO has anti-proliferative effects on VSMCs and pro-proliferative effects on ECs, indicating that this signalling molecule could promote the optimal conditions to limit vascular remodelling. The phenotypic switch of VSMCs involves extensive modulation of Ca$^{2+}$. 
signalling, which in turn involves the maintenance of $[\text{Ca}^{2+}]_i$, appropriate for cell proliferation and gene expression. Both the T-type $\text{Ca}^{2+}$ channel and TRPC channels appear to have prominent roles in proliferative VSMCs, as their expression is heavily linked to the cell cycle, and they allow $\text{Ca}^{2+}$ influx at RMP. Our research group has recently discovered that CO can inhibit the T-type $\text{Ca}^{2+}$ channel, with no effect on TRPC channels. Therefore, the aim of this study was to investigate whether the VSMC T-type $\text{Ca}^{2+}$ channel could act as an anti-proliferative target for HO-1.
CHAPTER 2

Methods and Materials

2.1 Cell Isolation and Culture

2.1.1 WT HEK293 and HEK293/Ca,3.2 Cells

Wild-type (WT) HEK293 cells (European Collection of Cell Cultures (ECACC), Health Protection Agency Culture Collection (HPACC), Salisbury UK) were grown in minimum essential medium (MEM; Gibco, Cambridge UK), containing 10% foetal bovine serum (FBS; Biosera, Ringmer UK), 1% non-essential amino acids (Gibco, Cambridge UK), 1% antibiotic/antimycotic (Gibco, Cambridge UK), and 0.1% gentamicin (Gibco, Cambridge UK). HEK293/Ca,3.2 cells, engineered to over-express the human Ca,3.2 subunit of the T-type Ca²⁺ channel (gift from Prof. E. Perez-Reyes; University of Virginia, USA), were cultured in WT HEK293 media as above, yet additionally supplemented with 1mg/ml G-418 (Gibco, Cambridge UK) to maintain selection for the transfected cells. HEK293 cells were passaged on a weekly basis from 75cm² flasks as follows: culture media was aspirated from the flask and replaced by 10ml of Dulbecco’s phosphate buffered saline (PBS; Gibco, Cambridge UK), to wash the cells. The PBS was removed and replaced with 2ml of 0.05% trypsin-EDTA (Gibco, Cambridge UK) to promote cell detachment. After 2-3 minutes in a humidified incubator (37°C; 95% air, 5% CO₂), the cells had detached from the flask. This cell suspension was transferred to a 50ml falcon tube along with 10ml of complete growth media (outlined above, Ca,3.2 or WT as required) to neutralise the trypsin, and then centrifuged (600g for 6 minutes). The supernatant was removed leaving the cell pellet in the tube. If cells were to be propagated into new 75cm² flasks, 20ml of complete growth media (Ca,3.2 or WT as required) was added to the cell pellet and the cells resuspended. Dilutions of this cell suspension were then performed at 1:20 and 1:40 for HEK293/Ca,3.2 cells, and at 1:10 and 1:20 for WT HEK293 cells. Conversely, if cells were to be seeded at a specific density in 6- or 24-well plates, 1ml of complete media (Ca,3.2 or WT as required) was added to the cell pellet, and the cells resuspended and counted to enable the required aliquot of cell suspension to be calculated. Subsequent sections outline the protocols for seeding cells for specific experiments. HEK293/Ca,3.2 cells were used at passages between P1 and P8, and WT HEK293 cells were used at passages between P1 and P12.
2.1.2 A7r5 Cells
A7r5 cells (ECACC, HPACC, Salisbury UK) are smooth muscle cells derived from rat thoracic aorta (Kimes & Brandt, 1976). A7r5 cells were grown in Dulbecco’s minimum essential medium (DMEM; Gibco, Cambridge UK), containing 10% FBS and 1% glutamax (Gibco, Cambridge UK), (Hall et al., 2006), and kept in a humidified incubator (37°C; 95% air, 5% CO₂). A7r5 cells were passaged weekly from 75cm² flasks following the same procedure as described above for HEK293 cells. The cell dilutions seeded into 75cm² flasks varied depending on when the cells were required to be confluent, a range of 1:5 to 1:40 was often seeded on a weekly basis. A 1:20 dilution became 80-90% confluent within a week. To maintain optimum cell viability, half the media in the flasks was changed twice weekly. A7r5 cells were used at passages between P1 and P6.

2.1.3 Human Coronary Artery Smooth Muscle Cells (HCASMC)
HCASMCs (ECACC, HPACC, Salisbury UK) were grown in complete smooth muscle cell growth medium (470ml of basal medium plus 30ml of growth supplement) as supplied by HPACC and maintained in a humidified incubator (37°C; 95% air, 5% CO₂). HCASMCs were passaged weekly from 75cm² flasks following the same procedure as described above for HEK293 cells, with dilutions of 1:10 and 1:20 seeded into 75cm² flasks. To maintain optimum cell viability, half the media in the flasks was changed twice weekly. HCASMCs were used at passages between P1 and P6.

2.1.4 Human Saphenous Vein Smooth Muscle Cells (HSVSMC)
Smooth muscle cells were isolated from the saphenous vein of patients undergoing coronary bypass graft surgery at Leeds General Infirmary following ethical approval and informed patient consent. Ethical approval received from Leeds West Research Ethics Committee; reference number CA/01/040. Smooth muscle cell isolation was carried out using the medial pad of the vessel, after endothelial cells had been removed for culture. Segments of saphenous vein, around 1cm in length were cut open longitudinally, lumen facing upwards. The segment was then divided into two pieces. 2ml of complete medium (DMEM containing 10% foetal calf serum (FCS; Biosera, Ringmer UK), 1% L-glutamine (Gibco, Cambridge UK), and 1% penicillin/streptomycin (Gibco, Cambridge UK)), was transferred into a clean petri dish. A segment of vein was placed in the media. This was then cut up with a razorblade into fragments around 0.5cm² in size. This tissue and media mixture was then transferred to a 25cm² tissue
culture flask. Cells were kept in a humidified incubator at (37°C; 95% air, 5% CO₂). Cells migrated out from these tissue fragments within 7-10 days and when 80-90% confluent, the cells were passaged using 1ml of 0.05% trypsin-EDTA into a 75cm² flask, and thereafter passaged at a ratio of 1:3. Half the media in the flasks was changed twice weekly and passaged when 80-90% confluent. The flask was washed with 10ml of PBS and then 2ml of 0.05% trypsin-EDTA was added to the cells. The flask was incubated in a humidified incubator (37°C; 95% air, 5% CO₂) for 4-5 minutes until the cells detached. If propagation of more cells was required from this cell suspension, 30ml of complete medium was added to neutralise the trypsin then the suspension divided between three 75cm² flasks. Alternatively, if the cell suspension was required for seeding a specific density of cells, 10ml of complete medium was added to neutralise the trypsin then centrifuged (600g for 6 minutes). The supernatant was aspirated and the cell pellet resuspended in 1ml of complete medium, then the cells were counted to enable the required aliquot of cell suspension to be calculated. Subsequent sections outline the protocols for seeding cells for specific experiments. HSVSMCs were used at passages between P1 and P6.

2.2 Proliferation Assay

2.2.1 Proliferation Assay Protocol

The techniques used for proliferation assays and cell counting were based on longstanding protocols from our research group (Porter et al., 2002). Cells were plated in complete media at 1x10⁴ cells per well in 24-well plates. HSVSMCs and HCASMCs were allowed to adhere overnight and subjected to serum free or 0.5% serum containing media for 2.5 days respectively. This produced a quiescent state and cell cycle synchronisation of the whole cell population. As the growth medium for HCASMCs was purchased commercially, no details were given regarding the composition of the medium, except that it contained 5% serum and various growth factors. To quiesce the cells without inducing proliferation, a 1:10 dilution of the complete growth medium with basal medium was prepared to give a final serum concentration of 0.5%. This decision was also based on a preliminary experiment involving HSVSMCs, which is presented in results section 6.2.1. A7r5 cells, along with WT HEK293 and HEK293/Ca₃.2 cells, were allowed to adhere for 6 hours and then subjected to serum free media overnight. On day 0 of the assay, serum free media was removed and 1ml of the relevant complete media added to each well, in addition to the required drug or compound being investigated. To count cells the media was removed
from the well, cells were washed with 1ml of PBS, and 200µl 0.05% trypsin-EDTA was added (pre-warmed to 37°C). Post-incubation 800µl of complete media was added and the cell suspension centrifuged (600g for 6 minutes). Following removal of 950µl of media, 50µl of supernatant remained with the cell pellet, which was then re-suspended with 50µl of 0.4% Trypan Blue (Thermo Scientific, Rockford USA) to exclude unviable cells. Media was retained from one well of each treatment, processed in the same manner as the cell samples, and any cells present were counted as a quantification of non-viable, floating cells. Day zero counts and media counts were performed using a hemocytometer. All other counts were performed using a hemocytometer initially, until a TC10 Automated Cell Counter (Bio-Rad, Hemel Hempstead UK) was acquired. Data produced using the TC10 was validated by counting samples on both the hemocytometer and the TC10 over a period of 3 weeks with HSVSMCs, and WT HEK293 and HEK293/Ca,3.2 cells. All data was comparable with the exception of day 0 counts as fewer cells were present in these samples, and it was therefore decided that the hemocytometer would give more accurate day 0 data.

2.2.2 Determination of Proliferation Assay Length
Optimal assay length for HEK293 cells had been previously determined in the laboratory. A 3 day proliferation assay was adopted as this was adequate to demonstrate significant changes in the growth curves of HEK293/Ca,3.2 cells and WT HEK293 cells. A 3 day proliferation assay was also adopted for A7r5 cells based on the growth characteristics observed between passages in 75mm² flasks, and preliminary proliferation assays. The optimal assay length for HSVSMCs and HCASMCs was determined via the proliferative response to 0.4% and 10% serum, as described in results section 6.2.1.

2.3 Sodium-Dodecyl Sulphate Polyacrylamide Gel Electrophoresis

2.3.1 Cell Lysis and Protein Extraction of samples
HSVSMCs, A7r5 and HEK293 cells used for western blotting were plated at 3x10⁴ cells/ml in 6-well plates. The cells were allowed to establish and become 80-90% confluent, then the wells were replenished with 0.4% serum media and the required treatment added. Post-treatment, the cells were washed once with PBS and lysed via incubation for 30 minutes with 200µl Mammalian Protein Extraction Reagent (M-PER™) (Thermo Scientific, Rockford USA) containing Complete Mini protease inhibitor
(Roche Diagnostics Ltd, Lewes UK; 1x Complete Mini protease inhibitor tablet per 10ml Mammalian Protein Extraction Reagent). The cell lysates were retrieved in a 1.5ml microcentrifuge tube using a cell scraper, centrifuged on a short spin for 10 seconds, and frozen at -20ºC until required.

2.3.2 Membrane Enrichment of HSVSMC samples
To detect the Ca,3.2 and Ca,3.1 T-type Ca²⁺ channels via western blotting in A7r5 cells and HSVSMCs the cell lysates required membrane enrichment. The following protocol was used for lysates from a 6-well plate. Subsequently the harvested lysates were kept on ice at all times.

Cells were washed in ice-cold PBS and incubated with 1ml of 0.05% trypsin-EDTA for 3-4 minutes. To neutralise the trypsin 3ml of ice-cold PBS was added to the wells and all the cell suspension removed into a 50ml falcon tube. A further 10ml of ice-cold PBS was added then the suspension centrifuged (600g for 2 minutes at 4ºC). The supernatant was discarded and cell pellets homogenized (passed x12) using a teflon homogeniser (Wheaton, Millville, USA) in 1ml ice-cold membrane enrichment buffer (50mM Tris HCl, 140mM KCl, 1mM EGTA, 1mM MgCl₂, 1x Complete Mini protease inhibitor tablet, pH 7.4). This suspension was then centrifuged (600g for 2 minutes at 4ºC) to pull down any remaining intact cells. The supernatants were then removed and centrifuged (1600g for 40 minutes at 4ºC). The cell pellets were then solubilised in 100µl M-PER™ containing Complete Mini protease inhibitor via ultrasonic agitation. Lysates were frozen at -20ºC until required, and kept on ice when defrosted until used.

2.3.3 Immunoprecipitation
Immunoprecipitation was also employed to improve detection of the Ca,3.2 and Ca,3.1 channels via western blotting in A7r5 cells and HSVSMCs. The following protocol was used for lysates from a 6 well plate. The harvested lysates were kept on ice at all times. Cell lysates were solubilised in 500µl ice-cold M-PER™ containing Complete Mini protease inhibitor and centrifuged at 10,000g for 5 minutes. Following retrieval of the supernatant, 15µl protein A sepharose beads (Sigma, Gillingham UK), 15µl protein G sepharose beads (Sigma, Gillingham UK) and 5µg of Ca,3.2 or Ca,3.1 antibody was added, then the sample placed on a GyroMini™ nutating mixer overnight at 4ºC. The following day the sample was centrifuged (5000g for 5 minutes), the supernatant discarded, and the beads were then washed to remove any unbound proteins with 1ml
of sterile PBS. The sample was then placed on a GyroMini™ nutating mixer at 4°C for 20 minutes. This step was repeated for a total of 3 washes. The sample was then centrifuged (20,000g for 5 minutes), the supernatant was discarded, and 20μl of 4x sample buffer (detailed in table 2.1) was added to the beads. This was allowed to incubate for 20 minutes to maximise protein elution, followed by centrifugation (20,000g for 5 minutes), and the sample then transferred to the gel for electrophoresis.

2.4 Bicinchoninic acid protein assay

This assay (Thermo Scientific, Rockford USA) allows quantification of total protein levels in samples, which enables normalisation of protein loading onto gels for electrophoresis. Under alkaline conditions, proteins in the sample reduce Cu²⁺, which is then chelated by bicinchoninic acid, producing a colour change from green to purple. The total protein level in each sample is proportional to the intensity of the purple colour formed, which is determined by colorimetry (Smith et al., 1985). The amount of protein in each sample can then be determined from a standard curve. Bovine serum albumin (BSA) protein standards were used with a range of 0-2000μg/ml. 10μl of standards and 2.5μl of samples with unknown protein levels were pipetted into separate wells of a 96-well plate and 200μl of working reagent added to each well. After a 30 minute incubation period at 37ºC, the plate was allowed to cool to room temperature (RT) and absorbance read at 570nm. The appropriate ratio of sample to sample buffer, (detailed in table 2.1), was determined using Graphpad Prism 6. These sample solutions were allowed to stand for 15 minutes at RT to maximise protein denaturisation prior to loading onto the gel for electrophoresis.

2.5 Gel Electrophoresis

Gel electrophoresis was performed to separate the proteins in the cell lysate samples to allow subsequent isolation and visualisation of the protein band of interest. Separating gels were prepared using the reagents shown in table 2.2. The size of the protein of interest dictated the percentage of acrylamide in the gel. For example the HO-1 protein is approximately 32kDa, so a 10% or 12% gel is sufficient. However, the Ca,3.2 and Ca,3.1 T-type Ca²⁺ channels are much larger proteins of approximately 250kDa, therefore a gel with a larger pore size is required to allow the larger proteins to move through the gel, which dictates the use of a 7.5% acrylamide gel.
Reagent | 1x Sample buffer
---|---
Tris HCl | 125mM
SDS (w/v) | 2%
EDTA | 2mM
EGTA | 2mM
Glycerol (w/v) | 20%
β-mercaptoethanol (v/v) | 10%
Bromophenol blue (v/v) | 1%

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Resolving Gel</th>
<th>Stacking Gel</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acrylamide %</td>
<td>12%</td>
<td>10%</td>
</tr>
<tr>
<td>Acrylamide (30%)</td>
<td>6.25ml</td>
<td>5ml</td>
</tr>
<tr>
<td>Ammonium persulphate</td>
<td>1.5ml</td>
<td>1.5ml</td>
</tr>
<tr>
<td>Distilled Water</td>
<td>3.5ml</td>
<td>4.75ml</td>
</tr>
<tr>
<td>Separating Gel Buffer (1.5M Tris Base pH8.8, 0.4% w/v SDS)</td>
<td>3.75ml</td>
<td>3.75ml</td>
</tr>
<tr>
<td>TEMED</td>
<td>15µl</td>
<td>15µl</td>
</tr>
<tr>
<td>Stacking Gel Buffer Buffer (0.5M Tris Base pH6.8, 0.4% w/v SDS)</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 2.1 Composition of sample buffers used for gel electrophoresis
(All compounds from Sigma, Gillingham UK)

Table 2.2 Composition of electrophoretic gels

Gels were cast and a layer of isobutan-2-ol was pipetted on top of the separating gel to ensure a flat, even surface. Once the separating gel had polymerised, the isobutan-2-ol was poured off. A few grains of phenol red (Acros Organics, Geel Belgium) were added to the 4% stacking gel solution to allow visualisation of the wells, and this stacking gel solution was pipetted on top of the separating gel. 0.75mm combs were inserted at an angle to force out any air bubbles. Once polymerisation of the stacking gel had occurred, the gels were run on vertical mini gel (11 x 11cm) apparatus (Mini Protean III electrophoresis cell, Bio-Rad, Hemel Hempstead UK). The gel cassette sandwich was placed in the electrode assembly and running buffer added (25mM Tris, 192mM glycine, 0.1% w/v SDS, Bio-Rad, Hemel Hempstead UK). Combs were removed and
the samples and molecular weight markers pipetted slowly into the wells to prevent overflow. Running time was approximately 1 hour at 35mA, or until the markers of interest were in the correct position.

2.6 Western Blotting

2.6.1 Electrophoretic Transfer
After separation, proteins were transferred onto 0.45µm Immobilon-P polyvinylidene difluoride membrane (Millipore Corporation, Massachusetts USA). The membrane, along with x2 Mini Trans Blot filter paper (Bio-Rad, Hemel Hempstead UK) and x2 sponges, were soaked in methanol (Fisher Scientific, Rockford USA) and then in transfer buffer (600ml ddH₂O, 70ml Tris-Glycine transfer buffer (Invitrogen, Cambridge UK), and 30ml methanol). The blotting sandwich was assembled in cassettes as follows: Anode(+), sponge, filter paper, membrane, gel, filter paper, sponge, Cathode(-). The cassettes were placed in a Mini Trans-Blot electrophoretic transfer cell (Bio-Rad, Hemel Hempstead UK) and subjected to 30V overnight.

2.6.2 Immunodetection
Post transfer, the membranes were removed from the cassettes and soaked in methanol, followed by blocking in 5% (w/v) Marvel non-fat dried milk powder in TBST (tris-buffered saline (TBS) containing 0.05% (v/v) Tween-20) for 1 hour. The membranes were then incubated with primary antibody for 3 hours at RT in 5% Marvel in TBST (see table 2.3 for dilutions of the antibodies used). For loading control, β-actin (Sigma, Gillingham UK) was used at 1:4000. The membranes were then washed in TBST for 30 minutes, with the TBST changed every 5 minutes. Following this wash protocol, the membranes were then incubated with the corresponding anti-rabbit or anti-mouse peroxidase conjugated secondary antibody (GE Healthcare, Amersham UK) at 1:2000 dilution in 5% Marvel in TBST for 1 hour at RT. The wash protocol was then followed again. Protein bands were detected using the enhanced chemiluminescent (ECL) method (GE Healthcare, Amersham UK). The secondary antibodies used (see table 2.3), are conjugated to horseradish peroxidase (HRP) which catalyses a substrate in the ECL detection reagent, producing chemiluminescence that was detected on hyperfilm (GE Healthcare, 2012). The hyperfilm was scanned using Canon 5600F scanner and densitometric analysis performed using Image J (NIH UK). The expression of HO-1 was normalised to β-actin in each instance.
<table>
<thead>
<tr>
<th>Antibody (Supplier, Code)</th>
<th>Western Blotting Dilution</th>
<th>Western Blotting Secondary Antibody</th>
<th>Immunocytochemistry Dilution</th>
<th>Immunocytochemistry Secondary Antibody</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-HO-1 (Santa Cruz, SC-10789)</td>
<td>1:200</td>
<td>Anti-Rabbit ECL HRP Linked (GE Healthcare)</td>
<td>1:50</td>
<td>Goat Anti-Rabbit Alexa Fluor&lt;sup&gt;488&lt;/sup&gt; (Invitrogen, Cambridge UK)</td>
</tr>
<tr>
<td>Anti-Cav3.1 (Santa Cruz, SC-16259)</td>
<td>1:200</td>
<td>Anti-Goat ECL HRP Linked (GE Healthcare)</td>
<td>1:50</td>
<td>Donkey Anti-Goat Alexa Fluor&lt;sup&gt;488&lt;/sup&gt; (Invitrogen, Cambridge UK)</td>
</tr>
<tr>
<td>Anti-Cav3.2 (Santa Cruz, SC-16263)</td>
<td>1:200</td>
<td>Anti-Goat ECL HRP Linked (GE Healthcare)</td>
<td>1:50</td>
<td>Goat Anti-Goat Alexa Fluor&lt;sup&gt;488&lt;/sup&gt; (Invitrogen, Cambridge UK)</td>
</tr>
<tr>
<td>Anti-Cav3.1 (Alomone, ACC-021)</td>
<td>1:200</td>
<td>Anti-Rabbit ECL HRP Linked (GE Healthcare)</td>
<td>1:50</td>
<td>Goat Anti-Rabbit Alexa Fluor&lt;sup&gt;488&lt;/sup&gt; (Invitrogen, Cambridge UK)</td>
</tr>
<tr>
<td>Anti-Cav3.2 (Alomone, ACC-025)</td>
<td>1:200</td>
<td>Anti-Rabbit ECL HRP Linked (GE Healthcare)</td>
<td>1:50</td>
<td>Goat Anti-Rabbit Alexa Fluor&lt;sup&gt;488&lt;/sup&gt; (Invitrogen, Cambridge UK)</td>
</tr>
</tbody>
</table>

Table 2.3 Primary and secondary antibodies used in western blotting and immunocytochemistry
(Santa Cruz Biotechnology Santa Cruz USA, Alomone Jerusalem Israel)
2.7 Immunocytochemistry

Cells used for immunocytochemistry were plated on sterile glass coverslips (22x22mm, thickness 0) in 6-well plates at 1x10^4 cells/ml for A7r5 cells and HSVSMCs, and at 2x10^4 cells/ml for HEK293 cells. To enhance the adherence of HEK293 cells, 1.5ml polylysine (Sigma, Gillingham UK) was added to each well containing the coverslip and removed after 30 seconds. Once the wells were completely dry, the cells were then plated. This was not required for A7r5 or SVSMCs. If HO-1 induction was required, cells were allowed to adhere to the coverslips for 24 hours and then the correct protoporphyrin added for 48 hours. Post-treatment, the media was removed and the coverslips were washed with PBS (3x5 minutes). The cells were then fixed with 4% paraformaldehyde in PBS for 20 minutes. This was followed by incubation for 20 minutes at RT in PBS containing 0.2% Triton X100 and 10% normal goat serum (NGS; Sigma, Gillingham UK), or BSA (Sigma, Gillingham UK) if the primary antibody was raised in goat. The coverslips were then washed again with PBS (3x5 minutes), followed by a wash with PBS containing 1% NGS/BSA for 2 minutes. The primary antibody was diluted in PBS containing 1% NGS/BSA. See tables 2.3 and 2.4 for details of the antibodies used. The coverslips were incubated with primary antibody overnight at 4°C in an air-tight box lined with wet tissue paper.

The following day the coverslips were washed with PBS (3x5 minutes). The secondary antibody was used at 1:1000 in PBS containing 1% NGS/BSA. 1ml/well was incubated for 1 hour in the dark at RT. The coverslips were again washed with PBS (3x5 minutes). Coverslips were mounted on glass slides using 20µl Vectasheild containing DAPI (Vector Laboratories, Burlingame USA) and the edges sealed with nail varnish. The slides were allowed to dry in the dark, then visualised using a Zeiss laser scanning confocal microscope (LSM510), (Oberkochen, Germany), and Zeiss AIM software. LSM Image Browser software was used to produce images. Settings were identical for each condition.

2.7.1 HO-1

Immunocytochemistry was performed in HSVSMCs, A7r5, HEK293/Ca3.2, and WT HEK293 cells to visualise HO-1 after induction with Cobalt Protoporphyrin IX (CoPPIX; Sigma, Gillingham UK) or Hemin Chloride (Calbiochem, Darmstadt Germany). The cells were allowed to adhere for 24 hours then treated for the required time period. The details of the antibodies used are listed in table 2.3.
<table>
<thead>
<tr>
<th>Antibodies Description</th>
<th>Dilution</th>
<th>Polyclonal/Monoclonal</th>
<th>Secondary Antibodies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti α-SM Actin (Clone 1A4) (A2547, Sigma, Gillingham UK)</td>
<td>1:300</td>
<td>Mouse Monoclonal</td>
<td>Donkey Anti-Mouse Alexa Fluor&lt;sup&gt;555&lt;/sup&gt; (Life Technologies, Cambridge UK)</td>
</tr>
<tr>
<td>Anti-Vimentin (V9) (Santa Cruz Biotechnology sc-6260, Santa Cruz USA)</td>
<td>1:50</td>
<td>Mouse Monoclonal</td>
<td>Donkey Anti-Mouse Alexa Fluor&lt;sup&gt;555&lt;/sup&gt; (Life Technologies, Cambridge UK)</td>
</tr>
<tr>
<td>Anti-SM Myosin Heavy Chain (H-44) (Santa Cruz Biotechnology sc-98705, Santa Cruz USA)</td>
<td>1:50</td>
<td>Rabbit Polyclonal</td>
<td>Goat Anti-Rabbit Alexa Fluor&lt;sup&gt;488&lt;/sup&gt; (Life Technologies, Cambridge UK)</td>
</tr>
</tbody>
</table>

**Table 2.4 Primary and secondary antibodies used in immunocytochemistry for cell characterisation**

### 2.7.2 Cav3.2 and Ca<sub>3.1</sub> T-type Ca<sup>2+</sup> channels

Immunocytochemistry was performed in HSVSMCs, A7r5 cells, HEK293/Ca<sub>3.2</sub>, and WT HEK293 cells to demonstrate the presence or absence of the Ca<sub>3.2</sub> T-type Ca<sup>2+</sup> channel. The above protocol was followed using two different Ca<sub>3.2</sub> primary antibodies as listed in table 2.3.

### 2.7.3 Cell Characterisation

HSVSMCs and A7r5 cells were subject to immunocytochemistry using the antibodies listed in table 2.4 to characterise them as smooth muscle cells.
2.8 Detection of Caspase-3/7 Activation via CellEvent™
Activation of caspases 3 and 7 were monitored fluorogenically via CellEvent™ Caspase-3/7 detection reagent (Molecular Probes, Cambridge UK). The reagent consists of a nucleic acid binding dye conjugated to a four amino acid peptide. Upon activation of caspases 3 and 7, the four amino acid peptide is removed allowing the dye to bind to DNA and fluoresce. Maximal absorbance is measured at 530nm.

This experiment was employed as an alternative to trypan blue exclusion and media counts, to determine conclusively whether the drugs used in proliferation assays cause an inhibition of proliferation as opposed to apoptosis. A7r5 cells were plated at 2x10^4 cells/ml on sterile square glass coverslips (22x22mm, thickness 0) in a 6-well plate. Cells were allowed to adhere overnight then the following morning the media in the wells was replenished and treated with the appropriate compound. As a positive control, one well was treated with 2μM staurosporine (Sigma, Gillingham UK), an established inducer of apoptosis (Bertrand et al., 1994), for 3 hours on day 3 of the assay. All wells were then washed briefly with PBS, then 8μM CellEvent™ added to each well. Cells were incubated for 30 minutes at RT in the dark. All wells were washed again with PBS and two drops of NucBlue™ Live Cell Stain (Hoechst 33342), (Molecular Probes, Cambridge UK), added per ml of PBS. Cells were again incubated for 20 minutes at RT in the dark. Cells were then washed for 5 minutes with PBS, fixed with 4% paraformaldehyde for 20 minutes, mounted using 20µl Vectasheild without DAPI (Vector Laboratories, Burlingame USA), and sealed with nail varnish. Cells were imaged with a Nikon E600 light microscope (Nikon, Kingston upon Thames UK), x40 lens, and Q Imaging Micropublisher ACQuis (Syncroscopy) software.

2.9 Measurement and analysis of [Ca^{2+}]

2.9.1 Measurement of [Ca^{2+}] by microfluorimetry
Microfluorimetry was performed to monitor [Ca^{2+}] of A7r5, HEK293/Ca_{3.2} and WT HEK293 cells. Fura 2-AM (Invitrogen, Cambridge UK) was used as the [Ca^{2+}] indicator for the microfluorimetry experiments. Fura 2-AM is an acetoxymethyl (AM) ester and it is this AM group which confers hydrophobicity to the otherwise hydrophilic dye, allowing passage through the cell membrane (Paredes et al., 2008). The action of intracellular esterases ensures the dye remains inside the cell by hydrolysing the AM group. This high affinity fluorescent dye is ratiometric. On Ca^{2+} binding the peak excitation wavelength shifts from 380nm to 340nm (Paredes et al., 2008), which is
illustrated in figure 2.1. Higher $[\text{Ca}^{2+}]_i$ produces an increase in emission intensity at 510nm when Fura 2 is excited at 340nm, whereas lower $[\text{Ca}^{2+}]_i$ produces an increase in emission intensity at 510nm when Fura 2 is excited at 380nm. The ratiometric property of Fura 2 allows for any differences in dye loading, cell size, and cell volume in the recording field to be overcome, therefore allowing data from different experiments to be compared (Paredes et al., 2008), and for the shift in excitation wavelength to correlate directly to $[\text{Ca}^{2+}]_i$ (Duchen, 1992).

$[\text{Ca}^{2+}]_i$ can be determined from the Fura 2 ratio using the following equation (Gryniewicz et al., 1985):

$$[\text{Ca}^{2+}]_i = \frac{K_d S_{12}}{S_{b2}} \left( \frac{R - R_{\text{min}}}{R_{\text{max}} - R} \right)$$

Where:

$K_d$ is the dissociation constant for Fura 2, which is the $[\text{Ca}^{2+}]_i$ when the concentration of $\text{Ca}^{2+}$ bound and free Fura 2 are equal.

$R$ is the fluorescence ratio defined as the fluorescence intensity induced by $\lambda_1$ ($F_1$ at 340nm) divided by the fluorescence intensity induced by $\lambda_2$ ($F_2$ at 380nm), ($I_{340}/I_{380}$).

$R_{\text{min}}$ is the $R$ recorded when the $[\text{Ca}^{2+}]_i$ is 0.

$R_{\text{max}}$ is the $R$ recorded when the $[\text{Ca}^{2+}]_i$ is a maximum or much higher than $K_d$.

$S_{12}$ is $F_2$ when $\text{Ca}^{2+}$ is not bound to Fura 2 and $S_{b2}$ is $F_2$ when Fura 2 is fully bound to $\text{Ca}^{2+}$. 
Figure 2.1 Fluorescence excitation spectra of Fura 2-AM in solutions containing 0-39.8µM free Ca²⁺ (Diagram taken from www.invitrogen.com)
The determination of [Ca\textsuperscript{2+}], however, is not without limitations. To calculate [Ca\textsuperscript{2+}], precisely, $K_d$ must be determined for each cell type and fluorescent indicator (Neher, 2000), which varies with temperature, pH, and Mg\textsuperscript{2+} levels (Paredes et al., 2008). Additional issues associated with the indicator can also contribute to inaccuracies, such as compartmentalisation of the indicator, and sub maximal hydrolysis which produces fluorescence without Ca\textsuperscript{2+} sensitivity (Duchen, 1992; Neher, 2000) For these reasons, changes in [Ca\textsuperscript{2+}], were expressed as changes in Fura 2 ratio in this thesis.

For all Ca\textsuperscript{2+} microfluorimetry experiments A7r5 and HEK293 cells were plated on circular glass coverslips (10mm, thickness 0) in 24 well plates at a 1:3 dilution for A7r5 cells, and at a 1:5 dilution for HEK293 cells. Previous to cell plating, 1ml polylsine was added to each well containing the coverslip and removed after 30 seconds. Once the wells were completely dry the cells were then plated and kept in a humidified incubator (37°C; 95% air, 5% CO\textsubscript{2}), until the cell monolayer was confluent. The coverslip was transferred to a 35mm petri dish and cells were loaded with 4µM Fura 2-AM (dissolved in Ca\textsuperscript{2+} containing buffer) for 40 minutes. The cells were then washed with 1ml of Ca\textsuperscript{2+} containing buffer and then incubated in Ca\textsuperscript{2+} containing buffer for 15 minutes to allow de-esterification of the loaded dye. During both incubations the petri dish was wrapped in foil and kept in a dark drawer at RT. Table 2.5 lists the buffer compositions.

<table>
<thead>
<tr>
<th></th>
<th>Normal (Ca\textsuperscript{2+}-containing)</th>
<th>Ca\textsuperscript{2+}-Free</th>
<th>20mM K\textsuperscript{+}</th>
<th>80mM K\textsuperscript{+}</th>
<th>80mM K\textsuperscript{+}/Ca\textsuperscript{2+} Free</th>
</tr>
</thead>
<tbody>
<tr>
<td>NaCl</td>
<td>135mM</td>
<td>135mM</td>
<td>120mM</td>
<td>60mM</td>
<td>60mM</td>
</tr>
<tr>
<td>KCl</td>
<td>5mM</td>
<td>5mM</td>
<td>20mM</td>
<td>80mM</td>
<td>80mM</td>
</tr>
<tr>
<td>MgCl\textsubscript{2}</td>
<td>1.2mM</td>
<td>1.2mM</td>
<td>1.2mM</td>
<td>1.2mM</td>
<td>1.2mM</td>
</tr>
<tr>
<td>HEPES</td>
<td>5mM</td>
<td>5mM</td>
<td>5mM</td>
<td>5mM</td>
<td>5mM</td>
</tr>
<tr>
<td>D-Glucose</td>
<td>10mM</td>
<td>10mM</td>
<td>10mM</td>
<td>10mM</td>
<td>10mM</td>
</tr>
<tr>
<td>Sucrose</td>
<td>300mOsm</td>
<td>300mOsm</td>
<td>300mOsm</td>
<td>300mOsm</td>
<td>300mOsm</td>
</tr>
<tr>
<td>CaCl\textsubscript{2}</td>
<td>2.5mM</td>
<td>-</td>
<td>2.5mM</td>
<td>2.5mM</td>
<td>-</td>
</tr>
<tr>
<td>EGTA</td>
<td>-</td>
<td>1mM</td>
<td>-</td>
<td>-</td>
<td>1mM</td>
</tr>
</tbody>
</table>

Table 2.5 Composition of 1L buffers used in Ca\textsuperscript{2+} microfluorimetry
(All compounds from Sigma, Gillingham UK)
Composition of Ca\(^{2+}\)-containing buffer (in mM): NaCl 135, KCl 5, MgSO\(_4\) 1.2, CaCl\(_2\) 2.5, HEPES 5, glucose 10, osmolarity adjusted to 300 mOsm with sucrose, pH 7.4. Ca\(^{2+}\)-free buffer as above minus CaCl\(_2\) 2.5, plus 1mM EGTA.

Coverslip segments were loaded into a perfusion chamber (volume approximately 80µl) on an inverted epi-fluorescence microscope with the required buffer perfused via gravity at 2-3ml/min. The perfusion system consisted of four 60ml disposable syringes which acted as reservoirs (Merck, Feltham UK), connected to a 6 way tap (Hamilton GB Ltd., Birmingham UK) via Tygon tubing (2.5mm outside diameter, 0.83mm inside diameter; Merck, Feltham UK). Buffer was delivered from the tap to the perfusion chamber by Tygon tubing. Various compounds and drugs were used to alter the activity of the T-type Ca\(^{2+}\) channels, L-type Ca\(^{2+}\) channels and HO-1 (see section 2.14 and specific results chapters for details), and these were applied to the perfusion chamber from the appropriate reservoir via the Hamilton tap as and when required. A suction tube connected to a peristaltic pump (Gilson, Minipulse 3, Anachem, Luton UK) was used to continuously remove the perfusate from the chamber.

The cellular Ca\(^{2+}\) responses were recorded using a Cairn Research ME-SE Photometry system (Cairn Research, Faversham UK). Acquisition Engine 1.6.1 software was used to visualise the wavelength traces. Plotting and analysis of the data was done using Graphing (in house program) and GraphPad Prism version 6 (GraphPad Software, Inc., La Jolla USA).

### 2.9.2 Analysis of microfluorimetry traces from A7r5 cells

It was noted that the response of A7r5 cells to 20mM K\(^+\) buffer declined over time with each subsequent exposure. This can be seen in Figure 2.2 (A), the response to each exposure numbered from 1 to 3. These three consecutive responses on the control traces were analysed to determine the standard to which to compare the effects of any drugs or compounds. Two sets of data were retrieved for each exposure to 20mM K\(^+\) buffer; these were the change in Fura 2 ratio, and spikes per second (spikes/s). The change in Fura 2 ratio is illustrated in Figure 2.2 (B), and calculated by subtracting the basal Fura 2 level (F\(_1\)) from the Fura 2 level in response to K\(^+\) buffer (F\(_2\)). These Fura 2 ratio values were taken as the response reached plateau. Spikes/s were achieved by dividing the time period (in seconds) of each exposure to 20mM K\(^+\) buffer, by the number of spikes for the response during this exposure. This is illustrated in Figure 2.2 (C). The same analyses were performed on the traces from A7r5 cells in response to various compounds or drugs.
The Graphing program was also used to calculate the integral of the response of A7r5 cells to 80mM K⁺ buffer. Exposure to 80mM K⁺ buffer was timed, and the integral of the curve for the initial 200 seconds was determined. This is illustrated in Figure 2.3; the integral of the curve bound by the red lines was calculated for all traces. This time-point was chosen to demonstrate the different responses to the various compounds used as some responses were extremely brief with a rapid return to baseline, whereas the control traces would continue to decline slowly, possibly not returning to baseline within an ideal timeframe in which to monitor the cells. Therefore, a snapshot of the initial response was assessed for all traces.

2.9.3 Analysis of microfluorimetry traces from HEK293 cells
An example of how traces from HEK293/Ca,3.2 and WT HEK293 cells were analysed is shown in Figure 2.4. The response to normal buffer (F₁) was compared to the response to Ca²⁺ free buffer, or normal buffer plus specified compound (F₂) on each trace. The Fura 2 ratio of each response was recorded from a plateau level.

2.10 Real-Time Polymerase Chain Reaction (RT-PCR)
The basal expression of Ca,3.2 and Ca,3.1 mRNA in A7r5 cells and HSVSMCs was quantified via RT-PCR. This technique was then used to monitor changes in mRNA expression post-siRNA knockdown of the Ca,3.1 gene (CACNA1G) in A7r5 cells.

2.10.1 RNA generation
To determine the expression levels of Ca,3.2 and Ca,3.1 channels, T25 flasks of 70-80% confluency were washed with PBS and cells dissociated using 0.5ml 0.05% trypsin-EDTA for 3 minutes (37°C; 95% air, 5% CO₂). Enzyme activity was halted by adding 0.5ml ice-cold PBS, the cell suspension was then centrifuged (600g for 6 minutes). If RNA was not to be generated immediately, the supernatant was discarded and the cell pellets dispersed in 100µl of RNA/later® (Ambion, Cambridge UK) and frozen at -20°C until required.

RNA was generated from whole cell lysates using the Aurum Total RNA Mini Kit (Bio-Rad, Hemel Hempstead UK). The RNA/later® solution containing the cells was centrifuged (600g for 6 minutes) then the supernatant discarded. 350µl of lysis solution was added to each cell pellet, and the cells were dispersed by pipetting up and down
Figure 2.2 Details of how A7r5 traces were analysed

(A) Representative A7r5 control trace. (B) Enlarged view of the highlighted centre section demonstrating how the change in Fura 2 ratio was determined. (C) Demonstration of how spikes per second were calculated.
Figure 2.3 Illustration of the 200s integral calculated for all A7r5 cell traces in response to 80mM K\textsuperscript{+} buffer

Figure 2.4 Details of how HEK293 traces were analysed
approximately 15 times. Then 350μl of 70% ethanol (molecular biology grade, Sigma, Gillingham UK) was added, and the solution mixed by pipetting up and down approximately 15 times. Each lysate was transferred to a spin column inserted in a 2ml collection tube and centrifuged (13000g for 30 seconds). Flowthrough was discarded and 700μl of low stringency wash was added, the columns then centrifuged (13000g for 30 seconds). Again flowthrough was discarded and 75μl DNase Incubation Mix (5μl DNase I: 75μl DNase Dilution Solution) added to each column. This was incubated at RT for 15 minutes then centrifuged at 13000g for 30 seconds. Flowthrough was discarded, 700μl of high stringency wash solution was added, then the columns centrifuged (13000 g for 30 seconds). Flowthrough was again discarded, 700μl low stringency wash added and the columns centrifuged (13000g for 1 minute). Again, flowthrough was discarded and the columns centrifuged (13000g for a further 2 minutes). Each spin column was then placed in a new elution tube, 80μl of elution solution (pre-warmed to 70°C) was added and incubated for 1 minute at RT. RNA was eluted by centrifugation (13000g for 2 minutes). RNA samples were frozen at -70°C if cDNA was not generated immediately.

### 2.10.2 cDNA generation

A cDNA template was generated from RNA samples using the iScript cDNA Synthesis Kit (Bio-Rad, Hemel Hempstead UK). Firstly, 20μl of the reaction solution, as shown in table 2.6, was transferred into a dome-capped 0.2ml PCR tube, and placed in a bench top thermocycler (Applied Biosystems). The reaction samples were subjected to 5 minutes at 25°C, followed by 30 minutes at 42°C, 5 minutes at 85°C, and then held at 4°C.

<table>
<thead>
<tr>
<th>Component</th>
<th>Volume per Reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>5x iScript reaction mix</td>
<td>4μl</td>
</tr>
<tr>
<td>Reverse Transcriptase</td>
<td>1μl</td>
</tr>
<tr>
<td>Nuclease-free water</td>
<td>12.5μl</td>
</tr>
<tr>
<td>RNA template</td>
<td>2.5μl</td>
</tr>
</tbody>
</table>

Table 2.6 Composition of iScript reaction solution
2.10.3 RT-PCR

The reaction mix for each primer was prepared as outlined in table 2.7. The details of the primers used are outlined in table 2.8; rat primers employed for A7r5 cells, and human primers employed for HSVSMCs. Firstly, 18μl of RT-PCR reaction mix was added to the required wells of a 96 well PCR plate (Applied Biosystems, Cambridge UK), followed by 2μl of sample cDNA in the same pattern. The plate was then sealed with an optical adhesive cover, centrifuged briefly, and then placed in an RT-PCR machine (Applied Biosystems, Cambridge UK). The RT-PCR reaction was as follows: 2 minutes at 50°C, 10 minutes at 95°C, 15 seconds at 95°C for 60 cycles, then 1 minute at 60°C.

<table>
<thead>
<tr>
<th>Component</th>
<th>Volume per Reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taqman Universal PCR Master Mix (Roche Diagnostics Ltd, Lewes UK)</td>
<td>10μl</td>
</tr>
<tr>
<td>Taqman Primer</td>
<td>0.5μl</td>
</tr>
<tr>
<td>RNase/DNase-free water (Gibco Cambridge UK)</td>
<td>7.5μl</td>
</tr>
</tbody>
</table>

Table 2.7 Composition of RT-PCR reaction mix

<table>
<thead>
<tr>
<th>Primer</th>
<th>Species</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPRT1 (hypoxanthine phosphoribosyltransferase 1)</td>
<td>Rat/Human</td>
<td>Endogenous House Keeper</td>
</tr>
<tr>
<td>B2M (β2microglobulin)</td>
<td>Rat/Human</td>
<td>Endogenous House Keeper</td>
</tr>
<tr>
<td>CACNA1G</td>
<td>Rat/Human</td>
<td>Target</td>
</tr>
<tr>
<td>CACNA1H</td>
<td>Rat/Human</td>
<td>Target</td>
</tr>
</tbody>
</table>

Table 2.8 RT-PCR Primer details (all from Applied Biosystems, Cambridge UK)

2.11 Stable Transfection of A7r5 cells with pcDNAhHO-1

To generate a cell line stably expressing human (hH-O1) HO-1, referred to hereafter as A7r5/hHO-1, cells were initially transfected with the pcDNA3.1/Neo (hHO-1) construct using the Genejammer transfection reagent (Agilent Technologies, Stockport UK) according to manufacturer’s instructions. Stable A7r5/hHO-1 cell lines were achieved by antibiotic selection with 1mg/ml G-418, added to the medium 3 days after transfection. Selection was applied for 3-4 weeks (media changed every 4-5 days),
after which time individual colonies were isolated. To isolate individual clones, first the cells were washed with PBS, the top of the T75 flask broken and removed, and individual colonies enclosed with a greased cloning ring. Specifically, 200μl 0.05% trypsin-EDTA was added to each ring for 2 minutes then neutralised with an equal volume of FCS, gently triturated and subsequently transferred to an upright T25 and allowed to reach confluence. Next, cells were harvested by trypsinization and then transferred to T75 flasks for further culture and examination of hHO-1 expression. Generation of the pcDNA3.1/Neo (hHO-1) construct and A7r5/hHO-1 cell line was performed by Dr Jason L. Scragg.

Four clones were screened via western blotting for the HO-1 protein, and a clone which demonstrated a high level of HO-1 overexpression was chosen for further experiments. A7r5/hHO-1 cells were compared to control A7r5 cells via proliferation assays and monitoring of [Ca\(^{2+}\)] responses by microfluorimetry, (as described previously), with or without HO-1 induction with 10μM CoPPIX.

2.12 Cell Transfection with HO-1-targeting siRNA
HSVSMCs were transfected using hHO-1-targeting siRNA (sc-35554; Santa Cruz Biotechnology, Santa Cruz USA). Numerous parameters needed to be confirmed in order to optimise the cell transfection protocol including which concentration of HO-1 siRNA produced the optimal mRNA knock-down, how long the mRNA knock-down would last, and as the HMOX1 gene is inducible, at what time-point the CoPPIX should be added to the cells.

2.12.1 Transfection Protocol for a 6 well plate
HSVSMCs were plated in four wells of a 6-well plate at 1x10\(^5\) cells/well (as determined by previous experiments) in complete growth medium without penicillin/streptomycin, and allowed to attach overnight. Mock and transfected cell groups were utilised. Mock groups were subjected to all transfection reagents with the exception of siRNA. On the day of transfection, Optimem (Invitrogen, Cambridge UK) and 0.4% FCS-containing media without penicillin/streptomycin were pre-warmed to 37°C. Lipofectamine 2000® (Invitrogen, Cambridge UK) was used as the transfection reagent. The transfection solutions for a 6-well plate format are shown in tables 2.9-2.11. Tubes 1 and 2 were prepared separately, mixed gently, and left to stand for 5 minutes at RT. Tubes 1 and 2 were then combined and left to stand for 20 minutes at RT. Tube 3 was then added to
the solution and mixed gently. Media was removed from the cells, followed by a PBS wash, and 1.5ml of the appropriate solution (Mock or Transfected) was then added to each well. After 6 hours in a humidified incubator (37°C; 95% air, 5% CO₂), the transfection media was removed and replaced with complete growth medium and the cells were then incubated for 2 days. Cell lysates were removed at the end of the incubation period using 200µl M-PER™ plus Complete Mini protease inhibitor per well. The plate was rocked for 30 minutes at RT. The wells were then scraped using a cell scraper, the lysates collected and centrifuged on a short spin for 10 seconds, and then frozen at -20°C until required for western blotting.

<table>
<thead>
<tr>
<th>Cell Group</th>
<th>Tube 1</th>
<th>Tube 2</th>
<th>Tube 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>10µM siRNA</td>
<td>Optimem</td>
<td>Lipofectamine</td>
<td>Optimem</td>
</tr>
<tr>
<td>Mock</td>
<td>-</td>
<td>375µl</td>
<td>5µl</td>
</tr>
<tr>
<td>Transfected</td>
<td>15µl</td>
<td>360µl</td>
<td>5µl</td>
</tr>
</tbody>
</table>

Table 2.9 Transfection volumes per well of each experimental group using 100nM siRNA

<table>
<thead>
<tr>
<th>Cell Group</th>
<th>Tube 1</th>
<th>Tube 2</th>
<th>Tube 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>10µM siRNA</td>
<td>Optimem</td>
<td>Lipofectamine</td>
<td>Optimem</td>
</tr>
<tr>
<td>Mock</td>
<td>-</td>
<td>375µl</td>
<td>5µl</td>
</tr>
<tr>
<td>Transfected</td>
<td>7.5µl</td>
<td>367.5µl</td>
<td>5µl</td>
</tr>
</tbody>
</table>

Table 2.10 Transfection volumes per well of each experimental group using 50nM siRNA

<table>
<thead>
<tr>
<th>Cell Group</th>
<th>Tube 1</th>
<th>Tube 2</th>
<th>Tube 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>10µM siRNA</td>
<td>Optimem</td>
<td>Lipofectamine</td>
<td>Optimem</td>
</tr>
<tr>
<td>Mock</td>
<td>-</td>
<td>375µl</td>
<td>5µl</td>
</tr>
<tr>
<td>Transfected</td>
<td>3.75µl</td>
<td>371.25µl</td>
<td>5µl</td>
</tr>
</tbody>
</table>

Table 2.11 Transfection volumes per well of each experimental group using 25nM siRNA
2.12.2 First transfection – determination of optimal HO-1-targeting siRNA
Transfection was performed in 6-well plates to evaluate the efficiency of mRNA knock-down using 25nM, 50nM, and 100nM siRNA following the protocol stated above, and protein knockdown verified by western blotting of protein lysates at 48 hours post transfection.

2.12.3 Second transfection – determination of the period of gene knock-down
Once the optimal concentration of siRNA had been determined, the experiment was performed once again, but over 4 days to determine the maximal time frame of mRNA knockdown. At day 2, the media and CoPPIX were replenished. Protein lysates were prepared sequentially each day for 4 days.

2.12.4 Proliferation assay post-transfection
Once the time period of gene knockdown and optimal siRNA concentration had been established, the transfection was performed in 24-well plates. Initially cells were plated at 1x10^4 cells/well, prior to a 4 day proliferation assay in which cells were counted daily. Cells were plated in parallel at 1x10^5 in 6 well plates to retrieve protein lysates for western blotting at days 2 and 4. The transfection protocol was performed as stated in 2.12.1, but with a smaller volume of 300µl transfection media per well for the 24 well plate format. The transfection solutions for a 24-well plate are stated in table 2.12.

<table>
<thead>
<tr>
<th>Cell Group</th>
<th>Tube 1</th>
<th>Tube 2</th>
<th>Tube 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10µM siRNA</td>
<td>Optimem</td>
<td>Lipofectamine</td>
</tr>
<tr>
<td>Mock</td>
<td>-</td>
<td>75µl</td>
<td>1µl</td>
</tr>
<tr>
<td>Transfected</td>
<td>1.5µl</td>
<td>73.5µl</td>
<td>1µl</td>
</tr>
</tbody>
</table>

Table 2.12 Transfection volumes per well of each experimental group using 100nM siRNA

2.13 Cell Transfection with Ca,3.1-targeting siRNA
Preliminary RT-PCR was performed on cDNA from A7r5 cells to determine the expression level of Ca,3.2 and Ca,3.1 T-type Ca^{2+} channels, and to screen β2microglobulin (β2M) and hypoxanthine phosphoribosyltransferase 1 (HPRT1) as possible housekeeper genes. Once expression levels were known, and the appropriate
housekeeper gene chosen, cells were transfected using ON-TARGETplus SMARTpool rat CACNA1G siRNA (Dharmacon, Waltham USA). The protocol described in section 2.12.1 was followed, with the exception of the final step as cells were retrieved using trypsin, the activity of which was halted with ice-cold PBS, and the cells stored in 100µl RNAlater® until RNA generation.

2.13.1 First transfection – determination of optimal Ca₃.₁-targeting siRNA concentration

Three concentrations of Ca₃.₁-targeting siRNA were employed; 25nM, 50nM and 100nM, and all cells retrieved at 48 hours post-transfection. The transfection volumes for a 6-well plate format are shown in tables 2.13-2.15. Dharmafect 2 (Dharmacon, Waltham USA) was utilised as the transfection reagent, as gene knock-down proved unsuccessful when Lipofectamine 2000® was utilised.

<table>
<thead>
<tr>
<th>Cell Group</th>
<th>Tube 1</th>
<th>Tube 2</th>
<th>Tube 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5µM siRNA</td>
<td>Optimem</td>
<td>Dharmafect 2</td>
</tr>
<tr>
<td>Mock</td>
<td>-</td>
<td>200µl</td>
<td>3.5µl</td>
</tr>
<tr>
<td>Transfected</td>
<td>20µl</td>
<td>180µl</td>
<td>3.5µl</td>
</tr>
</tbody>
</table>

Table 2.13 Volumes for 50nM siRNA transfection for 1 well of each experimental group.

<table>
<thead>
<tr>
<th>Cell Group</th>
<th>Tube 1</th>
<th>Tube 2</th>
<th>Tube 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5µM siRNA</td>
<td>Optimem</td>
<td>Dharmafect 2</td>
</tr>
<tr>
<td>Mock</td>
<td>-</td>
<td>200µl</td>
<td>3.5µl</td>
</tr>
<tr>
<td>Transfected</td>
<td>10µl</td>
<td>190µl</td>
<td>3.5µl</td>
</tr>
</tbody>
</table>

Table 2.14 Volumes for 25nM siRNA transfection for 1 well of each experimental group.
<table>
<thead>
<tr>
<th>Cell Group</th>
<th>Tube 1</th>
<th>Tube 2</th>
<th>Tube 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>5µM siRNA</td>
<td>Optimem</td>
<td>Dharmafect 2</td>
<td>Optimem</td>
</tr>
<tr>
<td>Mock</td>
<td>-</td>
<td>200µl</td>
<td>3.5µl</td>
</tr>
<tr>
<td>Transfected</td>
<td>4µl</td>
<td>196µl</td>
<td>3.5µl</td>
</tr>
</tbody>
</table>

Table 2.15 Volumes for 10nM siRNA transfection for 1 well of each experimental group.

### 2.13.2 Second transfection – determination of the period of gene knock-down

A 3 day time-course was then performed with 50nM Ca,3.1-targeting siRNA. This concentration was chosen on the basis of adequate knock-down, as demonstrated by RT-PCR. The cell transfection process was performed as described above, in 6-well plates and 24-well plates. Post-transfection, cells were counted daily from a 24-well plate, and retrieved daily for RT-PCR from both 6-well and 24-well plates, for a total of three days. The volumes for a 24-well plate are given in table 2.16. An untransfected cell group, which contained 0.4% FCS medium only, was also included in this experiment to determine whether any minor fluctuations seen with the housekeeper were due to the transfection process or a natural occurrence for this cell line.

<table>
<thead>
<tr>
<th>Cell Group</th>
<th>Tube 1</th>
<th>Tube 2</th>
<th>Tube 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>5uM siRNA</td>
<td>Optimem</td>
<td>Dharmafect 2</td>
<td>Optimem</td>
</tr>
<tr>
<td>Mock</td>
<td>-</td>
<td>50µl</td>
<td>1µl</td>
</tr>
<tr>
<td>Transfected</td>
<td>5µl</td>
<td>45µl</td>
<td>1µl</td>
</tr>
<tr>
<td>Untransfected</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 2.16 Volumes for 50nM siRNA transfection for 1 well of each experimental group.

### 2.14 Drugs

Table 2.17 outlines all the drugs used in experiments. Figure legends in results chapters provide more specific details.
<table>
<thead>
<tr>
<th>Reagent</th>
<th>Solvent</th>
<th>Storage</th>
<th>Concentration used</th>
</tr>
</thead>
<tbody>
<tr>
<td>CoPPIX</td>
<td>100mM NaOH</td>
<td>Freezer -20°C,</td>
<td>0.1 - 30 μM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>dark</td>
<td></td>
</tr>
<tr>
<td>Hemin</td>
<td>100mM NaOH</td>
<td>Freezer -20°C,</td>
<td>1 - 100 μM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>dark</td>
<td></td>
</tr>
<tr>
<td>QC-15</td>
<td>Distilled water</td>
<td>Freezer -20°C</td>
<td>10 μM</td>
</tr>
<tr>
<td>Mibefradil</td>
<td>Distilled water</td>
<td>Freezer -20°C</td>
<td>0.3 - 30 μM</td>
</tr>
<tr>
<td>NNC55-0396</td>
<td>Distilled water</td>
<td>Freezer -20°C</td>
<td>3 μM</td>
</tr>
<tr>
<td>Nickel</td>
<td>Distilled water</td>
<td>Made fresh</td>
<td>1 - 250 μM</td>
</tr>
<tr>
<td>Nifedipine</td>
<td>100% Ethanol/DMSO</td>
<td>Freezer -20°C,</td>
<td>0.5 - 4 μM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>dark</td>
<td></td>
</tr>
<tr>
<td>CORM-3</td>
<td>Distilled water</td>
<td>Freezer -20°C</td>
<td>1 - 60 μM</td>
</tr>
<tr>
<td>iCORM-3</td>
<td>Distilled water</td>
<td>Freezer -20°C</td>
<td>1 - 60 μM</td>
</tr>
</tbody>
</table>

Table 2.17 Drugs used in experiments

**2.15 Statistical Analysis**

Statistical analysis was performed using GraphPad Prism 6. Data are presented as mean ± standard error of the mean (s.e.m.). With regards to proliferation assay data, in some cases there was large variation in Day 0 counts, which impacted on the Day 3 or Day 4 comparisons. A higher Day 0 count inevitably resulted in a much higher end of assay count due to the exponential growth of the cells. In order to compare equivalent proliferative responses, the cell counts were normalised to Day 0 counts. This data was then transformed using the Y=log(Y) function, and the statistical analysis performed on this transformed data. Statistical significance is displayed on graphs showing the original, untransformed data. Ratio repeated measures one-way ANOVA was performed on concentration response curve data, with Dunnett’s or Bonferroni’s multiple comparison test as appropriate. With regards to time-course proliferation data, each proliferation curve was normalised, transformed, and then analysed by a two-way repeated measures ANOVA, with sample matching by time point. This was followed by Sidak’s multiple comparison test between control and treated groups for each time point.

Samples from individual western blotting experiments were processed on the same gel, and run on duplicate gels within the same electrophoresis tank. The amount of protein loaded was maximised in every instance, but varied between experiments. The time...
spent developing the films was also another source of variation, as this was dependent on how fresh the developer was, and also how much protein was loaded. Therefore, the use of repeated measures ANOVA is not appropriate for this data. HO-1 and β-actin levels of each gel lane were expressed as percentage area of the total blot, then HO-1 normalised to the corresponding β-actin. Densitometry data from western blots was analysed via one-way ANOVA, with Dunnett’s or Bonferroni’s multiple comparison test as appropriate.

All microfluorimetry data was analysed by two-tailed, paired t-test, excluding data in Figures 4.15, 4.16, 4.17, 5.2, 5.7, and 5.11, which was analysed via one-way ANOVA followed by Tukey’s multiple comparison test. The 200s integrals from 80mM K+ experiments on A7r5 cells were analysed by one-way ANOVA with Bonferroni’s multiple comparison test. The corresponding sections of the bar graph were then shown in separate figures, as the data are presented systematically based on the drug used. RT-PCR data was analysed by one-way ANOVA, or two-way ANOVA, as appropriate, with Bonferroni’s multiple comparison test.
CHAPTER 3

The role of T-type Ca\textsuperscript{2+} channels in cell proliferation and the inhibitory effects of CO and HO-1

3.1 Introduction

HO-1 is an inducible, stress-response protein that has cytoprotective effects within the vasculature, as discussed in detail in Chapter 1. HO-1 induction has been linked with many favourable effects on cardiovascular pathology; it is anti-oxidative, anti-apoptotic, anti-inflammatory, anti-proliferative, and it promotes vasodilation (Kim et al., 2011b). Each of the by-products of HO-1 induction have positive attributes, yet CO is able to mediate the vast majority of these protective effects (Wu & Wang, 2005). Heme proteins are cellular targets of CO, one of which is sGC. Activation of sGC by CO is one pathway through which CO mediates its cytoprotective effects, another is via p38/MAPK activation (Kim et al., 2006). The emerging topic of gasotransmitter regulation of ion channels links CO to alternative cellular targets. CO has been shown to be a modulator of numerous ion channels producing variable physiological effects (Peers, 2011; Wilkinson & Kemp, 2011; Peers & Steele, 2012). Our research group has made a novel discovery, that of Ca\textsubscript{v}3.2 T-type Ca\textsuperscript{2+} current inhibition by CORM-2, and these currently unpublished findings led to this PhD project. The experimental use of CORMs has further validated our understanding that CO is a cytoprotective molecule at low doses (Motterlini et al., 2003). T-type Ca\textsuperscript{2+} channels have proven to be central to cell proliferation in cancer (Taylor et al., 2008), to be involved in de-differentiation of mouse embryonic stem cells (Rodriguez-Gomez et al., 2012), and in disorders involving VSMCs (Rodman et al., 2005; Cribbs, 2006; Pluteanu & Cribbs, 2011).

HEK293 cells have been used as a model system to over-express T-type Ca\textsuperscript{2+} channel subtypes. This cell line offers a simple system in which to investigate the physiological effects of T-type Ca\textsuperscript{2+} channel expression and their modulation. HEK293 cells engineered to over-express the Ca\textsubscript{v}3.2 T-type Ca\textsuperscript{2+} channel (HEK293/Ca\textsubscript{v}3.2 cells) were used in this project, as the Ca\textsubscript{v}3.2 channel sub-type has been described as the most prominent cardiovascular sub-type (Cribbs, 2006). HEK293/Ca\textsubscript{v}3.2 cells are an ideal cell line in which to explore the role of the Ca\textsubscript{v}3.2 T-type Ca\textsuperscript{2+} channel in proliferation as the WT HEK293 cells act as an adequate control cell line. Experiments...
were carried out on HEK293/Ca₃.2 and WT HEK293 cells to examine the effects of T-type Ca²⁺ channel inhibition, CO availability, and HO-1 induction on cell proliferation and [Ca²⁺]. Three compounds were used to inhibit T-type Ca²⁺ channels. Mibefradil, first described as Ro 40-5967, is a T-type Ca²⁺ channel antagonist, and was found to inhibit T-type Ca²⁺ currents after dihydropyridine abolition of L-type Ca²⁺ currents in rat smooth muscle cells (Mishra & Hermansmeyer, 1994). The structure of mibefradil has been modified to produce a compound named NNC55-0396, which has higher selectivity for T-type Ca²⁺ channels over L-Type Ca²⁺ channels, given that no detectable inhibition of L-type Ca²⁺ currents was detected using 100µM NNC55-0396 (Huang et al., 2004). NNC55-0396 has also been employed here, in addition to Ni²⁺. Ni²⁺ has been demonstrated as a selective T-type Ca²⁺ channel inhibitor, with varying affinities for the different channel subtypes, and the Ca₃.2 subtype exhibiting the highest sensitivity (Lee et al., 1999). The effect of CO was examined using CORM-3. CORMs are transition metal carboxyls that release CO by various mechanisms; CORM-3 releases CO by ligand substitution (Foresti et al., 2008). CORM-3 has a biological ligand incorporated into the molecular structure, resulting in a less toxic compound that is water soluble, and therefore more compatible with experiments involving live cells, (Motterlini et al., 2003), which is the reason for using CORM-3 in these experiments. The metalloporphyrin cobalt protoporphyrin IX (CoPPIX) was used to induce HO-1 as it does not act as a substrate for the enzyme, unlike hemin (Shan et al., 2000).

It is evident that HO-1 is important in cardiovascular health, the product CO can exert anti-proliferative effects, and also appears to be capable of modulating T-type Ca²⁺ channel function. T-type Ca²⁺ channels themselves have a role in the maintenance of [Ca²⁺], and cell proliferation (Gray et al., 2004). Therefore, in disorders of the vasculature, where excess VSMC proliferation is a shaping feature of vessel integrity, could T-type Ca²⁺ channels be a target of stress-induced HO-1?

3.2 Results

3.2.1 Characterisation of HEK293/Ca₃.2 cells

Immunocytochemistry was performed on the two cell lines to provide evidence of the difference in expression of Ca₃.2 T-type Ca²⁺ channels. Figure 3.1 demonstrates the
Figure 3.1 Identification of the Ca_{3.2} T-type Ca^{2+} channel in HEK293 cells

Immunocytochemistry of HEK293/Ca_{3.2} cells (P7) and WT HEK293 cells (P2) labelled with anti-Ca_{3.2} (green) from Alomone (panels A and D respectively), with anti-Ca_{3.2} from Santa Cruz (panels B and E respectively), and control without primary antibody (panels C and F respectively). Cell nuclei were stained blue with DAPI. Panels (A-C) are representative images of 6 fields of view from n=3 experimental repeats. Panels (D-F) are representative images of 4 fields of view from n=2 experimental repeats.
presence of Ca\textsubscript{v}3.2 channels in HEK293/Ca\textsubscript{v}3.2 cells and WT HEK293 cells using two different antibodies. Applying the Ca\textsubscript{v}3.2 antibody from Alomone, the image in panel (A) shows the Ca\textsubscript{v}3.2 T-type Ca\textsuperscript{2+} channel to be located throughout the cell, with nuclear puncta also visible. Using the Ca\textsubscript{v}3.2 antibody from Santa Cruz, the image in panel (B) shows the Ca\textsubscript{v}3.2 T-type Ca\textsuperscript{2+} channel to be denser at the cell membrane, with graded expression through the cytoplasm towards the nuclei. Images of WT HEK293 cells are shown in Figure 3.1, panels (D-F). Some isolated nuclear staining can be seen in panel (D) which exhibits the Ca\textsubscript{v}3.2 antibody from Alomone. However, no staining is visible in panel (E) showing the Ca\textsubscript{v}3.2 antibody from Santa Cruz.

Basal levels of [Ca\textsuperscript{2+}] in the two cell lines were assessed by microfluorimetry. Figure 3.2 shows the changes in [Ca\textsuperscript{2+}] levels in response to normal (Ca\textsuperscript{2+}-containing) or Ca\textsuperscript{2+}-free buffer. The representative trace of HEK293/Ca\textsubscript{v}3.2 cells in panel (A), shows a significant change in [Ca\textsuperscript{2+}], when the cells were subjected to Ca\textsuperscript{2+}-free buffer. In contrast, there were minimal changes in [Ca\textsuperscript{2+}], in WT HEK293, shown in panel (B). The mean data in the bar graph in panel (C) demonstrate that HEK293/Ca\textsubscript{v}3.2 cells (grey bars) have a significantly higher basal level of [Ca\textsuperscript{2+}], than WT HEK293 cells (white bars) when subjected to normal buffer. The HEK293/Ca\textsubscript{v}3.2 cells also demonstrated a larger response to Ca\textsuperscript{2+}-free buffer compared to WT HEK293 cells; [Ca\textsuperscript{2+}] was reduced by 12% and 4% respectively.

Proliferation assays were performed to assess the growth characteristics of both HEK293/Ca\textsubscript{v}3.2 and WT HEK293 cells, to determine whether over-expression of the Ca\textsubscript{v}3.2 channel could influence cell proliferation. Figure 3.3 shows the differences in the growth characteristics of the two cell lines. The HEK293/Ca\textsubscript{v}3.2 cells (grey bars) proliferated at a significantly faster rate over the three day assay than the WT HEK293 cells (white bars). Indeed, the over-expression of the Ca\textsubscript{v}3.2 T-type Ca\textsuperscript{2+} channel augments proliferation, in addition to providing a route for an enhanced level of [Ca\textsuperscript{2+}].

### 3.2.2 The effect of T-type Ca\textsuperscript{2+} channel inhibition on [Ca\textsuperscript{2+}], and proliferation

To examine the effects of T-type Ca\textsuperscript{2+} channel inhibition on basal [Ca\textsuperscript{2+}], 3\textmu M mibefradil was assessed by microfluorimetry. The representative trace shown in Figure 3.4 (A) demonstrates the significant decrease in [Ca\textsuperscript{2+}], caused by 3\textmu M mibefradil in
Figure 3.2 HEK293/Ca,3.2 cells have elevated basal [Ca\textsuperscript{2+}]\textsubscript{i} levels

Representative traces of HEK293/Ca,3.2 and WT HEK293 cells (A and B respectively) illustrate the disparate basal [Ca\textsuperscript{2+}]\textsubscript{i} levels in these two cell lines, and the different magnitude of the decrease in [Ca\textsuperscript{2+}]\textsubscript{i} in response to Ca\textsuperscript{2+}-free buffer. The bar graph (C) shows the mean (± s.e.m.) basal [Ca\textsuperscript{2+}]\textsubscript{i} levels in response to normal and Ca\textsuperscript{2+}-free buffers. Data were analysed by one-way ANOVA with Bonferroni's multiple comparison test; * p<0.05, *** p<0.001 as indicated above. n=108, r.u.=ratio units, s=seconds.
Figure 3.3 Augmented proliferation of HEK293/Ca\textsubscript{3.2} cells

Bar graph showing the higher fold increase in cell number of HEK293/Ca\textsubscript{3.2} cells compared to WT HEK293 cells, over a 3-day proliferation assay. Data are represented as fold increase (± s.e.m.), and were analysed by a two-tailed paired t-test, * p<0.05, n=7.
Figure 3.4 Treatment with 3µM mibefradil reduces [Ca^{2+}]_i in HEK293/Ca_{v}3.2 cells

Representative traces showing the effect of 3µM mibefradil on basal [Ca^{2+}]_i levels in HEK293/Ca_{v}3.2 (A) and WT HEK293 cells (B). Bar graphs showing the mean (± s.e.m.) decrease in Fura 2 ratio in HEK293/Ca_{v}3.2 cells (C) and WT HEK293 cells (D) when 3µM mibefradil was added to the normal buffer. Data were analysed by a two-tailed paired t-test, *** p<0.001, n=6.
HEK293/Ca$_v$3.2 cells. In contrast, Figure 3.4 (B) shows there is no effect of 3µM mibebradil on [Ca$^{2+}$] in WT HEK293 cells. The slight and insignificant increase in Fura 2 ratio in WT HEK293 cells over time can be attributed to the natural behaviour of the cells during the experimental conditions, as it was noted that the Fura 2 ratio had a tendency to drift when the cells were constantly exposed to normal buffer. The bar graphs in Figure 3.4 (C) and (D) demonstrate the mean changes in [Ca$^{2+}$] in response to mibebradil. [Ca$^{2+}$], was reduced by 12% in HEK293/Ca$_v$3.2 cells, with no significant reduction in WT HEK293 cells. Proliferation assays were performed with the addition of 3µM mibebradil to determine whether inhibition of the Ca$_v$3.2 T-type Ca$^{2+}$ channel would subsequently inhibit cell proliferation. The IC$_{50}$ of Ca$_v$3.2 current inhibition in HEK293/Ca$_v$3.2 cells by mibebradil has been quoted to range between 1.1µM and 1.4µM (Cribbs et al., 1998; Martin et al., 2000). Although, the optimal concentration of mibebradil required to significantly inhibit proliferation, as determined from previous concentration response curves performed within our research group, was 3µM. Figure 3.5 shows the inhibition of HEK293/Ca$_v$3.2 proliferation by mibebradil on day 3 of the assay. 3µM mibebradil inhibited HEK293/Ca$_v$3.2 cell proliferation by 26% over the 3 day period. There was no significant difference in the proliferation of WT HEK293 cells.

The effect of NNC55-0396, a more selective T-type Ca$^{2+}$ channel blocker, on [Ca$^{2+}$], was also investigated. The IC$_{50}$ of NNC55-0396 for HEK293/Ca$_v$3.2 cells is stated to be 7µM (Huang et al., 2004). However, a preliminary proliferation assay involving HEK293/Ca$_v$3.2 and WT HEK293 cells revealed NNC55-0396 was more potent than mibebradil; and the drug was cytotoxic at concentrations above 5µM. Therefore, concentrations ranging from 1-3µM were tested using microfluorimetry, and 3µM was selective for HEK293/Ca$_v$3.2 cells. Figure 3.6 (A) demonstrates there was a significant decrease in [Ca$^{2+}$] in HEK293/Ca$_v$3.2 cells in response to 3µM NNC55-0396, with no effect in WT HEK293 cells as shown in 3.6 (B). The bar graph in Figure 3.6 (C) shows a 12% decrease in [Ca$^{2+}$], caused by 3µM NNC55-0396 in HEK293/Ca$_v$3.2 cells. Regarding WT HEK293 cells, Figure 3.6 (D) shows there is no significant reduction in the mean Fura 2 ratio with the addition of NNC55-0396.

The effect of Ni$^{2+}$, a differentially selective T-type Ca$^{2+}$ channel blocker, was also investigated. The IC$_{50}$ for Ni$^{2+}$ in HEK293/Ca$_v$3.2 cells has been quoted to be 13µM.
Figure 3.5 Mibefradil inhibits proliferation of HEK293/Ca\textsubscript{3.2} cells

Bar graphs showing the mean (± s.e.m.) cell number of HEK293/Ca\textsubscript{3.2} cells (A) and WT HEK293 cells (B). 3µM mibefradil inhibited HEK293/Ca\textsubscript{3.2} cell proliferation on day 3 with no effect on WT HEK293 cells. Data were analysed by a two-tailed paired t-test * p<0.05, n=3.
Figure 3.6 Treatment with 3µM NNC55-0396 reduces $[\text{Ca}^{2+}]_i$ in HEK293/Ca$_{3.2}$ cells

Representative traces showing the effect of 3µM NNC55-0396 on $[\text{Ca}^{2+}]_i$ levels in HEK293/Ca$_{3.2}$ (A) and WT HEK293 cells (B). Bar graphs showing the mean (± s.e.m.) decrease in Fura 2 ratio in HEK293/Ca$_{3.2}$ cells (C) and WT HEK293 cells (D) when 3µM NNC55-0396 is added to the normal buffer. Data were analysed by a two-tailed paired t-test ** p<0.001, n=8.
In these experiments 30µM Ni^{2+} was utilised to ensure Ca_{v3.2} channel block. Figure 3.7 (A) demonstrates that 30µM Ni^{2+} significantly decreases \([\text{Ca}^{2+}]_{i}\) in HEK293/Ca_{v3.2} cells, in contrast to the lack of effect in WT HEK293 cells (B). The mean data shown in the bar graph in Figure 3.7 (C) illustrate that 30µM Ni^{2+} reduced \([\text{Ca}^{2+}]_{i}\) by 11%. Figure 3.7 (D) shows mean \([\text{Ca}^{2+}]_{i}\) was unchanged in the presence of 30µM Ni^{2+} in WT HEK293 cells.

In summary, inhibition of the Ca_{v3.2} Ca^{2+} channel by Ni^{2+} NNC55-0396, and mibebradil decreases \([\text{Ca}^{2+}]_{i}\), and the latter also significantly inhibits augmented proliferation of HEK293/Ca_{v3.2} cells, with no effect on WT HEK293 cells.

### 3.2.3 The effect of CO on \([\text{Ca}^{2+}]_{i}\) and proliferation

It has been previously demonstrated by our research group, using the patch-clamp technique, that CORM-2 can inhibit the Ca_{v3.2} T-type Ca^{2+} current. The effect of CORM-3 on basal \([\text{Ca}^{2+}]_{i}\) in HEK293/Ca_{v3.2} cells was assessed in this project by microfluorimetry, in order to validate such a novel finding using an alternative technique. A concentration of 3µM CORM-3 was employed in microfluorimetry experiments as this was the lowest concentration that was able to selectively reduce \([\text{Ca}^{2+}]_{i}\) in HEK293/Ca_{v3.2} cells over WT HEK293 cells, after testing the effects of 1, 3, 10 and 30µM CORM-3. Figure 3.8 (A) shows a representative trace of the HEK293/Ca_{v3.2} cells in response to 3µM CORM-3; \([\text{Ca}^{2+}]_{i}\) was significantly reduced by CO, in contrast to the lack of effect seen in WT HEK293 cells in panel (B). The bar graphs in panels (C) and (D) show the mean data; the presence of 3µM CORM-3 reduced \([\text{Ca}^{2+}]_{i}\) in HEK293/Ca_{v3.2} cells by 11%. There was minimal change in Fura 2 ratio in WT HEK293 cells in response to CORM-3. The proliferation assays in panels (E) and (F) were produced by Dr Hannah E. Boycott previous to this PhD project. Panel (E) shows the proliferative response of HEK293/Ca_{v3.2} cells to CORM-3 and iCORM-3, inactivated CORM-3, over a 3 day proliferation assay. There was a significant inhibition of HEK293/Ca_{v3.2} cell proliferation by 3µM CORM-3, but not iCORM-3, demonstrating that CO has anti-proliferative effects in this cell line. Panel (F) shows the proliferative response of WT HEK293 cells to CORM-3 and iCORM-3 over a 3 day proliferation assay. The proliferation of WT HEK293 cells was not affected by CO, implying that CO is able to modulate the Ca_{v3.2} T-type Ca^{2+} channel, which subsequently inhibits cell proliferation. Figure 3.9 shows the effect of 3µM iCORM-3 on \([\text{Ca}^{2+}]_{i}\). The representative trace of HEK293/Ca_{v3.2} cells in panel (A) shows an unexpected,
Figure 3.7 Treatment with 30μM Ni^{2+} reduces [Ca^{2+}]_{i} in HEK293/Ca_{v}3.2 cells

Representative traces showing the effect of 30μM Ni^{2+} on [Ca^{2+}]_{i} levels in HEK293/Ca_{v}3.2 (A) and WT HEK293 cells (B). Bar graphs showing the mean (± s.e.m.) decrease in Fura 2 ratio in HEK293/Ca_{v}3.2 cells (C) and WT HEK293 cells (D) when 30μM Ni^{2+} is added to the normal buffer. Data were analysed by a two-tailed paired t-test ** p<0.001, n=6.
Figure 3.8 The effect of CORM-3 on $[\text{Ca}^{2+}]_i$, and proliferation

Representative traces showing the effect of $3\mu\text{M}$ CORM-3 on $[\text{Ca}^{2+}]_i$ levels in HEK293/Ca$_3.2$ (A) and WT HEK293 cells (B). Bar graphs showing the mean ($\pm$ s.e.m.) decrease in Fura 2 ratio in HEK293/Ca$_3.2$ cells (C) and WT HEK293 cells (D) when $3\mu\text{M}$ CORM-3 is added to the normal buffer. Data were analysed by a two-tailed paired t-test, *** $p<0.001$, $n=6$. Line graphs showing mean ($\pm$ s.e.m.) cell number monitored in HEK293/Ca$_3.2$ (E) and WT HEK293 (F) cells. Cells were cultured in the absence of drugs (solid circles), or in the presence of either CORM-3 (30$\mu\text{M}$; open circles) or iCORM (30$\mu\text{M}$ solid triangles), ** $p<0.01$, $n=3$. The data in panels (E) and (F) was generated by Dr Hannah E. Boycott.
Figure 3.9 The effect of 3µM iCORM-3 on [Ca^{2+}]_i.

Representative traces showing the effect of 3µM iCORM-3 on [Ca^{2+}]_i levels in HEK293/Ca_{3.2} (A) and WT HEK293 cells (B). Bar graphs showing the mean (± s.e.m.) Fura 2 ratio in HEK293/Ca_{3.2} cells (C) and WT HEK293 cells (D) when 3µM iCORM-3 is added to the normal buffer. Data were analysed by a two-tailed paired t-test, * p<0.05, n=6.
significant decrease in $[\text{Ca}^{2+}]$, with a 7% reduction of mean Fura 2 ratio in the presence of iCORM-3. This is shown in panel (C). $[\text{Ca}^{2+}]$ was unchanged by iCORM-3 in WT HEK293 cells, which is demonstrated by the representative trace in panel (B), and the mean data in panel (D). In summary, CO is able to inhibit the Ca$_{\text{v}3.2}$ T-type Ca$^{2+}$ channel, with a subsequent reduction in $[\text{Ca}^{2+}]$ and inhibition of proliferation.

3.2.4 The effect of HO-1 induction on $[\text{Ca}^{2+}]$, and proliferation

Immunocytochemistry was performed to demonstrate the induction of HO-1 by CoPPIX. Figure 3.10 (A) illustrates how HO-1 is induced by 10µM CoPPIX, and panel (B) illustrates HO-1 induction by 10µM hemin in HEK293/Ca$_{\text{v}3.2}$ cells. Panel (D) shows that HO-1 is induced by 3µM CoPPIX, and panel (E) illustrates HO-1 induction by 3µM hemin in WT HEK293 cells. There is minimal staining in panel (F), which shows the control image without induction. As the DAPI could not be visualised at this time, it is unclear as to where the cells are localised in Figure 3.10 (F).

A range of CoPPIX concentrations were applied to the cells for a 48h period to assess the corresponding level of HO-1 induction via western blotting, and subsequently decide on an adequate concentration to use in microfluorimetry experiments. Figure 3.11 (A) demonstrates that HO-1 was induced in HEK293/Ca$_{\text{v}3.2}$ cells to a level of 55 ± 11.50% of β-actin using 10µM CoPPIX, compared to 1.2 ± 0.14% the control group. Panel (B) shows a representative western blot of HO-1 protein with the corresponding β-actin loading control underneath. Figure 3.12 (A) demonstrates that HO-1 was induced in WT HEK293 cells to a level of 49.06 ± 12.90% of β-actin by 7µM, and 40.07 ± 20.16% by 10µM CoPPIX, vs 2.42 ± 2.30% for the control group. However, analysis via one-way ANOVA demonstrated a P value of 0.0647. Panel (B) shows a representative western blot of HO-1 protein with the corresponding β-actin loading control underneath.

To investigate whether the CO produced as a result of HO-1 induction could affect $[\text{Ca}^{2+}]$ levels, the cells were subjected to normal and Ca$^{2+}$-free buffers after a 48h incubation with CoPPIX. Disparate concentrations of 10µM and 3µM CoPPIX were applied to HEK293/Ca$_{\text{v}3.2}$ cells and WT HEK293 cells respectively. These
Figure 3.10 Identification of HO-1 induction in HEK293 cells

Immunocytochemistry of HEK293/Ca₃.2 cells (P7) labelled with anti-HO-1 (green) after a 48h incubation with 10µM CoPPIX (panel A), with 10µM Hemin (panel B), and control without induction (panel C). Cell nuclei were stained blue with DAPI. Immunocytochemistry of WT HEK293 cells (P4) labelled with anti-HO-1 after a 24h incubation with 3µM CoPPIX (panel D), with 3µM Hemin (panel E), and control without induction (panel F). At the time of images D-F being taken, visualisation of DAPI was unavailable. Panels (A-C) are representative images of 10 fields of view from n=5. Panels (D-F) are representative images of 6 fields of view from n=3 experimental repeats.
Figure 3.1 CoPPIX induces HO-1 protein expression in HEK293/CaV3.2 cells

Bar graph showing the mean (± s.e.m.) relative HO-1 protein expression in HEK293/CaV3.2 cells after normalisation of densitometric analyses relative to β-actin. (A). Data were analysed by one-way ANOVA with Dunnett’s multiple comparison test, * p<0.05 vs control levels n=3. Representative Western Blot of HO-1 and the corresponding β-actin loading control (B). The arrows represent the position of the molecular weight markers (top, 37KDa; bottom, 25kDa).
Figure 3.12 CoPPIX induces HO-1 protein expression in WT HEK293 cells

Bar graph showing the mean (± s.e.m.) relative HO-1 protein expression in WT HEK293 cells after normalisation of densitometric analyses relative to β-actin (A), n=3. Representative Western Blot of HO-1 and the corresponding β-actin loading control (B). The arrows represent the position of the molecular weight markers (top, 37KDa; bottom, 25kDa).
concentrations produced optimal HO-1 induction in the corresponding cell types, as determined from the data in Figures 3.11 and 3.12. Figure 3.13 (A) shows representative traces of experimental repeats. HEK293/Ca\textsubscript{v}3.2 cells from both the control group and the CoPPIX treated group (black and blue traces respectively), aligned side by side on the same axis. Panel (B) shows the corresponding traces from WT HEK293 cells. Panels (C) and (D) show the mean data of control and CoPPIX treated groups for HEK293/Ca\textsubscript{v}3.2 and WT HEK293 cells respectively. Concerning HEK293/Ca\textsubscript{v}3.2 cells, it is demonstrated in both panels (A) and (C) that basal [Ca\textsuperscript{2+}] was significantly lower in cells following HO-1 induction when compared to the control group. The mean Fura 2 ratio was 12% less in CoPPIX treated HEK293/Ca\textsubscript{v}3.2 cells. The response of the control group to Ca\textsuperscript{2+}-free buffer showed a significant reduction in [Ca\textsuperscript{2+}], in contrast the HO-1 group did not respond significantly; there was a 10% reduction compared to a 7% reduction in [Ca\textsuperscript{2+}], respectively. Panels (B) and (D) in Figure 3.13 show minimal changes in [Ca\textsuperscript{2+}] in WT HEK293 cells in response to HO-1 induction using 3\muM CoPPIX.

To investigate the effect of HO-1 induction, and therefore subsequent CO production, on cellular proliferation, a concentration-response curve to the HO-1 inducer, CoPPIX, was performed. Figure 3.14 (A) shows the effect of CoPPIX on HEK293/Ca\textsubscript{v}3.2 cell proliferation. 10\muM CoPPIX significantly inhibited cell proliferation, demonstrating a 27% decrease in cell number. Panel (B) shows the effect of CoPPIX on WT HEK293 cell proliferation. 10\muM CoPPIX surprisingly also inhibited the proliferation of WT cells, demonstrating a 79% reduction in cell number. However, it was observed that WT HEK293 cells became less viable when subjected to 10\muM CoPPIX, which undoubtedly contributed to the lower cell counts. From this point in the experiments it was decided that corresponding cell media would also be processed alongside trypsinised cells, and any cells present counted and documented as floating, non-viable cells. Graphs containing this data are shown from Chapter 4 onwards.

In summary, HO-1 induction requires a higher concentration of CoPPIX in HEK293/Ca\textsubscript{v}3.2 cells than WT HEK293 cells, which is reflected by western blots and proliferation assays. HO-1 induction significantly decreased [Ca\textsuperscript{2+}] in HEK293/Ca\textsubscript{v}3.2 cells, implying HO-1-derived CO is also able to inhibit the Ca\textsubscript{v}3.2 T-type Ca\textsuperscript{2+} channel.
Figure 3.13 Treatment with CoPPIX reduces [Ca^{2+}]_{i} in HEK293/Ca_{v}3.2 cells

Data showing the effects of a 48h pre-treatment with CoPPIX (blue traces and bars), in comparison to control cells without HO-1 induction (black traces and bars). Representative traces of HEK293/Ca_{v}3.2 cells (A) plus or minus incubation with 10µM CoPPIX. Representative traces of WT HEK293 cells (B) plus or minus incubation with 3µM CoPPIX. Bar graphs showing the mean (± s.e.m.) Fura 2 ratio in HEK293/Ca_{v}3.2 (C) n=16, and WT HEK293 cells (D) n=12, in response to Ca^{2+}-containing buffer and Ca^{2+}-free buffer. Data were analysed by one-way ANOVA with Bonferroni’s multiple comparison test, *** p<0.001, ** p<0.01.
Figure 3.14 HO-1 induction by CoPPIX inhibits cell proliferation

Bar graphs showing the mean (± s.e.m.) day 3 cell number of HEK293/Ca,3.2 cells (A) and WT HEK293 cells (B) in response to increasing concentrations of CoPPIX. Data were analysed by ratio repeated measures one-way ANOVA with Dunnett’s multiple comparison test, *** p<0.001, ** p<0.01 vs day 3 control, n=3.
3.3 Discussion

The images in Figure 3.1 illustrate the differing T-type Ca\textsuperscript{2+} channel expression levels between the two cell lines. The Ca\textsubscript{3.2} antibody from Alomone appears less specific as the image in panel (A) of both figures display varying degrees of punctate nuclear staining. The use of focus imaging, or Z-stack imaging, would be useful to allow greater depth of field and more specific localisation of the Ca\textsubscript{3.2} T-type Ca\textsuperscript{2+} channels in question. The use of HEK293/Ca\textsubscript{3.2} cells at P7 in this figure demonstrates that expression of the Ca\textsubscript{3.2} T-type Ca\textsuperscript{2+} channel is maintained at the older passages employed in the experiments shown in this chapter.

An important property of the Ca\textsubscript{3.2} T-type Ca\textsuperscript{2+} channel noted from these experiments is the influence this channel has on cell proliferation, as illustrated in Figure 3.3. The HEK293/Ca\textsubscript{3.2} cells proliferated at a faster rate than the WT HEK293 cells over the course of the assay. This enhanced proliferation by the HEK293/Ca\textsubscript{3.2} cells can be significantly inhibited by mibefradil, giving further integrity to the idea that T-type Ca\textsuperscript{2+} channels play a significant role in proliferation. A previous study, (Chemin et al., 2000), reported no proliferative advantage of the Ca\textsubscript{3.2} T-type Ca\textsuperscript{2+} channel using the same HEK293/Ca\textsubscript{3.2} cells as detailed in this project. This study by Chemin et al. assessed proliferation via bromodeoxyuridine (BrdU) labelling. While this is an established assay for detecting BrdU incorporation into DNA, it is an indirect assessment of proliferation (Taupin, 2007). The method of cell counting employed in this PhD project is a direct measure of proliferation. However, these negative findings were contradicted by a later study from the same group, in which they describe a direct, non-linear relationship between Ca\textsuperscript{2+} entry by the Ca\textsubscript{3.2} T-type Ca\textsuperscript{2+} channel, and proliferation of HEK293/Ca\textsubscript{3.2} cells (Gray et al., 2004). Together with another study, they link the augmented proliferation of HEK293/Ca\textsubscript{3.2} cells to a cell cycle control mechanism (Wang et al., 2002b). They describe a Ca\textsuperscript{2+} threshold that must be achieved in order to trigger an all or nothing proliferative response through the G\textsubscript{1}/S cell cycle boundary. T-type Ca\textsuperscript{2+} currents have been strongly linked to specific cell cycle phases, with proliferating cells evidenced as having a higher level of expression of T-type Ca\textsuperscript{2+} channels, and a larger proportion of T-type Ca\textsuperscript{2+} currents in the G\textsubscript{1} and S phases of the cell cycle (Kuga et al., 1996). As the cell cycle requires Ca\textsuperscript{2+} signalling to progress (Ciapa et al., 1994), the T-type Ca\textsuperscript{2+} channel could provide the route through which proliferating cells maintain adequate [Ca\textsuperscript{2+}]\textsubscript{i} levels. The window current associated with
T-type Ca\(^{2+}\) channels is due to a proportion of these channels remaining open during the resting membrane potential of the cell, allowing Ca\(^{2+}\) to move in (Crunelli et al., 2005). The disparate expression levels of the Ca\(_{3.2}\) T-type Ca\(^{2+}\) channel between HEK293/Ca\(_{3.2}\) and WT HEK293 cells, as shown in Figure 3.1, is consistent with the differing steady state levels of [Ca\(^{2+}\)], as shown in Figure 3.2, which can be attributed to the window current available in HEK293/Ca\(_{3.2}\) cells. HEK293/Ca\(_{3.2}\) cells displayed a higher level of basal [Ca\(^{2+}\)]\(_i\), together with a more pronounced response to Ca\(^{2+}\)-free buffer compared to WT HEK293 cells. The reduction of [Ca\(^{2+}\)] by various T-type Ca\(^{2+}\) channel blockers; mibefradil, NNC55-0396, and Ni\(^{2+}\), in HEK293/Ca\(_{3.2}\) cells but not in WT HEK293 cells, demonstrates that WT HEK cells express low levels of T-type Ca\(^{2+}\) channels, if any at all, and implicates the Ca\(_{3.2}\) T-type Ca\(^{2+}\) channel as being responsible for the higher basal [Ca\(^{2+}\)]\(_i\) levels. In keeping with this idea, the effect of mibefradil on the proliferation of HEK293/Ca\(_{3.2}\) cells, but not WT HEK293 cells, implicates the Ca\(_{3.2}\) T-type Ca\(^{2+}\) channel as a determining factor of proliferation. The effects of mibefradil on T-type Ca\(^{2+}\) current inhibition in HEK293/Ca\(_{3.2}\) cells have been previously studied, with IC\(_{50}\) values quoted at 1.4µM (Cribbs et al., 1998), and 1.1µM (Martin et al., 2000). Although the extent of Ca\(_{3.2}\) current inhibition appears to depend upon the charge carrier, Ca\(^{2+}\) or Ba\(^{2+}\), and also on temperature; the IC\(_{50}\) values increased with a shift from room temperature to physiological temperature (Martin et al., 2000). As stated previously, mibefradil also inhibits L-type Ca\(^{2+}\) channels (Eller et al., 2000). However, the concentration required to inhibit L-Type Ca\(^{2+}\) channels has been reported to be at least 10-fold higher than that for T-type Ca\(^{2+}\) channels (Bezprozvanny & Tsien, 1995; Martin et al., 2000). Mibebradil has been shown to block L-type Ca\(^{2+}\) channels at higher concentrations; with an IC\(_{50}\) of 12.9µM in HEK293/Ca\(_{1.2}\) cells (Martin et al., 2000). Given the fact that this chapter is concerned with data from HEK293 cells over-expressing the Ca\(_{3.2}\) channel, any effects of mibebradil on L-Type Ca\(^{2+}\) channels are likely to be insignificant. Concerning the effects of Ni\(^{2+}\), the level of [Ca\(^{2+}\)] begins to recover as the buffer is changed back to normal buffer, as shown in Figure 3.7 (A). In contrast to NNC55-0396, inhibition by Ni\(^{2+}\) is reversible (Lee et al., 1999; Kang et al., 2006), and if a longer wash-out period, or if a lower [Ni\(^{2+}\)] closer to the IC\(_{50}\) of 13µM had been employed in these experiments, the restoration in Ca\(_{3.2}\) T-type Ca\(^{2+}\) channel function may have been demonstrated. The possibility of reversible Ca\(_{3.2}\) T-type Ca\(^{2+}\) channel inhibition by mibebradil was not assessed in these experiments, yet this has been shown previously (Martin et al., 2000).
Preliminary data gathered by Dr H. E. Boycott prior to this PhD project demonstrate that CO, delivered via CORM-3, is anti-proliferative. Figure 3.8, in concordance with Figure 3.3, show that the HEK293/Ca\textsubscript{3.2} cells proliferated at a faster rate than WT HEK293 cells, and that CO is able to inhibit this proliferation. The molecular backbone of CORM-3 that remains post CO release, namely iCORM-3, was shown to have no effect on proliferation, which supports existing studies demonstrating that CO is anti-proliferative in rat aortic VSMCs (Togane et al., 2000; Peyton et al., 2002; Peyton et al., 2002), in human airway smooth muscle cells (Song et al., 2002), in HO-1 transduced primary rat VSMCs, and primary mouse HO-1\textsuperscript{−/−} smooth muscle cells (Otterbein et al., 2003b). CO also significantly reduced [Ca\textsuperscript{2+}]\textsubscript{i} levels in HEK293/Ca\textsubscript{3.2} cells, which validates the notion that CO acts by inhibiting the Ca\textsubscript{3.2} T-type Ca\textsuperscript{2+} channel, as WT HEK293 cells were unaffected. However, iCORM-3 did also reduce [Ca\textsuperscript{2+}]\textsubscript{i} levels in HEK293/Ca\textsubscript{3.2} cells. This could be attributed to incomplete inactivation of CORM-3.

To inactivate the CORM-3 solution, which was made up with distilled water, the solution was exposed to the atmosphere for 48h to allow CO to be released. An alternative method to ensure complete inactivation would be to dissolve solid CORM-3 in Dulbecco’s PBS as opposed to water, and then leave exposed for 48h (Motterlini et al., 2003). However, the iCORM-3 employed by Dr H. E. Boycott in the proliferation assay was also made with distilled water. It is possible that any CO still available within the iCORM-3 solution was enough to produce a significant effect when applied acutely and monitored via Ca\textsuperscript{2+} microfluorimetry, which is essentially a snapshot of a short window of activity. iCORM-3 applied chronically over a proliferation assay did not produce any significant effects therefore, implying that any residual CO cannot prevent the level of [Ca\textsuperscript{2+}]\textsubscript{i} from falling below the required threshold to trigger cell cycle progression and proliferation, as discussed previously (Wang et al., 2002b; Gray et al., 2004). Together with the preliminary proliferation data produced by Dr H. E. Boycott, the effect of CORM-3 on [Ca\textsuperscript{2+}]\textsubscript{i} levels in HEK293/Ca\textsubscript{3.2} cells demonstrates a novel finding that CO appears to inhibit the Ca\textsubscript{3.2} T-type Ca\textsuperscript{2+} channel. This was investigated further by utilising the HEK293 HO-1 system to assess the effects of endogenous CO production.

CoPPIX successfully induced HO-1 in both HEK293/Ca\textsubscript{3.2} and WT HEK293 cells, as illustrated by immunocytochemistry in Figure 3.10. The cellular location of HO-1 in these images appears to be generally cytoplasmic, with no clear organelle locale. In HEK293 cells, HO-1 has been localised to the nucleus (Lin et al., 2007), whereas in other cell types, HO-1 has been localised to caveolae (Kim et al., 2004), mitochondria...
(Converso et al., 2006), and the endoplasmic reticulum where it is synthesised (Shibahara et al., 1980). Figure 3.13 shows that HO-1 induction by 10µM CoPPIX significantly reduced basal [Ca^{2+}] in HEK293/Ca_{3.2} cells. Additionally, the response of the HO-1 group to Ca^{2+}-free buffer was lower than that of the control group. These data imply the window current was smaller as a result of HO-1 induction, which could be attributed to CO-mediated inhibition of the Ca_{3.2} T-type Ca^{2+} channels. The disparate concentrations of CoPPIX used to induce optimally, HO-1 in HEK293/Ca_{3.2} and WT HEK293 cells, is a limitation of the experiment. However, these concentrations were selected based on western blotting data in Figures 3.11 and 3.12, to ensure HO-1 was induced without cytotoxicity as a result of CoPPIX exposure.

The proliferative profile in response to CoPPIX in HEK293/Ca_{3.2} cells inversely correlates to the profile of HO-1 induction by CoPPIX, as validated by the increased expression of the HO-1 protein, shown in Figures 3.14 (A) and 3.11 respectively. However, there was no clear concentration-response to CoPPIX in WT HEK293 cells, shown in Figure 3.12, and HO-1 was also induced to higher levels than in HEK293/Ca_{3.2} cells. The pattern of HO-1 induction, and the extent of the physiological effect, was visibly different between the two cell lines. The proliferation of HEK293/Ca_{3.2} cells was reduced by 27% with 10µM CoPPIX, compared to a reduction of 79% by 10µM CoPPIX in WT HEK293 cells. One possible explanation for the fact that WT HEK293 cells are more susceptible to the effects of HO-1 induction than HEK293/Ca_{3.2} cells could be that the level of CO produced by HO-1 induction may not be as effective at inhibiting the Ca_{3.2} T-type Ca^{2+} channel when it is vastly over-expressed. There could be a proportion of Ca_{3.2} T-type Ca^{2+} channels that are unaffected by the available CO, which would leave a proportion of Ca_{3.2} T-type Ca^{2+} channels free to function normally. The window current would be active at these channels, and therefore CO inhibition at other Ca_{3.2} T-type Ca^{2+} channels would be ineffective at reducing [Ca^{2+}], to a level that would fall short of the threshold trigger of the G_{1}/S cell cycle boundary, in order to subsequently prevent proliferation, as discussed earlier (Wang et al., 2002b;Gray et al., 2004).

An alternative explanation for the differing effects of CoPPIX could be that the WT HEK293 cells were simply more sensitive to this compound, and other effects were unsubstantiated. It is feasible that the HEK293/Ca_{3.2} cells are more robust due to their stable transfection. In WT HEK293 cells, there was a visible reduction in
proliferation by 3µM CoPPIX, albeit statistically non-significant. In contrast, HO-1 induction by 3µM CoPPIX had no effect on [Ca^{2+}]_i in WT HEK293 cells. These data imply that HO-1 induction, and subsequent CO production, inhibit proliferation by an alternative mechanism to Ca_{v3.2} T-type Ca^{2+} channel inhibition, as the immunocytochemistry in Figure 3.2 shows that there are no Ca_{v3.2} T-type Ca^{2+} channels to inhibit. Although, the most plausible explanation is that CoPPIX is cytotoxic at concentrations higher than 3µM in WT HEK293 cells, and had any floating cells in the media been counted, this theory would have been corroborated. With regards to how CoPPIX induces HO-1, it appears that a region of DNA upstream of the murine HO-1 gene is the convergence point for the different signalling pathways from numerous HO-1 inducers, including hemin and CoPPIX (Alam et al., 1995). It has also been demonstrated in chick embryonic liver cells that the response element for HO-1 induction by heme and CoPPIX differs from that of stress inducers such as heavy metals (Shan et al., 2000; Shan et al., 2002). The signalling pathway in human liver cells involves down-regulation of Bach1 and up-regulation of Nrf2 transcription factors (Shan et al., 2006). In summary, the induction pathways of HO-1 appear to be complex and specific to the type of inducer.

It is unknown how the levels of CO produced via CoPPIX induction of HO-1 correlate to those produced by CORM-3 addition. Micromolar concentrations of CORM-3 are deemed to be comparable to endogenous CO (Foresti et al., 2004). Conversely, it has been suggested that the exposure to exogenous, gaseous, CO would provide higher levels of CO than would be available as a result of HO-1 induction (Foresti et al., 2008). The fact that proliferation was inhibited to a greater extent by CORM-3 than by HO-1 induction in HEK293/Ca_{v3.2} cells, suggests more CO was available following CORM-3 exposure. It has also been suggested that a positive feedback loop exists within the HO-1/CO pathway, and that CO can directly induce the expression of HO-1 (Lee et al., 2006; Kim et al., 2007). This could explain why the more pronounced effects on proliferation were seen with CORM-3 exposure.

In conclusion, the data shown here demonstrate indirectly, that the Ca_{v3.2} T-type Ca^{2+} channel can be inhibited by T-type Ca^{2+} channel antagonists, CO via CORM-3, and HO-1 induction. The effects of which manifest as inhibition of HEK293/Ca_{v3.2} cell proliferation, and appear to be linked to the window current associated with T-type Ca^{2+} channels. The T-type Ca^{2+} channel window current is evidently the underlying
mechanism maintaining adequate $[\text{Ca}^{2+}]_i$ levels for numerous physiological processes. These include signal amplification in thalamacortical neurons, (Williams et al., 1997), human myoblast fusion (Bijlenga et al., 2000), and neuroendocrine differentiation of human prostate cancer cells, (Mariot et al., 2002). There is also a wealth of data linking T-type Ca$^{2+}$ channels currents to the pathological proliferation that underlies cancer development (Panner et al., 2005; Panner & Wurster, 2006; Zhang et al., 2012). In addition, the T-type Ca$^{2+}$ current has been linked to the proliferation of primary aortic VSMCs; as the VSMCs become more confluent, the percentage of T-type Ca$^{2+}$ current decreases, and the percentage of L-type current increases (Akaike et al., 1989). This led to investigations into a role for T-type Ca$^{2+}$ channels in pathological proliferation of VSMCs, reviewed by Cribbs, (2006). Therefore, to explore the effect of CO on the T-type Ca$^{2+}$ channel in a more physiologically relevant model, a smooth muscle cell line was employed with the aim of assessing relevant findings in the context of data previously published on the anti-proliferative effects of CO in the vasculature (Morita et al., 1997; Togane et al., 2000; Song et al., 2002; Otterbein et al., 2003b; Raman et al., 2006; Zuckerbraun et al., 2006; Ramlawi et al., 2007). This is examined in Chapter 4.
CHAPTER 4

Characterisation of Ca\(^{2+}\) channels in A7r5 cells

4.1 Introduction

VSMCs undergo a phenotypic switch, from a contractile to a proliferative state, in response to vascular injury (House et al., 2008). This phenotypic switch is accompanied by an up-regulation of T-type Ca\(^{2+}\) channels, and a down-regulation of L-type Ca\(^{2+}\) channels (Akaike et al., 1989; Richard et al., 1992; Kuga et al., 1996; Rodman et al., 2005; House et al., 2008). Pharmacological inhibition of T-type Ca\(^{2+}\) channels has been shown to inhibit cell proliferation in rat VSMCs (Schmitt et al., 1995), human lung adenocarcinoma cells (Heo et al., 2008), mouse glioblastoma cells (Keir et al., 2012), and human glioblastoma cells (Schmitt et al., 1995; Heo et al., 2008; Keir et al., 2012; Zhang et al., 2012). Moreover, the maintenance of adequate [Ca\(^{2+}\)]\(_i\) levels is central to the progression of the cell cycle (Ciapa et al., 1994). The window current of T-type Ca\(^{2+}\) channels may be an important route through which [Ca\(^{2+}\)]\(_i\) is maintained in proliferating cells; in VSMCs the window current is active at resting the membrane potential (-40mV to -55mV), providing a continuously functioning route of Ca\(^{2+}\) entry into the de-differentiated cells (Richard & Nargeot, 1998).

In order to study the effects of T-type Ca\(^{2+}\) channel modulation in the context of vascular biology, a VSMC line was employed. A7r5 cells are VSMCs that were originally isolated from embryonic rat aorta (Kimes & Brandt, 1976), and they have been shown to express both T- and L-type Ca\(^{2+}\) channels (Brueggemann et al., 2005). A7r5 cell depolarisation using the vasoconstrictor vasopressin has been utilised to demonstrate the occurrence of Ca\(^{2+}\) oscillations in these cells (Otun et al., 1992; Brueggemann et al., 2005). Ca\(^{2+}\) oscillations within VSMCs promote a depolarising current that advances to neighbouring VSMCs via gap junctions, which synchronises a change in VSMC tone along the vessel (Peng et al., 2001). The A7r5 cell line appears to be an ideal model in which to assess the contribution of T-type Ca\(^{2+}\) channels to changes of [Ca\(^{2+}\)]\(_i\), in addition to the proliferative response.
4.2 Results

4.2.1 Characterisation of A7r5 cells

Immunocytochemistry was performed on A7r5 cells to confirm their smooth muscle cell properties. Figure 4.1 illustrates positive staining for smooth muscle α-actin (panel A), smooth muscle myosin heavy chain (panel B), and vimentin (panel C). In addition, co-localisation of smooth muscle α-actin and myosin heavy chain can be seen in panel Figure 4.1 (F), as demonstrated by the orange staining across the cells. All images in Figure 4.1 were produced from cells at the same passage, and using the same microscopy settings. The images in Figure 4.1 panels (D-F) were modified to the same extent by reducing the contrast in order to effectively discern the positive staining when the images were printed onto paper. The presence of T-type Ca²⁺ channels was also demonstrated by immunocytochemistry. Figure 4.2 shows positive staining for Ca₃.1 and Ca₃.2, with denser staining of Ca₃.1 appearing in peri-nuclear regions. Anti-Ca₃.1 and Ca₃.2 antibodies sourced from Alomone were used to assess channel expression in A7r5 cells and human VSMC, as these antibodies produced consistent data upon experimental repeats. Demonstration of the presence of T-type Ca²⁺ channels by western blotting proved difficult; Figure 4.3 (A) shows the only successful identification of Ca₃.1 from membrane enriched A7r5 samples, with HEK293/Ca₃.1 cells used as the positive control. Figure 4.3 (B) shows the wide variation in mRNA expression levels of Ca₃.1 from eleven samples of A7r5 cells, from five passages ranging from P2 to P6, as determined by RT-PCR. There was no correlation between passage number and degree of channel expression. Figure 4.4 shows the mRNA expression levels of Ca₃.2, which was expressed at lower levels than Ca₃.1, and Ca₃.2 was undetected in some samples. Figure 4.5 shows example responses of A7r5 cells to 20mM K⁺ buffer. This level of raised extracellular [K⁺] was employed to cause modest depolarisation of the cell membranes, and therefore preferentially augment T-type voltage-gated Ca²⁺ channel activity. The example trace in panel (A) illustrates both the increase in [Ca²⁺], and the appearance of Ca²⁺ oscillations when A7r5 cells were exposed to 20mM K⁺ buffer. The change in Fura 2 ratio for each of the three exposures to 20mM K⁺ buffer is shown in panel (B). There was no significant difference between the first and second exposures. However, the response to 20mM K⁺ buffer decreased on each subsequent exposure which is demonstrated by the significant difference in the change in Fura 2 ratio between exposure 1 and exposure 3. It was decided that only exposures 1 and 2 would be used in analyses of subsequent traces involving the assessment of a drug or compound. Panel (C) shows the spike frequency (i.e. the number of oscillations per second) for each exposure to 20mM K⁺
Figure 4.1 Characterisation of A7r5 cells

Immunocytochemistry of A7r5 cells showing staining for smooth muscle α-actin (red) (A), myosin heavy chain (green) (B), and vimentin (red) (C). The images in panels (D-F) were generated from simultaneous incubation with anti-smooth muscle α-actin and anti-myosin heavy chain antibodies; Panel (D) shows smooth muscle α-actin (red), panel (E) shows myosin heavy chain (green), and panel (F) shows smooth muscle α-actin and myosin heavy chain co-localisation. The contrast of images (D-F) was reduced by 15 units in order to distinguish the staining when the image is printed. Cell nuclei were stained blue with DAPI. Cells were utilised at P6, and are representative images of 4 fields of view from n=2 experimental repeats.
Figure 4.2 T-type Ca\(^{2+}\) channel expression in A7r5 cells

Immunocytochemistry of A7r5 cells showing staining for Ca\(_{v}3.1\) (green) (A), and for Ca\(_{v}3.2\) (green) (B). Antibodies sourced from Alomone. Panel (C) shows a control image without primary antibody. Cell nuclei were stained blue with DAPI. Cells were utilised at P4, and are representative images of 14 fields of view from \(n=7\) experimental repeats.
Figure 4.3 Expression of the Ca\textsubscript{v}3.1 T-type Ca\textsuperscript{2+} channels in A7r5 cells

Panel (A) shows the only successful western blot of the Ca\textsubscript{v}3.1 T-type Ca\textsuperscript{2+} channel, using anti-Ca\textsubscript{v}3.1 antibody (Alomone), in various cell samples tested (A7r5: membrane enriched A7r5; HEK/Ca\textsubscript{v}3.1: HEK293/Ca\textsubscript{v}3.1 cells, positive control). The arrow represents the position of the 250kDa molecular weight marker. Below is the corresponding β-actin loading control blot. Panel (B) shows a bar graph of Ca\textsubscript{v}3.1 mRNA expression, relative to the endogenous control, HPRT1 (hypoxanthine phosphoribosyltransferase 1), in eleven samples of A7r5 cells from five different passages, as indicated by the x-axis label. The inset bar graph shows the A7r5 samples with lower expression levels not clearly visible on the main bar graph. Samples were analysed in triplicate and represented as mean ± s.e.m.
Figure 4.4 Expression of the Ca\textsubscript{v}3.2 T-type Ca\textsuperscript{2+} channel in A7r5 cells

Bar graph of Ca\textsubscript{v}3.2 mRNA expression, relative to the endogenous control, HPRT1. Twelve samples of A7r5 cells were analysed for Ca\textsubscript{v}3.2 mRNA expression, and the channel was detectable in four samples from three passages, as indicated by the x-axis label. Samples were analysed in triplicate and represented as mean ± s.e.m.
Figure 4.5 20mM K⁺ buffer causes Ca²⁺ oscillations and an increase in \([\text{Ca}^{2+}]_i\).

(A) Representative control trace showing the response of A7r5 cells to 20mM K⁺ buffer. The switch from normal buffer (Ca²⁺-containing) to 20mM K⁺ buffer causes a rapid increase in \([\text{Ca}^{2+}]_i\), and Ca²⁺ oscillations, as shown by the three exposures. (B) Trend graph showing the change in Fura 2 ratio for the three exposures to 20mM K⁺ buffer. (C) Trend graph showing the change in spikes/s for the three exposures to 20mM K⁺ buffer. Data were analysed by one-way ANOVA with Bonferroni's multiple comparison test, ** p<0.01, n=12.
buffer. There were no significant differences between exposures 1-3. Figure 4.6 shows the minimal change in \([\text{Ca}^{2+}]\) when extracellular \(\text{Ca}^{2+}\) is removed; Fura 2 ratio was reduced by 4%, which is representative of a small window current. Figure 4.7 (A) shows the response of A7r5 cells to 80mM K\(^+\) buffer. This level of extracellular [K\(^+\)] was used to strongly depolarise the cell membranes, and thereby stimulate \(\text{Ca}^{2+}\) influx preferentially via L-type \(\text{Ca}^{2+}\) channels. There was a rapid increase in \([\text{Ca}^{2+}]\), as 80mM K\(^+\) buffer was applied, which slowly declined during continued depolarisation, presumably because the L-type \(\text{Ca}^{2+}\) channels inactivate. Figure 4.7 (B) shows that removal of extracellular \(\text{Ca}^{2+}\) causes an almost complete loss of this response, as predicted, since \(\text{Ca}^{2+}\) was not available to move into the cell. Panel (C) shows the mean integrated response of five experiments, illustrated by Figure 4.7 (A) and (B).

In summary, \(\text{Ca}_{v}3.1\) is the more prominent T-type \(\text{Ca}^{2+}\) channel in A7r5 cells. A7r5 cells produce \(\text{Ca}^{2+}\) oscillations in response to 20mM K\(^+\) buffer, and rapid increases in \([\text{Ca}^{2+}]\), in response to both 20mM and 80mM K\(^+\) buffer, implicating the presence of both T- and L-type \(\text{Ca}^{2+}\) channels in A7r5 cells.

**4.2.2 The contribution of T-type and L-type \(\text{Ca}^{2+}\) channels to evoked \([\text{Ca}^{2+}]\), responses in A7r5 cells**

Mibebradil was employed to assess the changes in \([\text{Ca}^{2+}]\), as a result of T-type \(\text{Ca}^{2+}\) channel inhibition. After an initial exposure to 20mM K\(^+\) buffer, 3µM mibebradil was applied prior to, and throughout, the second exposure, which subsequently inhibited \([\text{Ca}^{2+}]\), by 58%, and also inhibited \(\text{Ca}^{2+}\) oscillations, as shown in Figure 4.8 (A). Unexpectedly, the responses of \([\text{Ca}^{2+}]\), to 80mM K\(^+\) buffer were also significantly reduced by 65% in the presence of 3µM mibebradil, as shown by the example trace and the mean integral in Figure 4.9.

The effect of Ni\(^{2+}\), a differentially selective T-type \(\text{Ca}^{2+}\) channel blocker, was also investigated. As the \(\text{Ca}_{v}3.1\) \(\text{Ca}^{2+}\) channel is the dominant subtype in A7r5 cells, the inhibitory effects of Ni\(^{2+}\) on \(\text{Ca}_{v}3.1\) channel activity in HEK293/\(\text{Ca}_{v}3.1\) cells were assessed within our research group using whole-cell patch clamp recordings. Peak current-voltage (I-V) relationship curves in response to a range of Ni\(^{2+}\) concentrations are shown in Figure 4.10, and were generated by Dr Jacobo Elies. The IC\(_{50}\) was found
Figure 4.6 The response of $[\text{Ca}^{2+}]_i$ on exposure to Ca$^{2+}$-free extracellular buffer

Representative trace showing the response of A7r5 cells to Ca$^{2+}$-free buffer (A). Bar graph of mean (± s.e.m.) Fura 2 ratio in response to Ca$^{2+}$-containing and Ca$^{2+}$-free extracellular buffer (B). Data were analysed by a two-tailed paired t-test, *** $p<0.001$, $n=3$. 
Figure 4.7 80mM K⁺ buffer causes a rapid increase in [Ca²⁺].

Representative control trace showing the response of A7r5 cells to cell depolarisation by 80mM K⁺ (A), exhibited as an increase in Fura 2 ratio. This is the control condition to which subsequent drug applications will be compared to. Representative trace showing the minimal change in [Ca²⁺] in response to 80mM K⁺/Ca²⁺-free buffer (B). Bar graph showing the mean (± s.e.m.) integral of the responses evoked by 80mM K⁺ or 80mM K⁺/Ca²⁺ free buffer (C). Data were analysed by one-way ANOVA, *** p<0.001, n=5.
Figure 4.8 3μM mibefradil inhibits $[\text{Ca}^{2+}]_i$ and $\text{Ca}^{2+}$ oscillations

Representative trace showing the response of A7r5 cells to 20mM K⁺ buffer in the presence of 3μM mibefradil (A). Panel (B) shows a trend graph of the decrease in Fura 2 ratio in response to 20mM K⁺ buffer followed by 20mM K⁺ buffer in the presence of 3μM mibefradil. Panel (C) shows a trend graph of the decrease in spikes/s for exposure to 20mM K⁺ buffer followed by 20mM K⁺ buffer in the presence of 3μM mibefradil. The mean (± s.e.m.) response is shown to the right and left of the corresponding individual data points on each graph. Data were analysed by a two-tailed paired t-test, **) p<0.01, n=5. mib. = mibefradil
Figure 4.9 Response to 80mM K\(^+\) buffer containing 3µM mibefradil

Representative trace showing the change of [Ca\(^{2+}\)]\(_i\) in response to 80mM K\(^+\) buffer (A) and the reduced response to 80mM K\(^+\) containing 3µM mibefradil (B). Bar graph showing the mean (± s.e.m.) integral of the curves produced in response to 80mM K\(^+\) buffer (control), and 80mM K\(^+\) buffer containing 3µM mibefradil (C). Data were analysed by one-way ANOVA, *** p<0.001, n=5.
**Figure 4.10 Inhibitory effects of Ni$^{2+}$ on Ca$_{3.1}$ channels**

Representative peak I-V curves showing control and Ni$^{2+}$ treated HEK293/Ca$_{3.1}$ cells. Peak I-V relationships were measured by stepping from a holding potential of -80mV to voltages between -110mV and +50mV in 10mV increments for 100ms each. Data generated by Dr Jacobo Elies.
to be 289 ± 11.3µM (n=3). Preliminary experiments investigating the effect of 250µM Ni²⁺ demonstrated the complete abolition of the response to 20mM K⁺ buffer. Therefore, a lower concentration of 30µM Ni²⁺ was utilised to assess the effects of low level T-type Ca²⁺ channel inhibition without producing off-target effects on L-type Ca²⁺ channels. Figure 4.11 shows the effects of 30µM Ni²⁺. Mean [Ca²⁺], was significantly reduced by 37% via 30µM Ni²⁺, yet Ca²⁺ oscillations were not significantly affected. The presence of 30µM Ni²⁺ did not alter the response to 80mM K⁺ buffer; the mean curve integral was comparable to that of the control cells, as shown in Figure 4.12.

Nifedipine was employed to assess the effects of L-type Ca²⁺ channel inhibition on [Ca²⁺], with the aim of establishing which responses could be attributed solely to T-type Ca²⁺ channel activity. The representative trace in Figure 4.13 (A) shows that 2µM nifedipine reduces the response to 20mM K⁺ buffer by 60%, and completely abolishes the Ca²⁺ oscillations. Figure 4.14 demonstrates that nifedipine also significantly inhibited the response to 80mM K⁺ buffer. The mean curve integral was reduced by 68% in the presence of 2µM nifedipine.

The simultaneous addition of 2µM nifedipine and 3µM mibefradil completely prevented the response to 20mM K⁺ buffer. There was no rise in [Ca²⁺], and no Ca²⁺ oscillations, as shown in Figure 4.15. Application of mibefradil and nifedipine, individually or simultaneously, significantly prevented an increase of [Ca²⁺], and the combined effect of both compounds on [Ca²⁺] was significantly different from each individual effect, as shown in Figure 4.15 (D). Simultaneous addition of 2µM nifedipine and 3µM mibefradil inhibited a significant rise in [Ca²⁺], in response to 80mM K⁺ buffer, as shown in Figure 4.16. The mean curve integral was reduced by 92%, which is comparable to the response to Ca²⁺-free 80mM K⁺ buffer, suggesting essentially all voltage-gated Ca²⁺ channels were blocked, as expected. However, the combined effect of both compounds on [Ca²⁺] was not significantly different from each individual effect, as shown in Figure 4.16 (C). Application of 2µM nifedipine and 30µM Ni²⁺, individually or simultaneously, significantly prevented an increase of [Ca²⁺], and completely abolished the oscillatory response to 20mM K⁺ buffer, as shown in Figure 4.17. Although, the combined effect of both compounds on [Ca²⁺] was not significantly different from each individual effect, as shown in Figure 4.17 (D). Concerning the oscillation frequency, Ni²⁺ caused no significant effect on the response to 20mM K⁺
Figure 4.11 30μM Ni^{2+} inhibits [Ca^{2+}], but not Ca^{2+} oscillations

Representative trace showing the response of A7r5 cells to 20mM K^{+} buffer in the presence of 30μM Ni^{2+} (A). Panel (B) shows a trend graph of the decrease in Fura 2 ratio in response to 20mM K^{+} buffer followed by 20mM K^{+} buffer in the presence of 30μM Ni^{2+}. Panel (C) shows a trend graph of the change in spikes/s for exposure to 20mM K^{+} buffer followed by 20mM K^{+} buffer in the presence of 30μM Ni^{2+}. The mean (± s.e.m.) response is shown to the right and left of the corresponding individual data points on each graph. Data were analysed by a two-tailed paired t-test, *** p<0.001, n=6.
Figure 4.12 Response to 80mM K⁺ buffer containing 30µM Ni²⁺

Representative trace showing the change of [Ca²⁺] in response to 80mM K⁺ buffer (A) and in response to 80mM K⁺ buffer containing 30µM Ni²⁺ (B). Bar graph showing the mean (± s.e.m.) integral of the curves produced in response to 80mM K⁺ buffer (control), and 80mM K⁺ buffer containing 30µM Ni²⁺ (C), n=6.
Figure 4.13 2µM nifedipine inhibits $[\text{Ca}^{2+}]_i$ and $\text{Ca}^{2+}$ oscillations

Representative control trace showing the response of A7r5 cells to 20mM K+ buffer in the presence of 2µM nifedipine (A). Trend graph showing the decrease in Fura 2 ratio in response to 20mM K+ buffer followed by 20mM K+ buffer in the presence of 2µM nifedipine. (B). Trend graph showing the decrease in spikes/s in response to 20mM K+ buffer followed by 20mM K+ buffer in the presence of 2µM nifedipine (C). The mean (± s.e.m.) response is shown to the right and left of the corresponding individual data points on each graph. Data were analysed by a two-tailed paired t-test, ** p<0.01, *** p<0.001, n=5. nif. = nifedipine
Figure 4.14 Response to 80mM K⁺ buffer containing 2µM nifedipine

Representative trace showing the change of [Ca²⁺] in response to 80mM K⁺ buffer (A) and the decreased response to 80mM K⁺ buffer containing 2µM nifedipine (B). Bar graph showing the mean (± s.e.m.) integral of the curves produced in response to 80mM K⁺ buffer (control), and 80mM K⁺ buffer containing 2µM nifedipine (C). Data were analysed by one-way ANOVA, *** p<0.001, n=7.
Figure 4.15 Simultaneous addition of 2µM nifedipine and 3µM mibefradil inhibits 
\([\text{Ca}^{2+}]_i\) and \(\text{Ca}^{2+}\) oscillations

Representative trace showing the response of A7r5 cells to 20mM K\(^+\) buffer in the 
presence of 2µM nifedipine and 3µM mibefradil (A). Trend graph showing the decrease 
in Fura 2 ratio (B) and the decrease in spikes/s (C) within individual traces in response 
to 20mM K\(^+\) buffer followed by 20mM K\(^+\) buffer in the presence of 2µM nifedipine and 
3µM mibefradil. The mean (± s.e.m.) response is shown to the right and left of the 
corresponding individual data points on each graph, n=4. Bar graph showing the mean 
(± s.e.m.) change in Fura 2 ratio (D) and the change in spikes/s (E) in response to 
20mM K\(^+\) buffer in the presence of the drug as indicated. Data analysed by one-way 
ANOVA followed by Tukey's multiple comparison test, * p<0.05, ** p<0.01 vs 
K\(^+\)/mib./nif. *** P<0.001, **** p<0.0001 vs K\(^+\). nif. = nifedipine, mib. = mibefradil
Figure 4.16 Response to 80mM K⁺ buffer containing 2µM nifedipine and 3µM mibefradil

Representative trace showing the change of [Ca^{2+}] in response to 80mM K⁺ buffer (A) and the decreased response to 80mM K⁺ buffer containing 2µM nifedipine and 3µM mibefradil (B). Bar graph showing the mean (± s.e.m.) integral of the curves produced in response to 80mM K⁺ buffer (control), and 80mM K⁺ buffer in the presence of the drug as indicated (C). Data were analysed by one-way ANOVA, *** p<0.001, n=6. nif. = nifedipine, mib. = mibefradil.
Figure 4.17 Simultaneous addition of 2µM nifedipine and 30µM Ni²⁺ inhibits [Ca²⁺]i and Ca²⁺ oscillations

Representative trace showing the response of A7r5 cells to 20mM K⁺ buffer in the presence of 2µM nifedipine and 30µM Ni²⁺ (A). Trend graph showing the decrease in Fura 2 ratio (B) and the decrease in spikes/s (C) within individual traces in response to 20mM K⁺ buffer followed by 20mM K⁺ buffer in the presence of 2µM nifedipine and 30µM Ni²⁺. The mean (± s.e.m.) response is shown to the right and left of the corresponding individual data points on each graph, n=6. Bar graph showing the mean (± s.e.m.) change in Fura 2 ratio (D) and the change in spikes/s (E) in response to 20mM K⁺ buffer in the presence of the drug as indicated. Data analysed by one-way ANOVA followed by Tukey’s multiple comparison test, **** p<0.0001 vs K⁺ or K⁺/Ni²⁺/nif. nif. = nifedipine
buffer, and there was no significant difference between the response to nifedipine or nifedipine and Ni\(^{2+}\) combined. The differing extents of reductions of evoked [Ca\(^{2+}\)] \_\_i rises by the T-type Ca\(^{2+}\) channel blockers, mibefradil and Ni\(^{2+}\), suggest that mibefradil has non-specific effects when used at 3µM. The lower level of [Ca\(^{2+}\)] \_\_i inhibition by 30µM Ni\(^{2+}\) is in accordance with the fact that the Ca\(_{\_3.2}\) T-type Ca\(^{2+}\) channels, which is the Ni\(^{2+}\) sensitive channel subtype, are expressed at low levels in A7r5 cells.

In summary, mibefradil appears to inhibit both T- and L-type Ca\(^{2+}\) channels when used at 3µM, whereas 30µM Ni\(^{2+}\) appears to selectively inhibit T-type Ca\(^{2+}\) channels. Nifedipine has significant effects during stimulation by 20mM K\(^{+}\) buffer, implying that L-type Ca\(^{2+}\) channels are also active upon weak depolarisation of the cells. The insignificant effects of Ni\(^{2+}\) during stimulation by 80mM K\(^{+}\) buffer confirm preferential activation of L-type Ca\(^{2+}\) channels upon strong depolarisation of the cells.

4.2.3 Inhibition of T-type and L-type Ca\(^{2+}\) channels and the effect on A7r5 proliferation

Proliferation of A7r5 cells was inhibited by mibefradil in a concentration dependent manner, as shown in Figure 4.18 (A). At higher concentrations of mibefradil, the non-viable cell count increased, as shown by the red line graph in panel (A). 3µM mibefradil decreased mean cell number by 32%, and caused 1.6% cell death. This concentration was subsequently applied to a three day time-course proliferation assay. Panel (B) shows the mean proliferative response over time; mibefradil reduced cell number by 40% on day 3. Cell Event™ was used as an indicator of caspase-3/7 activation, which is indicative of apoptosis. Representative images are shown in Figure 4.19 of 2µM staurosporine treated cells (positive control, panels A and B), and of 3µM mibefradil treated cells (panels C and D). The mean data of the percentage of Cell Event™ positive cells from all fields of view are shown in panel (E). Mibefradil treatment induced caspase-3/7 activation in 13% of cells, yet there was no significant effect on apoptosis by mibefradil vs negative control.

A7r5 cell proliferation was not affected by concentrations of Ni\(^{2+}\) ranging from 1µM to 30µM, and cell death was less than 0.5%, as shown in Figure 4.20. There was no concentration-dependent decrease in proliferation in response to increasing
Figure 4.18 Mibefradil inhibits A7r5 cell proliferation

Bar graph showing the proliferative response of A7r5 cells to increasing concentrations of mibefradil (left y-axis) (A). The overlaid red plot shows the corresponding non-viable cell count (right y-axis). Data were analysed by a ratio repeated measures one-way ANOVA with Dunnett’s multiple comparison test, * p<0.05, *** p<0.001 vs Day 3 Control, n=3. Line graph of the effects of 3μM mibefradil over a 3 day period. Data were analysed by two-way repeated measures ANOVA with sample matching by time point. This was followed by Sidak’s multiple comparison test between control and treated groups for each time point, ** p<0.01, n=4. Data are represented as mean ± s.e.m.
Figure 4.19 The effect of mibebradil on caspase-3/7 activation

Representative images of 2µM staurosporine treated A7r5 cells (positive control), Hoechst staining (A) and the corresponding Cell Event™ staining (B); and of 3µM mibebradil treated A7r5 cells, Hoechst staining (C) and the corresponding Cell Event™ staining (D). Scale bar=10µm. Bar graph of mean (± s.e.m.) % Cell Event positive cells for 2µM staurosporine treated A7r5 cells (positive control), untreated A7r5 cells (negative control) n=12 fields of view, and 3µM mibebradil treated cells, n=8 fields of view (E). Data were analysed by one-way ANOVA, with Bonferroni’s multiple comparison test, *** p<0.001.
Figure 4.20 Low Ni$^{2+}$ concentrations do not inhibit A7r5 cell proliferation

Bar graph showing the proliferative response of A7r5 cells to increasing concentrations of Ni$^{2+}$ (left y-axis). The overlaid red plot shows the corresponding non-viable cell count (right y-axis). n=3, data are represented as mean ± s.e.m.
concentrations of nifedipine, nor did it affect cell viability, as shown in Figure 4.21. Only at a concentration of 4µM did nifedipine significantly inhibit cell proliferation, with cell death at less than 0.5%. As stated previously, the IC<sub>50</sub> of T-type Ca<sup>2+</sup> channels to Ni<sup>2+</sup> differs for the channel subtypes, with Ca<sub>3.1</sub> being less sensitive. Ca<sub>3.1</sub> is expressed at higher levels than Ca<sub>3.2</sub> in A7r5 cells, as described in section 4.2.1. As our research group has demonstrated that the IC<sub>50</sub> of Ni<sup>2+</sup> for the HEK293/Ca<sub>3.1</sub> channel to be 289µM (see Figure 4.10), a higher concentration range of Ni<sup>2+</sup> was applied to A7r5 cells to isolate the effects of Ca<sub>3.1</sub> inhibition on cell proliferation. To block L-type Ca<sup>2+</sup> channels, and thus prevent any off-target effects of 250µM Ni<sup>2+</sup> on these channels, the assay was performed in the presence of 2µM nifedipine. Figure 4.21 has demonstrated that 2µM nifedipine had no effect on proliferation. Figure 4.22 demonstrates that 250µM Ni<sup>2+</sup> significantly inhibits proliferation, with no effect on cell viability, as shown by the red line graph. Cell number was reduced by 75% by 250µM Ni<sup>2+</sup>, and cell death was less than 0.5%.

In summary, the non-selective T-type Ca<sup>2+</sup> channel blocker, mibebradil, significantly inhibited A7r5 cell proliferation. The L-type Ca<sup>2+</sup> channel blocker, nifedipine, did not significantly inhibit A7r5 cell proliferation when used at a concentration of 2µM or less. Selective inhibition of Ca<sub>3.2</sub> channels by low concentrations of Ni<sup>2+</sup> did not limit cell proliferation, yet selective inhibition of Ca<sub>3.1</sub> channels by high concentrations of Ni<sup>2+</sup>, in the presence of 2µM nifedipine, did significantly inhibit A7r5 cell proliferation.

4.2.4 T-type Ca<sup>2+</sup> channel modulation by Ca<sub>3.1</sub> siRNA
As the Ca<sub>3.1</sub> T-type Ca<sup>2+</sup> channel is the more highly expressed sub-type in A7r5 cells, molecular techniques were employed to knock-down Ca<sub>3.1</sub> channel expression using Ca<sub>3.1</sub>-targeting siRNA, with the aim of assessing subsequent effects on cell proliferation. Initial assessment of Ca<sub>3.1</sub>-targeting siRNA was performed at 24h and 48h time-points using a range of concentrations. HPRT1 was chosen as the endogenous control mRNA as the associated C<sub>t</sub> values were comparable to the C<sub>t</sub> values of the Ca<sub>3.1</sub> mRNA in the A7r5 cell line. At the 24h time-point, 25nM and 50nM Ca<sub>3.1</sub>-targeting siRNA significantly reduced the expression of the Ca<sub>3.1</sub> T-type Ca<sup>2+</sup> channel, with 10nM, 25nM and 50nM all producing significant knock-down at 48h, as shown in Figure 4.23. A concentration of 25nM Ca<sub>3.1</sub>-targeting siRNA was then assessed over a 96h time-course, as shown in Figure 4.24. Significant knock-down of Ca<sub>3.1</sub> mRNA expression was demonstrated at 24h and 48h, but this did not continue
Figure 4.21 The effect of nifedipine on A7r5 cell proliferation

Bar graph showing the proliferative response of A7r5 cells to increasing concentrations of nifedipine (left y-axis). The overlaid red plot shows the corresponding non-viable cell count (right y-axis). Data were analysed by a ratio repeated measures one-way ANOVA with Dunnett’s multiple comparison test, * p<0.05 vs Day 3 Control, n=3, data are represented as mean ± s.e.m.
Figure 4.22 The effect of high Ni$^{2+}$ concentrations and 2µM nifedipine on A7r5 proliferation

Bar graph showing the proliferative response of A7r5 cells to increasing concentrations of Ni$^{2+}$, in the presence of 2µM nifedipine (right y-axis). The overlaid red plot shows the corresponding non-viable cell count (left y-axis). Data were analysed by a ratio repeated measures one-way ANOVA with Dunnett’s multiple comparison test, ** p<0.01 vs Day 3 Control, n=3, data are represented as mean ± s.e.m.
Figure 4.23 Preliminary assessment of Ca_{3.1}-targeting siRNA at 24h and 48h

Bar graph showing the relative expression of Ca_{3.1} 24h post 10nM, 25nM, or 50nM Ca_{3.1}-targeting siRNA treatment (A). Bar graph showing the corresponding HPRT1 C_{t} values at 24h (B). Bar graph showing the relative expression of Ca_{3.1} 48h post 10nM, 25nM, or 50nM Ca_{3.1}-targeting siRNA treatment (C). Corresponding HPRT1 C_{t} values at 48h (D). M; Mock, T; transfected, 6-well format. Data were analysed by a ratio repeated measures one-way ANOVA with Bonferroni’s multiple comparison test, * p<0.05, ** p<0.01, *** p<0.001, n=2, values in triplicate, data are represented as mean ± s.e.m. Cells at P3 and P4.
Figure 4.24 Assessment of 25nM Ca₃.1-targeting siRNA over a 96h time-course

Bar graph showing the relative expression of Ca₃.1 at time-points post 25nM Ca₃.1-targeting siRNA treatment (A). Bar graph showing the corresponding HPRT1 Ct values (B). M; Mock, T; transfected, 6-well format. Data were analysed by a two-way ANOVA and matched within each treatment group (M or T), with Bonferroni’s multiple comparison test, * p<0.05, ** p<0.01, **** p<0.0001, n=1, values in triplicate, data are represented as mean ± s.e.m. Cells at P5.
to 72h and 96h. Although mRNA knock-down was significant at 96h, this is likely due to the fact that the expression of the HPRT1 endogenous mRNA was increased in the transfected group at 96h. The assessment of 25nM Ca$_{3.1}$-targeting siRNA over 96h was therefore repeated, as shown in Figure 4.25. Knock-down of Ca$_{3.1}$ mRNA expression was demonstrated on day 0 at the start of the assay, but this was not maintained throughout the 96h time-course (panel A). The lack of effect on proliferation over this 96h time-course is shown in panel (B). As the expression of HPRT1 was variable in previous experiments, β2-microglobulin (β2M) was also employed as an endogenous control, although this mRNA was expressed at a higher level than both HPRT1 and Ca$_{3.1}$ in A7r5 cells. β2M was employed to establish whether HPRT1 was affected by the transfection process itself, or whether such endogenous control mRNA was subject to fluctuation across A7r5 cell passages. However, as shown in Figures 4.25, 4.26, and 4.27, both HPRT1 and β2M fluctuate between samples in the same pattern. As 25nM Ca$_{3.1}$-targeting siRNA caused no consistent effects on Ca$_{3.1}$ mRNA expression, nor on proliferation, 50nM Ca$_{3.1}$-targeting siRNA was assessed over a 96h time-course. There was a difference in cell proliferation at 48h using 50nM Ca$_{3.1}$-targeting siRNA, as shown in Figure 4.26 (panel B). Cell number was reduced by 36% in the transfected group in comparison to the mock group. However, this was not maintained at 96h, and the proliferative response did not correlate with the mRNA knock-down shown in panel (A). It appeared that Ca$_{3.1}$ mRNA knock-down was not attainable at 96h, therefore 50nM Ca$_{3.1}$-targeting siRNA was employed once more over a 72h assay period, as shown in Figure 4.27. An untransfected group was also added to this experiment to establish whether the transfection process was adversely affecting the mRNA expression levels of the proteins being assessed. However, there was variability in Ca$_{3.1}$ expression between the mock and untransfected groups, which suggests the transfection procedure itself adversely affected channel expression levels. Additionally, Figure 4.27 (A) demonstrates how the level of Ca$_{3.1}$ expression varies over time in A7r5 cells. Both mock and untransfected groups show an increase in Ca$_{3.1}$ expression between 0h and 24h, which then declines at 48h and 72h. However, this does not correlate with the proliferation data in Figure 4.27 (B), as the cell number did not increase until after 48h. Furthermore, Ca$_{3.1}$ mRNA knock-down could not be accurately assessed due to fluctuations in levels of endogenous controls. Due to time constraints, the assessment of Ca$_{3.1}$-targeting siRNA on A7r5 cell proliferation was not investigated further.
Figure 4.25 The effect of 25nM Ca\textsubscript{v}3.1-targeting siRNA on A7r5 proliferation over a 96h time-course

Bar graph showing the relative expression levels of Ca\textsubscript{v}3.1 at various time-points post 25nM Ca\textsubscript{v}3.1-targeting siRNA treatment (A). Data were analysed by a two-way ANOVA and matched within each treatment group (M or T), with Bonferroni’s multiple comparison test, ** p<0.01. Line graph showing the proliferative response of A7r5 cells post 25nM Ca\textsubscript{v}3.1 siRNA treatment (B). Bar graphs (C and D) showing the corresponding housekeeper C\textsubscript{t} values of HPRT1 and β2M respectively for 0h, 48h, and 96h time-points. M; Mock, T; transfected, 24-well format, n=1, values in triplicate, data are represented as mean ± s.e.m. Cells at P5.
Figure 4.26 The effect of 50nM Ca,v3.1-targeting siRNA on A7r5 proliferation over a 96h time-course

Bar graph showing the relative expression levels of Ca,v3.1 at various time-points post 50nM Ca,v3.1-targeting siRNA treatment (A). Data were analysed by a two-way ANOVA and matched within each treatment group (M or T), with Bonferroni’s multiple comparison test, * p<0.05, *** p<0.001. Line graph showing the proliferative response of A7r5 cells post 50nM Ca,v3.1-targeting siRNA treatment (B). Bar graphs (C and D) showing the corresponding housekeeper Ct values of HPRT1 and β2M respectively for 0h, 48h, and 96h time-points. M; Mock, T; transfected, 24-well format, n=1, values in triplicate, data are represented as mean ± s.e.m. Cells at P4.
Figure 4.27 The effect of 50nM Ca\textsubscript{v}3.1-targeting siRNA on A7r5 proliferation over a 72h time-course

Bar graph showing the relative expression levels of Ca\textsubscript{v}3.1 at various time-points post 50nM Ca\textsubscript{v}3.1 siRNA treatment (A). Data were analysed by a two-way ANOVA and matched within each treatment group (M or T), with Bonferroni’s multiple comparison test, *** p<0.001. Line graph showing the proliferative response of A7r5 cells post 50nM Ca\textsubscript{v}3.1-targeting siRNA treatment (B). Bar graphs (C and D) showing the corresponding housekeeper C\textsubscript{t} values of HPRT1 and β2M respectively for 0h, 48h, and 72h time-points. M: Mock, T; transfected, U; untransfected, 24-well format, n=1, values in triplicate, data are represented as mean ± s.e.m. Cells at P5.
4.3 Discussion
Figure 4.1 confirms positive staining for smooth muscle cell markers in A7r5 cells. The co-stained images in panels (D-F) exhibited fainter staining, despite being captured using the same microscopy settings, the same antibody dilutions, and using the same cells. This suggested that the presence of both antibodies prevented the effective binding and visualisation of either antibody. The expression of both Ca\textsubscript{3.1} and Ca\textsubscript{3.2} T-type Ca\textsuperscript{2+} channels was demonstrated by immunocytochemistry and RT-PCR, and both methods show Ca\textsubscript{3.1} to be the more prominently expressed T-type Ca\textsuperscript{2+} channel subtype in A7r5 cells, despite variable expression levels across passages. Such variation could be a result of the proliferative state of the cells and how confluent the cell monolayer was, as T-type Ca\textsuperscript{2+} channel expression is down-regulated by cell contact in confluent cell monolayers (Akaike et al., 1989; Richard et al., 1992). To try and minimise such variation, all A7r5 cell samples were retrieved when the monolayer was 80% confluent. However, differences in expression levels were still apparent, although a link to passage number was ruled out. Another group has also demonstrated that Ca\textsubscript{3.1} is more prominent than Ca\textsubscript{3.2} in rat arteries and A7r5 cells, in addition to a similar Ca\textsubscript{3.1} peri-nuclear staining pattern (Brueggemann et al., 2005).

Membrane enrichment of A7r5 cell samples prior to western blotting produced limited success of Ca\textsubscript{3.1} detection (Figure 4.3). These findings correlate to the fact that immunocytochemistry demonstrated minimal positive staining of the channels at the cell membrane (Figure 4.2). Therefore, even though Ca\textsubscript{3.1} expression is more prominent, absolute expression levels are still low.

A7r5 cells respond rapidly to modest membrane depolarisation caused by 20mM K\textsuperscript{+} buffer, with a rise of [Ca\textsuperscript{2+}], superimposed on which was the appearance of Ca\textsuperscript{2+} oscillations. The diminished response to consecutive exposures of 20mM K\textsuperscript{+} buffer, as shown in Figure 4.5, could be due to Ca\textsuperscript{2+} channel inactivation. T-type Ca\textsuperscript{2+} channels open in bursts during prolonged depolarisation, and the channels cycle between open, inactivated, and closed states (Perez-Reyes, 2003). Indeed, Ca\textsubscript{3.1} T-type Ca\textsuperscript{2+} channel gating has been shown to be modulated by Ca\textsuperscript{2+} ions, as free [Ca\textsuperscript{2+}], promote the cycling between channel states (Lacinova et al., 2006). The inactivation of L-type Ca\textsuperscript{2+} channels is voltage and also Ca\textsuperscript{2+} dependent, and these channels inactivate more slowly than T-type Ca\textsuperscript{2+} channels (Hille, 1992). As the length of the trace increased, the Ca\textsuperscript{2+} channels may have taken longer to recover, therefore preventing subsequent activation. This is more likely of T-type Ca\textsuperscript{2+} channels, which have longer tail currents (Hille, 1992). The phenomenon of ‘run-down’, described as the decline of Ca\textsuperscript{2+} current
over long recordings, is a documented problem associated with the whole-cell patch clamp technique (Belles et al., 1988). Run-down was proposed to be due to a loss of cellular constituents via the patch pipette, a rise in \([\text{Ca}^{2+}]_i\), and loss of high energy compounds. The idea of \(\text{Ca}^{2+}\) current run-down could be extrapolated to the diminished response of A7r5 cells seen here. Although, recording \([\text{Ca}^{2+}]_i\), by microfluorimetry does not involve a loss of cellular constituents as whole-cell patch clamp does, the coordination of the cellular responses could change over time. Furthermore, gap junctions have been shown to mediate the diffusion of \(\text{Ca}^{2+}\) to neighbouring human smooth muscle cells (Christ et al., 1992), and in HEK293 cells transfected with connexin-43 and the ryanodine receptor (Toyofuku et al., 1998). However, rises in \([\text{Ca}^{2+}]_i\), have been shown to reduce junctional conductance (Loewenstein, 1981). The contribution of gap junctions to the cell response to 20mM \(\text{K}^+\) buffer could be investigated by the use of a gap junction modulator, such as carbenoxolone. During long microfluorimetry traces, as illustrated in Figure 4.5, the depolarising response could diminish across the cell monolayer, which could produce variable movements of \(\text{Ca}^{2+}\) between cells. Taking this notion into account, with the additional possibility that voltage-gated \(\text{Ca}^{2+}\) channels may take longer to cycle through inactivated and deactivated states, as Lacinova et al. (2006) demonstrated that \([\text{Ca}^{2+}]_i\), facilitated \(\text{Ca}_{\text{v}}3.1\) T-type \(\text{Ca}^{2+}\) channel inactivation, these effects would likely be reflected by a smaller change in Fura 2 ratio as the length of the trace increases.

A pharmacological approach was taken to try to isolate the individual contributions of T-type and L-type \(\text{Ca}^{2+}\) channels to the response to 20mM \(\text{K}^+\) buffer. Taken together, the effects of all the compounds applied to A7r5 cells during 20mM \(\text{K}^+\) buffer exposure imply that both T-type and L-type \(\text{Ca}^{2+}\) channels are involved in the response. However, the data suggest that L-type \(\text{Ca}^{2+}\) channels have a more prominent role in the mediation of \(\text{Ca}^{2+}\) oscillations. The L-type \(\text{Ca}^{2+}\) channel blocker, nifedipine, significantly inhibited \([\text{Ca}^{2+}]_i\), reducing the response to 20mM \(\text{K}^+\) buffer by 60% relative to control, and nifedipine also abolished the \(\text{Ca}^{2+}\) oscillations. The T-type \(\text{Ca}^{2+}\) channel blocker mibefradil produced a similar effect, reducing the response to 20mM \(\text{K}^+\) buffer by 58%, although the oscillatory response was not completely abolished. Simultaneous application of nifedipine and mibefradil completely inhibited any change in \([\text{Ca}^{2+}]_i\). Nanomolar concentrations of mibefradil have been shown to inhibit A7r5 \(\text{Ca}^{2+}\) oscillations, and this study concluded that both T-type and L-type \(\text{Ca}^{2+}\) channels are involved in the oscillatory response in A7r5 cells (Brueggemann et al., 2005). However, this study also found that T-type \(\text{Ca}^{2+}\) channel over-expression did not increase \(\text{Ca}^{2+}\)
oscillation frequency, implying that T-type Ca\textsuperscript{2+} channels are not the major influence of such oscillations. Mibefradil has been shown to block L-type Ca\textsuperscript{2+} channels at higher concentrations; with an IC\textsubscript{50} of 12.9\,\mu M in HEK293/Ca\textsubscript{v}1.2 cells (Martin et al., 2000), an IC\textsubscript{50} of 18.6\,\mu M in L-type transfected Chinese hamster ovary cells (Mehrke et al., 1994), and an IC\textsubscript{50} of 3\,\mu M in rat ventricular cells (Leuranguer et al., 2000). It would seem likely, therefore, that 3\,\mu M mibefradil employed in these experiments also had inhibitory effects on L-type Ca\textsuperscript{2+} channels. The possible inhibition of L-type Ca\textsuperscript{2+} channels by mibefradil is also evidenced by the response to 80mM K\textsuperscript{+} buffer, which promotes strong membrane depolarisation and preferential activation of L-type Ca\textsuperscript{2+} channels. Mibefradil reduced the integrated response by 65%, nifedipine by 68%, and simultaneous application of both drugs by 92%. Contrastingly, one study has demonstrated that nifedipine can inhibit endogenous and recombinant T-type Ca\textsuperscript{2+} channels with an IC\textsubscript{50} of 109\,\mu M for Ca\textsubscript{v}3.1, and 5\,\mu M for Ca\textsubscript{v}3.2 (Shcheglovitov et al., 2005). Although a concentration of 2\,\mu M was used in the current experiments, and the fact that A7r5 cells express Ca\textsubscript{v}3.1 channels more abundantly, the data concerning proliferation suggest it is highly unlikely that nifedipine had any inhibitory effects on T-type Ca\textsuperscript{2+} channels.

The IC\textsubscript{50} of Ni\textsuperscript{2+} for Ca\textsubscript{v}3.1 and Ca\textsubscript{v}3.2 has been shown to be 250\,\mu M and 13\,\mu M respectively for recombinant channels expressed in HEK293 cells (Lee et al., 1999), and 304.8\,\mu M and 4.9\,\mu M (Kang et al., 2006) respectively for recombinant channels expressed in xenopus oocytes. 200\,\mu M Ni\textsuperscript{2+} was able to reversibly inhibit T-type Ca\textsuperscript{2+} currents in A7r5 cells (Brueggemann et al., 2005), and we have quantified the IC\textsubscript{50} to be 289\,\mu M in HEK293/Ca\textsubscript{v}3.1 cells. Preliminary microfluorimetry experiments using 250\,\mu M Ni\textsuperscript{2+} demonstrated complete abolition of the response to 20mM K\textsuperscript{+} buffer, therefore a lower concentration 30\,\mu M Ni\textsuperscript{2+} was utilised to assess the effects of partial T-type Ca\textsuperscript{2+} channel block, without producing off-target effects on L-type Ca\textsuperscript{2+} channels. The response to 20mM K\textsuperscript{+} buffer in the presence 30\,\mu M Ni\textsuperscript{2+} was reduced by 37% without altering oscillation frequency, and the simultaneous addition of Ni\textsuperscript{2+} and nifedipine inhibited the change in Fura 2 ratio by 48%. This implies that the effects of 30\,\mu M Ni\textsuperscript{2+} are limited to T-type Ca\textsuperscript{2+} channels, which is verified by the lack of effect of 30\,\mu M Ni\textsuperscript{2+} on [Ca\textsuperscript{2+}]\textsubscript{i} when the cells were exposed to 80mM K\textsuperscript{+} buffer. Indeed, Ni\textsuperscript{2+} was shown to inhibit L-Type Ca\textsuperscript{2+} channels with an ED\textsubscript{50} of 65\,\mu M quoted in human smooth muscle cells (Hollywood et al., 2003). Proliferation of A7r5 cells was not affected by concentrations of Ni\textsuperscript{2+} up to 30\,\mu M. This concentration of Ni\textsuperscript{2+} is selective for Ca\textsubscript{v}3.2 over Ca\textsubscript{v}3.1 channels, and the former are expressed at low levels in A7r5 cells, as demonstrated by Figure 4.4. The significant effects of 30\,\mu M Ni\textsuperscript{2+} on [Ca\textsuperscript{2+}]\textsubscript{i}, but not on
cell proliferation, suggest that Ca$_{v}^{3.2}$ channels do not notably contribute to proliferation of A7r5 cells. It is possible that chronic inhibition of Ca$_{v}^{3.2}$ channels over a period of 3 days during a proliferation assay did not reduce [Ca$^{2+}$], to sub-threshold levels, which would subsequently limit cell proliferation (Gray et al., 2004), as discussed previously in Chapter 3. Figure 4.11 demonstrates that acute inhibition of Ca$_{v}^{3.2}$ channels does significantly affect [Ca$^{2+}$], yet Figure 4.20 implies that chronic inhibition of Ca$_{v}^{3.2}$ channels does not lead to significant effects on proliferation. In the presence of 2µM nifedipine, concentrations of Ni$^{2+}$ increasing from 30µM to 250µM caused a concentration-dependent decrease in proliferation. It is likely that Ca$_{v}^{3.2}$ channels were inhibited by lower concentrations of Ni$^{2+}$, with Ca$_{v}^{3.1}$ channels additionally inhibited by concentrations of 120µM Ni$^{2+}$ and above. Significant inhibition of proliferation occurred in response to chronic exposure of 250µM Ni$^{2+}$, implying Ca$_{v}^{3.1}$ channels are central to the proliferative capacity of A7r5 cells, and to the maintenance of adequate [Ca$^{2+}$] levels to trigger cell cycle progression. Interestingly, sub-confluent A7r5 cells have been shown to have higher resting [Ca$^{2+}$] and are less excitable than confluent A7r5 cells (Otun et al., 1992). These data are consistent with the fact that T-type Ca$^{2+}$ channels are expressed at higher levels in proliferating cells (Kuga et al., 1996), and become less prominent on contact inhibition and in contractile cells (Akaike et al., 1989; House et al., 2008). The inhibitory effects on proliferation exerted by 3µM mibefradil can be attributed to T-type Ca$^{2+}$ channel inhibition and not off-target effects, as proliferation was not affected by L-type Ca$^{2+}$ channel inhibition. Non-viable cell counts show mibefradil to be cytotoxic at concentrations above 5µM, which is corroborated by the fact that 3µM mibefradil did not cause significant activation of caspase-3/7.

In the context of the [Ca$^{2+}$] responses shown in this chapter, the data may show an under-estimate of T-type Ca$^{2+}$ channel contribution. As coverslips of confluent A7r5 cells were utilised for microfluorometry experiments, T-type Ca$^{2+}$ channel expression could have declined, and therefore the effects of Ni$^{2+}$ upon moderate depolarisation demonstrated to be less significant than in sub-confluent proliferating cells. The higher resting [Ca$^{2+}$] in sub-confluent A7r5 cells described by Otun et al. (1992) could be attributed to the window current caused by T-type Ca$^{2+}$ channels. A negligible window current was demonstrated in A7r5 cells in the present experiments, as shown in Figure 4.6. This is consistent with the low level of T-type Ca$^{2+}$ channel expression shown in Figures 4.3 and 4.4. The sharp increases in [Ca$^{2+}$] shown on the trace in Figure 4.6 as the buffer is changed from Ca$^{2+}$-containing to Ca$^{2+}$-free may be indicative of internal
Ca\textsuperscript{2+} store emptying. The upsurge of [Ca\textsuperscript{2+}] when the buffer is switched back to a Ca\textsuperscript{2+}-containing buffer is likely attributable to the availability of extracellular Ca\textsuperscript{2+}, and possibly in conjunction with Ca\textsuperscript{2+}-induced Ca\textsuperscript{2+}-release (CICR). Although further experiments involving a sarcoplasmic endoplasmic reticulum Ca\textsuperscript{2+} ATPase (SERCA) inhibitor, such as cyclopiazonic acid for example, would need to be performed to conclude reliably how the internal Ca\textsuperscript{2+} stores contribute to the [Ca\textsuperscript{2+}] changes and the oscillatory response. Although, Otun et al. (1992) concluded that the oscillatory response of confluent A7r5 cells occurs as a result of extracellular Ca\textsuperscript{2+}, and therefore via voltage-gated Ca\textsuperscript{2+} channels, the possibility of a role for CICR was not assessed in this study.

The limited data produced from the experiments involving Ca\textsubscript{v}3.1-targeting siRNA were not consistent or elucidative. These experiments were carried out to validate the pharmacological findings involving Ni\textsuperscript{2+} at a molecular level. However, the level of Ca\textsubscript{v}3.1 mRNA expression fluctuated in mock samples, both within and among time-course experiments, but there was no correlation with passage number. This is illustrated in Figures 4.25 to 4.27. Indeed, T-type Ca\textsuperscript{2+} channels have been shown to be affected by the proliferative state of VSMCs, as a confluent cell monolayer influences the down-regulation of channel expression (Akaike et al., 1989;Richard et al., 1992). Panels (A and B) in Figure 4.25 illustrate this; as the time-course proceeds, the A7r5 cells became more confluent and Ca\textsubscript{v}3.1 mRNA expression in the mock samples declined. The fluctuations in HPRT1 values between mock and transfected groups within experiments undoubtedly had an effect on the calculation of relative Ca\textsubscript{v}3.1 expression levels. The amount of RNA within each sample was not normalised prior to the RT-PCR assay as the relative quantification of Ca\textsubscript{v}3.1 expression to HPRT1 expression is designed to remove RNA loading variability. Additionally, samples were assessed in triplicate. However, β2M also fluctuated in the same pattern as HPRT1, therefore the transfection process itself could have caused variations in the mRNA expression levels of all the proteins assessed. Alternatively, the mRNA levels in the cell samples from different time-points could have contained such large variation that the relative expression is not an accurate assessment. This is supported by the fact that the untransfected group shown in Figure 4.27 (A) did not follow the pattern of mock Ca\textsubscript{v}3.1 mRNA expression. Other commonly used endogenous controls such as β-actin and glyceraldehyde phosphate dehydrogenase (GAPDH) are expressed at much higher levels than Ca\textsubscript{v}3.1, and GAPDH expression has also been shown to be modulated by proliferation (Suzuki et al., 2000), so were therefore not utilised. The
siRNA employed in these experiments was chosen specifically as it was ON-
TARGETplus® SMARTpool® siRNA marketed to reduce off-target effects, but it is
possible that the correct target in A7r5 cells was not hit. If time had permitted, the next
stage of experiments could have involved short hairpin RNA (shRNA) to knock-down
Ca,3.1 mRNA expression. The use of shRNA has proven to be more efficient than
siRNA, as shRNA is incorporated directly into the endogenous miRNA pathway (Rao et
al., 2009). Higher concentrations of siRNA are required to produce mRNA knock-down
in comparison to the required number of shRNA copies, and this can subsequently
cause siRNA-mediated off-target effects (Rao et al., 2009). Knock-down of mRNA via
shRNA can be constitutive or inducible, although the use of an inducible system offers
more control of mRNA suppression regulation (Gossen & Bujard, 1992). The use of the
tetracycline inducible system produces reversible mRNA suppression which has been
utilised in colorectal cancer cells for the analysis of cell cycle arrest (van de Wetering et
al., 2003). This suggests it would be a suitable system for the investigation of the
proliferative effects of mRNA knock-down. This system has previously been employed
in our laboratory group.

In summary, these data suggest that both T-type and L-type Ca\(^{2+}\) channels are
activated upon modest cell depolarisation, yet L-type Ca\(^{2+}\) channels appear to have a
more prominent role in the generation of Ca\(^{2+}\) oscillations. L-type Ca\(^{2+}\) channels do not
have a role in the proliferative response, but the Ca,3.1 T-type Ca\(^{2+}\) channel is central
to A7r5 cell proliferation. As T-type Ca\(^{2+}\) channels have been demonstrated to be
present and functional in A7r5 cells, the effects of CO and HO-1 were next examined.
CHAPTER 5

The effect of HO-1 and CO on proliferation and \([\text{Ca}^{2+}]_i\) in A7r5 cells

5.1 Introduction

VSMCs are responsible for the maintenance of normal blood pressure and blood flow, and have a contractile phenotype in healthy vessels (Owens, 1995). In response to vascular injury, VSMCs undergo a phenotypic switch from contractile to synthetic cells, which migrate to the site of injury and proliferate. This proliferative response is a central feature of several cardiovascular disorders, such as atherosclerosis, hypertension, and restenosis (Rzucidlo et al., 2007). The environment encompassing such injury promotes HO-1 induction, which plays a role in limiting vessel damage (Durante, 2003). HO-1, via subsequent CO and bilirubin production, limits apoptosis, inflammation, oxidation, platelet aggregation, and proliferation. Indeed, the protective role of CO within the vasculature has been well defined, (Morita et al., 1997; Togane et al., 2000; Song et al., 2002; Otterbein et al., 2003b; Raman et al., 2006; Zuckerbraun et al., 2006; Ramlawi et al., 2007). CO has numerous intracellular targets, including heme-containing proteins such as NOS, catalase, peroxidase, cytochrome c oxidase, cytochrome P450, sGC, in addition to NADPH oxidase and BK\(_{\text{Ca}}\) channels (Motterlini & Otterbein, 2010). What remains to be fully elucidated are the cellular targets by which this gasotransmitter exerts specific anti-proliferative effects.

Redox signalling appears to be important for many effects associated with CO, including anti-proliferative effects. CO was shown to limit the proliferation of human airway smooth muscle cells by the inhibition of NADPH oxidase in addition to the production of mitochondrial ROS (Taille et al., 2005). This anti-proliferative mechanism involved a reduction of ERK1/2 phosphorylation and a subsequent increase in cyclin D1 expression. The involvement of ERK1/2 and the MAPK pathway, in addition to sGC and the cGMP pathway, have both been detailed as signalling pathways involved in the anti-proliferative effects of CO (Song et al., 2002; Stanford et al., 2003). Redox regulation also appears to have a role in the phenotypic switch of VSMCs; dehydroepiandrosterone is able to inhibit the phenotypic switch by enhancing the levels of glutaredoxin and glutathione (Urata et al., 2010), which are involved in the defence against oxidative stress (Fernandes & Holmgren, 2004). Our research group has demonstrated that CO can inhibit the L-type Ca\(^{2+}\) channel, with an IC\(_{50}\) of 14.8\(\mu\)M in
HEK/Ca.1.2 cells, and given these channels provide an important route for Ca\textsuperscript{2+} entry in VSMCs, this has important implications during situations of vascular stress, when CO production is enhanced via HO-1 induction (Scragg et al., 2008). CO was shown to increase mitochondrial ROS, which caused redox modulation of cysteine residues within the L-type Ca\textsuperscript{2+} channel. Inhibition of the T-type Ca\textsuperscript{2+} channel by CO has been recently demonstrated via electrophysiological methods by our research group, and it is possible that redox modulation may also underlie this mechanism. CO and HO-1 induction, in addition to the use of a reducing agent, were therefore examined in A7r5 cells, and the effects on [Ca\textsuperscript{2+}]i and proliferation assessed.

5.2 Results

5.2.1 The effect of CO on [Ca\textsuperscript{2+}]i and cell proliferation

The effect of CO on [Ca\textsuperscript{2+}]i was assessed by application of CORM-3. After an initial exposure to 20mM K\textsuperscript{+} buffer, 10µM CORM-3 was applied prior to, and throughout the second exposure, which subsequently inhibited [Ca\textsuperscript{2+}]i and reduced the Ca\textsuperscript{2+} oscillation frequency, as shown in Figure 5.1 panels (A), (D), and (G). There was no difference in the mean change in Fura 2 ratio or in mean oscillation frequency upon addition of 10µM iCORM-3, as shown in Figure 5.1 panels (B), (E), and (H). To assess whether the redox state of the cellular environment affected the response to CORM-3, A7r5 cells were pre-treated with a reducing agent, dithiothreitol (DTT), before applying CORM-3. Pre-treatment with 2µM DTT prior to 10µM CORM-3 application did not significantly reduce the Ca\textsuperscript{2+} oscillation frequency, as shown in Figure 5.1 (I), yet there appears to be a trend towards a lower oscillation frequency on the representative trace in panel (C). DTT pre-treatment did not completely prevent a decrease in [Ca\textsuperscript{2+}]i, as shown in Figure 5.1 panels (C) and (F). When compared to the effect of CORM-3 alone via one-way ANOVA, DTT pre-treatment caused no significant difference in [Ca\textsuperscript{2+}]i or oscillation frequency, as shown in Figure 5.2. The response of A7r5 cells to 80mM K\textsuperscript{+} buffer in the presence of 10µM CORM-3 was comparable to the control cell response, as shown in Figure 5.3. CORM-3 had no inhibitory effect on the mean integrated response when the cells were strongly depolarised; [Ca\textsuperscript{2+}] was not affected. CORM-3 was assessed in a proliferation assay; A7r5 cell number was reduced by 5%, 8%, and 16% in response to 3µM, 10µM, and 30µM CORM-3 respectively, yet proliferation was not significantly inhibited, as shown in Figure 5.4. Cell death was limited to 1% or less.
Figure 5.1 The effect of 10µM CORM-3, iCORM-3 and 2µM DTT on [Ca^{2+}]_i and Ca^{2+} oscillations

Representative traces showing the response of A7r5 cells to 20mM K^{+} buffer in the presence of 10µM CORM-3, 10µM iCORM-3, and 10µM CORM-3 post 2µM DTT pre-treatment (panels A-C). Trend graphs showing the change in Fura 2 ratio between K^{+} exposures, in the presence of 10µM CORM-3, 10µM iCORM-3, and 10µM CORM-3 post 2µM DTT pre-treatment (panels D-F). Trend graphs showing the change in spikes/s between K^{+} exposures, in the presence of 10µM CORM-3, 10µM iCORM-3, and 10µM CORM-3 post 2µM DTT pre-treatment (panels G-I). The mean (± s.e.m.) response is shown to the right and left of the corresponding individual data points on each graph. Data were analysed by a two-tailed, paired t-test, ** p<0.01, n=5.
Figure 5.2 DTT does not significantly prevent the effects of CORM-3

Bar graph showing the mean (± s.e.m.) change in Fura 2 ratio (A) and the change in spikes/s (B) in response to 20mM K⁺ buffer in the presence of 10μM CORM-3, plus or minus pre-treatment with 2μM DTT. n=5
Figure 5.3 The change in $[Ca^{2+}]_{i}$ in response to 80mM K$^+$ buffer containing 10µM CORM-3

Representative trace showing the change of $[Ca^{2+}]_{i}$ in response to 80mM K$^+$ buffer (A) and in response to 80mM K$^+$ buffer containing 10µM CORM-3 (B). Bar graph showing the mean (± s.e.m.) integrated response to 80mM K$^+$ buffer, plus or minus the addition of 10µM CORM-3 (C). n=6.
Bar graph showing the proliferative response of A7r5 cells to increasing concentrations of CORM-3 (left y-axis). The overlaid red plot shows the corresponding non-viable cell count (right y-axis). Data are represented as ± s.e.m., n=6.
Co-application of 3µM mibefradil with concentrations of CORM-3 ranging from 1µM to 30µM significantly inhibited cell proliferation without affecting cell viability, as shown in Figure 5.5. Cell death was limited to 1.6% or less. The application of 3µM mibefradil in isolation caused a 43% reduction of proliferation, as shown in the inset of Figure 5.5, whereas the co-application of 3µM mibefradil with 1µM, 3µM, 10µM and 30µM CORM-3 caused a 26%, 34%, 35%, and a 36% reduction of proliferation respectively. These data imply competition for the same cellular target, namely the T-type Ca\(^{2+}\) channel. Although, no direct comparison can be made between the inset and the main graph in Figure 5.5, as the assays were performed at different times. The lack of effect of 10µM CORM-3 on cell viability demonstrated by the red line graph in Figure 5.4 was verified by the lack of caspase-3/7 activation shown in Figure 5.6.

The simultaneous application of 2µM nifedipine and 10µM CORM-3 was examined to see how the response compared to the effects of nifedipine and Ni\(^{2+}\) co-application, and assess whether both the T-type and L-type components of the response to 20mM K\(^+\) buffer could be inhibited. Together, nifedipine and CORM-3 completely abolished the oscillatory response and significantly reduced \([\text{Ca}^{2+}]_i\) by 48%, as shown in Figure 5.7 (A). The co-application of nifedipine and Ni\(^{2+}\) also significantly reduced \([\text{Ca}^{2+}]_i\) by 48%, as shown in Figure 4.17 in chapter 4. Simultaneous application of 2µM nifedipine and 10µM CORM-3 significantly prevented the response to 20mM K\(^+\) buffer, as shown in Figure 5.7 (D) and (E). There was no significant difference between the response to CORM-3 and nifedipine vs the response to CORM-3 or nifedipine alone. Cell proliferation was inhibited by co-application of a range of CORM-3 concentrations with 2µM nifedipine, as shown in Figure 5.8. 1µM, 3µM, 10µM, and 30µM CORM-3 caused a 41%, 62%, 68%, and a 62% reduction of cell number respectively. Cell death was limited to 6% or less.

In summary, CORM-3 significantly limited a rise in \([\text{Ca}^{2+}]_i\) in response to moderate depolarisation, and also significantly inhibited Ca\(^{2+}\) oscillations. This effect was not significantly prevented by redox modulation. CORM-3 had no effect on \([\text{Ca}^{2+}]_i\) when the cells were strongly depolarised, nor did CORM-3 have a significant effect on cell proliferation. The simultaneous application of CORM-3 and nifedipine caused no additive effect on \([\text{Ca}^{2+}]_i\) levels, yet this combination significantly inhibited cell proliferation.
Figure 5.5 Co-application of CORM-3 and mibefradil inhibits A7r5 proliferation

Bar graph showing the proliferative response of A7r5 cells to increasing concentrations of CORM-3, in the presence of 3μM mibefradil (left y-axis). The overlaid red plot shows the corresponding non-viable cell count (right y-axis). Data were analysed by a ratio repeated measures one-way ANOVA with Dunnett’s multiple comparison test, ** p<0.01, *** p<0.001 vs Day 3 Control. Data are represented as ± s.e.m., n=6. Inset is a replication of Figure 4.18 showing the effects of mibefradil on A7r5 cell proliferation.
Figure 5.6 CORM-3 and iCORM-3 do not induce caspase-3/7 activation

Bar graph showing that neither 10μM CORM-3, nor 10μM iCORM-3, induced activation of caspase-3/7, n=11 and n=7 fields of view respectively. 2μM staurosporine treatment represented the positive control, A7r5 cells acted as the negative control, n=12 fields of view. Data are represented as mean ± s.e.m. Data were analysed by one-way ANOVA, with Bonferroni’s multiple comparison test, ** p<0.01, *** p<0.001 vs positive control.
Simultaneous addition of 10µM CORM-3 and 2µM nifedipine inhibits [Ca\(^{2+}\)]\(_i\) and Ca\(^{2+}\) oscillations

Representative trace showing the response of A7r5 cells to 20mM K\(^+\) buffer in the presence of 10µM CORM-3 and 2µM nifedipine (A). Trend graph showing the decrease in Fura 2 ratio (B) and the decrease in the change in spikes/s (C) in response to 20mM K\(^+\) buffer followed by 20mM K\(^+\) buffer in the presence of 10µM CORM-3 and 2µM nifedipine. The mean (± s.e.m.) response is shown to the right and left of the corresponding individual data points on each graph. Bar graph showing the mean (± s.e.m.) change in Fura 2 ratio (D) and the change in spikes/s (E) in response to 20mM K\(^+\) buffer in the presence of the drug as indicated. Data were analysed by one-way ANOVA, followed by Tukey’s multiple comparison test, ** p<0.01, **** p<0.0001 vs K\(^+\), n=6. nif. = nifedipine.
Figure 5.8 CORM-3 inhibits A7r5 proliferation in combination with nifedipine

Bar graph showing the proliferative response of A7r5 cells to increasing concentrations of CORM-3, in the presence of 2µM nifedipine (left y-axis). The overlaid red plot shows the corresponding non-viable cell count (right y-axis). Data were analysed by ratio repeated measures one-way ANOVA with Dunnett’s multiple comparison test, ** p<0.01, *** p<0.001 vs Day 3 Control. Data are represented as mean ± s.e.m., n=3.
5.2.2 The effect of HO-1 modulation on \([\text{Ca}^{2+}]_i\) and cell proliferation

HO-1 induction by 10µM CoPPIX and 10µM hemin over a 24h period was verified by immunocytochemistry and is shown in Figure 5.9. The effects of HO-1 induction in response to modest depolarisation are shown in Figure 5.10. The level of \([\text{Ca}^{2+}]_i\) was visibly lower in cells with HO-1 induction as shown by the example traces in panels (A) and (B); the mean change in Fura 2 ratio was reduced by 30% with respect to the control group, as shown in panel (C). The oscillation frequency was also visibly reduced, as shown in Figure 5.10 (D). It appears that there was a trend towards lower \([\text{Ca}^{2+}]_i\) and \(\text{Ca}^{2+}\) oscillation frequency in response to CoPPIX pre-treatment, yet the data did not reach statistical significance. Figure 5.11 (A) shows the effect of nifedipine in comparison to the effects of nifedipine post HO-1 induction in Figure 5.11 (B). As stated in Chapter 4, nifedipine significantly reduced \([\text{Ca}^{2+}]_i\) by 60% in comparison to control data. The addition of 2µM nifedipine after a 48h incubation with 10µM CoPPIX also completely abolished the \(\text{Ca}^{2+}\) oscillations, and significantly reduced \([\text{Ca}^{2+}]_i\) by 70% in comparison to control data. The representative trace in Figure 5.11 (B) shows the diminished response to 20mM K\(^+\) buffer, as indicated by the lower baseline of the \(\text{Ca}^{2+}\) oscillations. Furthermore, the amplitude of the oscillations appears to be increased, although this was not quantitatively assessed. Incubation of the cells with 10µM CoPPIX, individually or followed by application of 2µM nifedipine, prevented a significant increase of \([\text{Ca}^{2+}]_i\) in response to 20mM K\(^+\) buffer, as shown in Figure 5.11 (C). Incubation of the cells with 10µM CoPPIX followed by application of 2µM nifedipine, completely abolished \(\text{Ca}^{2+}\) oscillations, as shown in Figure 5.11 (D).

HO-1 induction by a range of CoPPIX concentrations was verified by western blotting and is shown in Figure 5.12. At the 48h time-point, HO-1 protein expression was induced to a level of 57.72 ± 20.55% of \(\beta\)-actin in response to 10µM CoPPIX, and to a level of 55.92 ± 11.60% of \(\beta\)-actin in response to 30µM CoPPIX. CoPPIX was added to the cells as a single application on Day 0, and subsequent induction of the HO-1 protein is shown in Figure 5.13. However, without re-application of CoPPIX, HO-1 expression appears to begin to decline over the 3 day period, although not to a level of statistical significance. A7r5 cell proliferation was inhibited in a concentration dependent manner, as shown in Figure 5.14 (A), with no effect on cell viability as shown by the red line graph. Mean cell number was reduced by 30% and 41% for 10µM and 30µM CoPPIX respectively, and cell death was limited to 1.6% or less. Cell
Figure 5.9 HO-1 induction by CoPPIX and hemin

Immunocytochemistry of HO-1 induction (green) in A7r5 cells. Panel (A) illustrates HO-1 expression after a 24h incubation with 10µM CoPPIX. Panel (B) illustrates HO-1 expression after a 24h incubation with 10µM hemin. Panel (C) shows a control image without HO-1 induction. Cell nuclei were stained blue with DAPI. Cells were utilised at P6, and are representative images of 12 fields of view from n=6 experimental repeats.
Figure 5.10 The effect of 10µM CoPPIX on 

Representative control trace showing the response of A7r5 cells to 20mM K⁺ buffer (A), and the response of A7r5 cells to 20mM K⁺ buffer after a 48h incubation with 10µM CoPPIX (B). Bar graph showing the mean (± s.e.m.) change in Fura 2 ratio in response to 20mM K⁺ buffer, plus or minus pre-treatment with 10µM CoPPIX (C). Bar graph showing the mean (± s.e.m.) spikes/s in response to 20mM K⁺ buffer, plus or minus pre-treatment with 10µM CoPPIX (D). n=4.
Figure 5.11 A7r5 \([\text{Ca}^{2+}]_i\) and \(\text{Ca}^{2+}\) oscillations are inhibited by simultaneous CoPPiX and nifedipine treatment

Representative trace showing the response of A7r5 cells to 20mM \(\text{K}^+\) buffer in the presence of 2\(\mu\)M nifedipine (A). Representative trace showing the response of A7r5 cells, after a 48h incubation with 10\(\mu\)M CoPPiX, to 20mM \(\text{K}^+\) buffer in the presence of 2\(\mu\)M nifedipine (B). Bar graph showing the change in Fura 2 ratio (C) and the change in spikes/s (D) in response to 20mM \(\text{K}^+\) buffer in the presence of the drug as indicated. Data are represented as mean (± s.e.m.) and were analysed by one-way ANOVA, followed by Tukey’s multiple comparison test, ** \(p<0.01\), *** \(p<0.001\) vs \(\text{K}^+\), \(n=6\). nif. = nifedipine.
Bar graph showing relative HO-1 protein expression in A7r5 cells in response to a 48h incubation with a range of CoPPIX concentrations, densitometric analyses were normalised relative to β-actin (A). Data are represented as mean ± s.e.m. and were analysed by one-way ANOVA with Dunnett’s multiple comparison test, * p<0.05 vs Control levels, n=3. Representative western blot of HO-1 and the corresponding β-actin loading control (B). The arrows represent the position of the molecular weight markers (top, 37KDa; bottom, 25kDa).

Figure 5.12 CoPPIX induces HO-1 protein expression in A7r5 cells
Bar graph showing relative HO-1 protein expression in A7r5 cells following incubation with 10µM CoPPIX for 24h, 48h, and 72h, densitometric analyses were normalised relative to β-actin (A). Data are represented as mean ± s.e.m., n=3. Representative western blot of HO-1 and the corresponding β-actin loading control (B). The arrows represent the position of the molecular weight markers (top, 37KDa; bottom, 25kDa).

Figure 5.13 HO-1 induction by CoPPIX over a 3 day period
Figure 5.14 HO-1 induction by CoPPIX inhibits A7r5 cell proliferation in a concentration-dependent manner

Panel (A) shows a bar graph of the proliferative response of A7r5 cells to increasing concentrations of CoPPIX (left y-axis). The overlaid red plot shows the corresponding non-viable cell count (right y-axis). Data were analysed by ratio repeated measures ANOVA with Dunnett’s multiple comparison test, ** p<0.01, *** p<0.001 vs Day 3 Control, n=5. Line graph showing the effects of 10μM CoPPIX over a three day period; cell counts were taken daily to produce a 3 day time-course (B). Data were analysed by a two-way repeated measures ANOVA, with sample matching by time point. This was followed by Sidak’s multiple comparison test between control and treated groups for each time point, *** p<0.001, n=4. Data are represented as mean ± s.e.m.
number in response to 10µM CoPPIX was monitored daily for a period of 3 days to produce a 3 day time-course of proliferation. The line graph in Figure 5.14 (B) demonstrates that 10µM CoPPIX significantly reduced cell number by day 3. The minimal effect of 10µM CoPPIX on cell viability demonstrated by media counts in Figure 5.14 (A) was verified by the lack of caspase-3/7 activation shown in Figure 5.15.

HO-1 induction by 10µM hemin over a 24h period was verified by immunocytochemistry and is shown in Figure 5.9 (B). HO-1 induction by a range of hemin concentrations was verified by western blotting and is shown in Figure 5.16. At the 48h time-point, HO-1 was induced to a level of 51.99 ± 1.73% of β-actin for 10µM hemin. After the addition of hemin on Day 0, the HO-1 protein was induced, but expression decreased over a 3 day period, as shown in Figure 5.17. Mean A7r5 cell number was reduced by 18% and 50% in response to 10µM and 30µM hemin respectively, as shown in Figure 5.18 (A). Cell death was 1% or less. Over a 3 day time-course, hemin inhibited the proliferative response of A7r5 cells, although not to a level of statistical significance, as shown in Figure 5.18 (B).

A7r5 cells stably over-expressing human HO-1 (A7r5/hHO-1 cells) demonstrated a decline in HO-1 expression as they were passaged weekly over a three week period, which is demonstrated in Figure 5.19. The response of A7r5 cells and A7r5/hHO-1 cells to moderate depolarisation by 20mM K⁺ buffer is shown in Figure 5.20. A7r5/hHO-1 cells demonstrated a smaller change in Fura 2 ratio than A7r5 cells, as shown by the bar graph in Figure 5.20 (C), yet the data did not reach statistical significance. There was a wide variation in the oscillatory response of A7r5/hHO-1 cells, as shown by Figure 5.20 (D). Figure 5.21 shows the proliferative response of A7r5 cells and A7r5/hHO-1 cells in the presence or absence of 10µM CoPPIX over a 3 day time-course. The application of 10µM CoPPIX to A7r5 cells reduced the mean cell number by 38%. The addition of CoPPIX to the A7r5/hHO-1 cell group had an additional effect on the proliferative response, reducing mean cell number by a further 11% on day 3. The proliferative response between A7r5 cells and A7r5/hHO-1 cells was significantly different on day 2 and day 3, as shown in Figure 5.21 (B).
Figure 5.15 CoPPIX does not induce caspase-3/7 activation

Bar graph showing that 10µM CoPPIX does not induce apoptosis by caspase-3/7 activation. 2µM staurosporine treatment represented the positive control, untreated A7r5 cells acted as the negative control, n=12 fields of view for each group. CoPPIX treated, n=6 fields of view. Data were analysed by a one-way ANOVA, with Bonferroni’s multiple comparison test, ** p<0.01, *** p<0.001. Data are represented as ± s.e.m.
Figure 5.16 Hemin induces HO-1 protein expression in A7r5 cells

Bar graph showing relative HO-1 protein expression in A7r5 cells in response to a 48h incubation with a range of hemin concentrations, densitometric analyses were normalised relative to β-actin (A). Data are represented as mean ± s.e.m., and data were analysed by one-way ANOVA with Dunnett’s multiple comparison test, * p<0.05 vs Control levels, n=3. Representative western blot of HO-1 and the corresponding β-actin loading control (B). The arrows represent the position of the molecular weight markers (top, 37KDa; bottom, 25kDa).
Figure 5.17 HO-1 induction by hemin declines over a 3 day period

Bar graph showing relative HO-1 protein expression in A7r5 cells following incubation with 10µM hemin for 24h, 48h, and 72h, densitometric analyses were normalised relative to β-actin (A). Data are represented as mean ± s.e.m., and data were analysed by one-way ANOVA with Dunnett’s multiple comparison test, * p<0.05, ** p<0.01 vs Control levels, n=3. Representative western blot of HO-1 and the corresponding β-actin loading control (B). The arrows represent the position of the molecular weight markers (top, 37KDa; bottom, 25kDa).
Figure 5.18 The effect of hemin on A7r5 cell proliferation

Panel (A) shows a bar graph of the proliferative response of A7r5 cells to increasing concentrations of hemin (left y-axis). The overlaid red plot shows the corresponding non-viable cell count (right y-axis). Data were analysed by ratio repeated measures one-way ANOVA with Dunnett’s multiple comparison test, *** \( p<0.001 \) vs Day 3 Control, \( n=3 \). Line graph showing the effects of 10µM hemin; cell counts were taken daily to produce a three day time-course (B), \( n=3 \). Data are represented at mean ± s.e.m.
Figure 5.19 HO-1 expression by A7r5/hHO-1 cells

Illustrative western blot showing the decline in HO-1 protein expression by A7r5/hHO-1 cells over 3 passages. Underneath is the corresponding β-actin loading control. The arrows represent the position of the molecular weight markers (top, 37kDa; bottom, 25kDa). n=1
Figure 5.20 [Ca^{2+}]_i and Ca^{2+} oscillations in A7r5 vs A7r5/hHO-1 cells

Representative control trace showing the response of A7r5 cells to 20mM K^+ buffer (A). Representative trace showing the response of A7r5/hHO-1 cells to 20mM K^+ buffer (B). Bar graph showing the mean change in Fura 2 ratio in response to 20mM K^+ buffer, for A7r5 cells and A7r5/hHO-1 cells. (C). Bar graph showing the mean spikes/s in response to 20mM K^+ buffer, for A7r5 cells and A7r5/hHO-1 cells. Data are represented mean ± s.e.m., n=9.
Figure 5.21 Stable over-expression of HO-1 inhibits A7r5 cell proliferation

Line graph showing the proliferative response of A7r5 cells and hHO-1/A7r5 cells ±10µM CoPPIX over a 3 day period; cell counts were taken daily to produce a 3 day time-course (A). Line graph showing the significant difference in proliferation between A7r5 cells and hHO-1/A7r5 cells on days 2 and 3 of the assay (B). Data were analysed by two-way repeated measures ANOVA, with sample matching by time point. This was followed by Sidak’s multiple comparison test between A7r5 and hHO-1 cell groups for each time point, * p<0.05, ** p<0.01 hHO-1 vs A7r5, n=5. Data are represented as mean ± s.e.m.
QC-15 is a non-competitive inhibitor of HO-1 that binds to the distal side of the heme binding pocket within the enzyme (Rahman et al., 2012). Various combinations of CoPPIX and QC-15 (a gift from Prof. Kanji Nakatsu, Queen’s University, Kingston, Canada) were assessed in attempt to establish how the effects of this novel HO-1 inhibitor were exerted. One group of cells were treated with QC-15 and this was added to media already containing CoPPIX, to investigate whether inhibition was possible in the presence of an inducer. Another group of cells were treated with QC-15, but this was added to fresh media after the cells had been previously exposed to CoPPIX, in order to establish whether the effect of the inducer could be reversed. Figure 5.22 shows that QC-15 was able to reduce the level of CoPPIX induced HO-1 expression when CoPPIX containing media was removed from the cells, and fresh media added containing 10µM QC-15. This is shown by the HO-1 protein levels; 3.91 ± 1.30% of β-actin for 24h CoPPIX/48h QC-15, and 33.84 ± 4.58% of β-actin for 48h CoPPIX/24h QC-15. The level of HO-1 induction was higher when CoPPIX remained in the media with QC-15; 62.95 ± 26.91% of β-actin for 24h CoPPIX+48h QC-15, 53.46 ± 5.66% of β-actin for 48h CoPPIX+24h QC-15. With regards to the proliferative response of A7r5 cells to such combinations of CoPPIX and QC-15, the presence of CoPPIX in any combination significantly inhibited proliferation, as shown in Figure 5.23. The effect of QC-15 independent of CoPPIX also appeared to reduce cell proliferation, but did not reach statistical significance. There was no effect on cell viability by CoPPIX or QC-15, as demonstrated by the red line graph.

In summary, HO-1 induction by CoPPIX and hemin was verified by immunocytochemistry and western blotting. CoPPIX treatment caused a trend towards lower [Ca\(^{2+}\)], and Ca\(^{2+}\) oscillations, but did not reach a level of statistical significance. Treatment of A7r5 cells with CoPPIX also appeared to increase the amplitude of Ca\(^{2+}\) oscillations. The combined effect of CoPPIX and nifedipine treatment produced additive effects on [Ca\(^{2+}\)], compared to nifedipine alone. HO-1 induction by CoPPIX significantly inhibited cell proliferation. Treatment with hemin produced a trend towards lower cell number, but data did not reach statistical significance. hHO-1/A7r5 cells proliferated significantly less than A7r5 cells, yet no significant effect were seen on [Ca\(^{2+}\)] levels. The novel HO-1 inhibitor, QC-15, was able to limit HO-1 induction to a greater extent in the absence of CoPPIX, but QC-15 also appeared to negatively regulate A7r5 cell proliferation.
Figure 5.22 The effect of QC-15 on HO-1 induction by CoPPIX

(A) Bar graph showing relative HO-1 protein expression in A7r5 cells in response to 10µM CoPPIX, 10µM QC-15, or combinations of the two compounds; CoPPIX initially for 24h then fresh media with QC-15 for 48h; CoPPIX initially for 24h, then QC-15 for 48h in addition to the existing media; CoPPIX initially for 48h then fresh media with QC-15 for 24h; CoPPIX initially for 48h, then QC-15 for 24h in addition to the existing media. Densitometric analyses were normalised relative to β-actin, n=3. Data are represented as mean ± s.e.m., and data were analysed by one-way ANOVA with Dunnett’s multiple comparison test, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 vs CoPPIX levels. (B) Representative western blot of HO-1 and the corresponding β-actin loading control. Each lane corresponds to the above bar on the graph. The arrows represent the position of the molecular weight markers (top, 37KDa; bottom, 25kDa).
Figure 5.23 The effect of QC-15 on A7r5 cell proliferation

Bar graph showing the proliferative response of A7r5 cells to 10μM CoPPIX, 10μM QC-15, or combinations of the two compounds (left y-axis); CoPPIX initially for 24h then fresh media with QC-15 for 48h; CoPPIX initially for 24h, then QC-15 for 48h in addition to the existing media; CoPPIX initially for 48h then fresh media with QC-15 for 24h; CoPPIX initially for 48h, then QC-15 for 24h in addition to the existing media. The overlaid red plot shows the corresponding non-viable cell count (right y-axis). Data are represented as mean ± s.e.m., and data were analysed by one-way ANOVA with Dunnett’s multiple comparison test, ** p<0.01, *** p<0.001 vs Day 3 Control, n=4.
5.3 Discussion

Taken together, Figures 5.1 and 5.3 suggest that CORM-3 is able to inhibit T-type Ca²⁺ channels. Significant effects on [Ca²⁺]i and Ca²⁺ oscillations were demonstrated when the cells were modestly depolarised (20mM K⁺ buffer), but not when they were strongly depolarised (80mM K⁺ buffer), implying T-type Ca²⁺ channels were preferentially inhibited. Given that Ni²⁺ did not affect Ca²⁺ oscillation frequency (Figure 4.11, Chapter 4), but mibefradil did significantly reduce Ca²⁺ oscillations (Figure 4.8, Chapter 4), possibly as a result of non-selective effects on L-type Ca²⁺ channels, it appears logical to conclude that by significantly reducing Ca²⁺ oscillations, CORM-3 also has non-selective effects. However, the fact that CORM-3 had no effect on [Ca²⁺]i when L-type Ca²⁺ channels were preferentially activated, suggests that CORM-3 preferentially inhibits T-type Ca²⁺ channels. CORM-3 caused a significant decrease in [Ca²⁺]i regardless of DTT pre-treatment, yet Ca²⁺ oscillations were not significantly affected, despite there being a trend towards a lower oscillation frequency. Our research group has demonstrated that CO can inhibit L-type Ca²⁺ currents in cardiac myocytes and HEK293 cells expressing the human Caᵥ1.2 subunit, although at a higher concentration of 30µM CORM-2, and also that DTT is able to prevent the effects of CO on this channel (Scragg et al., 2008). Therefore, the non-significant effect of DTT pre-treatment on Ca²⁺ oscillations could also be attributed to the preventative effect on L-type Ca²⁺ channels. CO has also been shown to augment human recombinant interstitial smooth muscle L-type Ca²⁺ channels (Lim et al., 2005). The study by Scragg et al. details how reactive oxygen species produced by electron transport chain modulation alter the redox state of the cell and the L-type Ca²⁺ channel, thereby altering the channel function. T-type Ca²⁺ channels have been shown to be modulated by a variety of endogenous ligands and pathways. The reducing agent L-cysteine has been demonstrated to augment T-type Ca²⁺ currents in sensory neurons (Nelson et al., 2005). The neurotransmitter Zn²⁺ has been shown to preferentially inhibit Caᵥ3.2 channels via an extracellular histidine residue at position 191 (His191) in domain I of the Caᵥ3.2 α₁ subunit (Traboulsie et al., 2007), and this can be prevented by Zn²⁺ ion chelation via reducing agents (Nelson et al., 2007b). His191 is also the site implicated in preferential Ni²⁺ inhibition (Kang et al., 2006), and the site of metal-catalysed oxidation by ascorbate, which subsequently inhibits the channel (Nelson et al., 2007a). Evidently, redox sites within the T-type Ca²⁺ channel are important for modulation. DTT has been shown to inhibit Caᵥ3.1 T-type Ca²⁺ channels in HEK293/Caᵥ3.1 cells by causing a hyperpolarising shift of current activation (Karmazinova et al., 2010). Through Caᵥ3.1 mutagenesis, this study demonstrated that extracellular cysteine residues are required for current inhibition by DTT. If DTT had produced significant
effects on \([\text{Ca}^{2+}]\); in the present study, further experiments to elucidate which residues were affected by CO and DTT would be required. T-type \(\text{Ca}^{2+}\) channel mutagenesis followed by electrophysiological assessment of channel currents would be the logical next step. Cysteine residues are modified by the redox status of the cell (Chung et al., 2013), and are a likely target for redox modulation within the \(\text{Ca}_{\text{v}}3.1\) T-type \(\text{Ca}^{2+}\) channel protein (Karmazinova et al., 2010).

CORM-3 did not significantly inhibit A7r5 cell proliferation, and in combination with 3\(\mu\)M mibefradil, CORM-3 caused no additive inhibitory effects in comparison to the effect of mibefradil alone. CORM-3 is stable for over 24h at 37°C when dissolved in water, and releases CO upon ligand exchange in physiological solutions with a half-life of 4-18 minutes (Clark et al., 2003). It has been proposed that CORM-3 reacts with plasma proteins \textit{in vivo} to form ruthenium-protein adducts, and these adducts then decay slowly to liberate CO (Santos et al., 2012). In the present experiment, CORM-3 was applied to the medium twice daily to ensure the cells were consistently exposed to CO. The myoglobin assay provides a method for the quantitation of CO released from CORMs, (Motterlini et al., 2002; Atkin et al., 2011), and was employed by our research group during preliminary investigations of CORM-3 activity prior to the use of this compound in proliferation assays. However, the low expression levels of T-type \(\text{Ca}^{2+}\) channels in A7r5 cells likely constrained the elucidation of the anti-proliferative effects of CO within this cell line. When CORM-3 was applied in combination with 2\(\mu\)M nifedipine, proliferation was significantly inhibited. The proliferative response of the cells in Figure 5.8 was lower than in other proliferation assays. An explanation for this could be that as the cells reached P6, it was discovered that they proliferated at a slower rate. The passages used in the Figure 5.8 were a combination of passages 4, 5, and 6. However, the effects of both nifedipine and CORM-3 on \([\text{Ca}^{2+}]\) when applied simultaneously were less than the effect of nifedipine alone; \([\text{Ca}^{2+}]\) reached a higher level in the presence of both compounds. The fact that the proliferative response to both compounds does not reflect the change \([\text{Ca}^{2+}]\) levels is unexpected. These data imply that L-type \(\text{Ca}^{2+}\) channels, or a proportion of these channels, are active upon modest depolarisation therefore, it is possible that this activity is masking the activity of T-type \(\text{Ca}^{2+}\) channels. The effects of 2\(\mu\)M nifedipine on \([\text{Ca}^{2+}]\) levels, as shown in Figure 4.13 in Chapter 4, demonstrate that L-type channels are prominent in A7r5 cells, yet Figure 4.21 shows that 2\(\mu\)M nifedipine has no inhibitory effect on proliferation. As CO has been shown to modulate both L-type and T-type \(\text{Ca}^{2+}\) channel activity, it is possible that when L-type \(\text{Ca}^{2+}\) channels are inhibited by nifedipine, the inhibitory effect
of CO on T-type Ca\(^{2+}\) channels is unmasked. This is likely to be more apparent in the setting of a proliferation assay, as a proportion of T-type Ca\(^{2+}\) channels are active at RMP, and the contribution of these channels to resting [Ca\(^{2+}\)] levels is greater than that of L-type Ca\(^{2+}\) channels.

HO-1 induction via 10\(\mu\)M CoPPIX pre-treatment reduced [Ca\(^{2+}\)] and Ca\(^{2+}\) oscillation frequency, but not to a level of statistical significance. However, the trends may have proven significant if the number of experimental repeats was increased. The application of nifedipine after CoPPIX pre-treatment reduced [Ca\(^{2+}\)] levels by a greater extent than nifedipine treatment alone; implying HO-1 induction and subsequent CO exposure is able to reduce [Ca\(^{2+}\)], by a mechanism independent of L-type Ca\(^{2+}\) channels. This additional effect by CoPPIX, which was not produced by CORM-3 in the presence of nifedipine, may be attributable to the prolonged exposure of the cells to CO as a result of a 48h exposure to CoPPIX. Interestingly, the amplitude of the Ca\(^{2+}\) oscillations produced in response to HO-1 induction in both Figures 5.10 and 5.11 appear to be increased in comparison to the control traces. In hindsight, analysis of the Ca\(^{2+}\) oscillation amplitude between control and HO-1-induced traces should have been performed. Figure 5.11 (C) shows that Fura 2 ratio was significantly reduced by HO-1 induction, yet the representative traces in Figures 5.10 and 5.11 (B) imply that Ca\(^{2+}\) oscillation frequency decreases with HO-1 induction. These observations suggest that HO-1-derived CO is able to limit [Ca\(^{2+}\)], possibly by inhibition of T-type Ca\(^{2+}\) channels (as suggested by Figures 3.13 and 5.10), but that Ca\(^{2+}\) movement with each oscillation is increased, possibly via L-type Ca\(^{2+}\) channels. The potential inhibition of T-type Ca\(^{2+}\) channels by HO-1-derived CO may have revealed the full response of L-type Ca\(^{2+}\) channels and their influence on Ca\(^{2+}\) oscillations.

Proliferation of A7r5 cells was significantly inhibited by 10\(\mu\)M CoPPIX. There was also a general trend of decreased cell proliferation in response to hemin, although a level of statistical significance was not reached. The anti-proliferative effects of hemin were less potent than the effects of CoPPIX. This is surprising as hemin also acts as a substrate for HO-1, therefore one would expect higher enzyme activity and more CO production. If time had permitted, the levels of HO-1 activity after induction by the two metalloporphyrins could have been assessed using the biliverdin reductase assay (Huber, III et al., 2009). Taking into consideration the significant effects of CORM-3 and CoPPIX on HEK293/Ca\(_{v}\)3.2 cell proliferation and [Ca\(^{2+}\)], it is tempting to speculate that
the significant inhibitory effects of CoPPIX on A7r5 proliferation are due to T-type Ca\(^{2+}\) channel inhibition. However, this cannot be reliably concluded given the insignificant effects of CORM-3 on proliferation, and of CoPPIX on [Ca\(^{2+}\)]\(_i\) levels.

As the level of HO-1 expression deteriorated during the passage of A7r5/hHO-1 cells, early passage numbers were utilised in the proliferation assays and microfluorimetry recordings. A7r5/hHO-1 proliferation was significantly lower than A7r5 cell proliferation, implying the level of HO-1 activity as a result of over-expression is comparable to the effects of 10µM CoPPIX and 30µM hemin. As A7r5/hHO-1 proliferation was lower than the CoPPIX induced anti-proliferative effects in A7r5 cells, it is feasible that the constant level of over-expressed HO-1 activity, and subsequent CO production, continuously limited the proliferative response. Indeed, rat VSMC proliferation was also inhibited by HO-1 over-expression using a retroviral vector (Zhang et al., 2002). However, the mechanism underlying this response was not fully elucidated. As the application of CoPPIX reduces the proliferative response of A7r5/hHO-1 by a further 12%, it appears there is scope for further HO-1 induction. The level of A7r5/hHO-1-mediated CO production was not high enough to reduce [Ca\(^{2+}\)]\(_i\) significantly in A7r5/hHO-1 cells. The microfluorimetry data provide a snapshot of Ca\(^{2+}\) handling over a short time window, whereas proliferation assays provide a continuous assessment of the cell response. Therefore, the chronic exposure of the cells to HO-1 and CO is more accurately assessed by the latter.

The densitometry data in Figure 5.22 (A) imply that QC-15 is able to inhibit HO-1 induction by CoPPIX after a 24h exposure, but induction will still occur if CoPPIX is maintained in the media. This suggests that there was a level of competition between the two compounds because, if CoPPIX was present in addition to QC-15, HO-1 induction ensued. The inhibition of A7r5 proliferation in Figure 5.23 by QC-15 was surprising given that this compound was developed as a HO-1 inhibitor, as it is HO-1 induction that has demonstrated anti-proliferative effects previously (Duckers et al., 2001; Tulis et al., 2001; Peyton et al., 2002; Zhang et al., 2002; Choi et al., 2009; Hyvelin et al., 2010). The anti-proliferative effects of combinations of QC-15 and CoPPIX cannot be solely attributed to the induction of HO-1, as QC-15 also negatively affected the proliferative response. Further evidence of this notion is given by the fact that HO-1 was not induced by the 24h incubation with CoPPIX which was then replaced by QC-15 for a further 48h, as demonstrated in Figure 5.22, yet proliferation was inhibited by
this combination. HO-1 is inhibited more potently by QC-15 than HO-2, and QC-15 has been shown to have little effect on other heme-containing enzymes, such as sGC and NOS (Kinobe et al., 2006). However, there appears to be additional off-target effects with regards to A7r5 proliferation. Indeed, neointima formation has been shown to be reduced in iNOS knockout mice (Chyu et al., 1999), therefore even minimal off-target effects of QC-15, on NOS for example, may have limited the proliferative response of A7r5 cells.

In summary, despite the minimal effects of CORM-3 alone on A7r5 cell proliferation, microfluorimetry data indirectly imply that CO can inhibit native T-type Ca\(^{2+}\) channels in these cells. HO-1 induction or over-expression, and subsequent CO production, have anti-proliferative effects and visibly reduce [Ca\(^{2+}\)]. Although, the inhibitory effect of CORM-3 on [Ca\(^{2+}\)], was not significantly prevented by redox modulation, transient receptor potential channels have been shown to be modulated by the extracellular redox protein, thioredoxin (Beech & Sukumar, 2007). Thioredoxin has an important role in maintaining cellular redox status (Yamawaki et al., 2003), and oxidative stress is a feature of many cardiovascular disorders (Paravicini & Touyz, 2006; Kim et al., 2011b; Chung et al., 2013). Excess pathological proliferation and T-type Ca\(^{2+}\) channel up-regulation (Rodman et al., 2005; Cribbs, 2006; Pluteanu & Cribbs, 2011), in addition to HO-1 induction and subsequent CO production (Wang & Chau, 2010), are central to such disorders, therefore a possible role for thioredoxin as a modulator of T-type Ca\(^{2+}\) channels warrants investigation. Indeed, ROS have been shown to increase VSMC differentiation (Su et al., 2001), therefore the redox status of VSMCs during the response to injury may provide the specific environment for CO to exert effects on the T-type Ca\(^{2+}\) channel.
CHAPTER 6

The effect of T-type Ca\textsuperscript{2+} channel inhibition, HO-1 induction, and CO on human smooth muscle cell proliferation

6.1 Introduction

Vascular injury and ensuing complications arise from endothelial dysfunction or damage. Interventions such as stenting and angioplasty, and disorders such as hypertension and atherosclerosis, compromise the integrity of the endothelium and an inflammatory response ensues, followed by an increase in oxidative stress and remodelling (Rzucidlo et al., 2007). In response to this injury, VSMCs de-differentiate, re-enter the cell cycle, migrate to the site of injury and proliferate (Rzucidlo et al., 2007). Excessive VSMC proliferation can be detrimental to vascular function, as they produce extracellular matrix that contributes to the formation of atherosclerotic plaques and hyperplastic lesions (Rzucidlo et al., 2007), and neointima formation can reduce or even occlude blood flow. Under such conditions of oxidative and inflammatory stress, HO-1 is induced, and the by-product of HO-1 activity, CO, has been shown to have anti-proliferative effects in VSMCs (Kim et al., 2011b). The anti-proliferative effects of HO-1 and CO have been demonstrated across different species. HO-1 induction was shown to limit vascular remodelling in vivo following balloon injury in rats (Tulis et al., 2001), and HO-1 derived CO reduced neointima formation and inhibited proliferation of rat aortic VSMCs (Togane et al., 2000; Peyton et al., 2002). VSMC proliferation was reduced in a pig model of arterial injury after HO-1 induction (Duckers et al., 2001), and HO-1 induction in stented rat aorta and rabbit iliac arteries limited neointimal hyperplasia, in addition to apoptosis and inflammation (Hyvelin et al., 2010).

Previous chapters have detailed the anti-proliferative effects of CO in HEK293/Ca\textsubscript{v3.2} cells and rat aortic VSMCs. The hypothesis that the T-type Ca\textsuperscript{2+} channel is a target of CO has been strengthened by the data generated thus far. Primary VSMCs were employed in order to assess the effects of HO-1 induction, CO and T-type Ca\textsuperscript{2+} channel inhibition on proliferation in a model with greater relevance to human disease. Both human saphenous vein smooth muscle cells (HSVSMC) and human coronary artery smooth muscle cells (HCASMC) were utilised.
6.2 Results

6.2.1 Characterisation of HSVSMCs

Immunocytochemistry was performed on HSVSMCs to confirm their smooth muscle cell properties. Figure 6.1 illustrates positive staining for smooth muscle α-actin (panels A and E), smooth muscle myosin heavy chain (panels B and F), and vimentin (panel C). In addition, a degree of co-localisation of smooth muscle α-actin and myosin heavy chain can be seen in Figure 6.1 panel (D), as demonstrated by the orange staining in the cell in the centre of the image. The corresponding α-actin and myosin heavy chain images are shown in panels (E) and (F). The presence of T-type Ca^{2+} channels were also demonstrated by immunocytochemistry. Figure 6.2 shows positive staining for Ca,3.1 and Ca,3.2, with denser staining of Ca,3.1 in peri-nuclear regions and what appears to be an association with the Golgi network. Figure 6.3 (A) shows the only successful identification of Ca,3.1 via western blot. The channel is represented most clearly in lanes 2 and 4, which correspond to a membrane enriched and an untreated HSVSMC sample respectively. HEK293/Ca,3.1 cells were used as the positive control. Immunoprecipitation of the T-type Ca^{2+} channels was attempted on two occasions without success. Figure 6.3 (B) shows the wide variation in mRNA expression levels of Ca,3.1 from six patient samples of HSVSMCs, the cell passages ranged from P2 to P6. Figure 6.4 shows the mRNA expression levels of Ca,3.2, detectable in only two patient samples, which exhibit a trend of considerably lower expression than Ca,3.1. Figure 6.5 demonstrates the growth characteristics of HSVSMCs in response to 0.4% or 10% serum-containing medium. The 10% serum-containing medium was utilised to encourage cell proliferation, whilst the 0.4% serum-containing medium was employed to induce cell senescence. There was a significant difference in cell number between the 10% and 0.4% experimental groups at days 3 and 4 of the assay. Subsequent proliferation assays involving human VSMCs were therefore performed over 4 days in order to detect reliably, the significant effects of compounds used in this study.

6.2.2 The effect of T-type Ca^{2+} channel inhibition on HSVSMC and HCASMC proliferation

Proliferation of both HSVSMCs and HCASMCs was significantly inhibited by mibefradil, as shown in Figures 6.6 and 6.7 respectively. There was a concentration-dependent decrease in HSVSMC proliferation, as shown in Figure 6.6 (A), yet concentrations of 10µM and 30µM mibefradil reduced cell viability to 50%. Cells were counted daily for a
Figure 6.1 Characterisation of HSVSMCs

Immunocytochemistry of HSVSMCs showing smooth muscle α-actin staining (red) (A), smooth muscle myosin heavy chain staining (green) (B), vimentin staining (red) (C), smooth muscle α-actin and myosin heavy chain co-localisation (D). Panels (E) and (F) show the corresponding smooth muscle α-actin (red) and smooth muscle myosin heavy chain (green) of image (D). Cell nuclei were stained blue with DAPI. Cells were utilised at P5, and are representative images of 12 fields of view from n=6 experimental repeats.
Figure 6.2 Expression of Ca_{v}3.1 and Ca_{v}3.2 in HSVSMCs

Immunocytochemistry of HSVSMCs showing staining for Ca_{v}3.1 (green) (A), and for Ca_{v}3.2 (green) (B). Panel (C) shows a control image without primary antibody. Cell nuclei were stained blue with DAPI. Cells were utilised at P3, and are representative images of 10 fields of view from n=5 experimental repeats.
Figure 6.3 Expression of the Ca\textsubscript{v}3.1 T-type Ca\textsuperscript{2+} channel in HSVSMCs

Western blot of Ca\textsubscript{v}3.1 T-type Ca\textsuperscript{2+} channel expression using an anti-Ca\textsubscript{v}3.1 antibody from Alomone (A), in various cell samples (SV; control HSVSMC, SV/M.E.; membrane enriched HSVSMC, Ca\textsubscript{v}3.1; HEK293/Ca\textsubscript{v}3.1 cells). The arrow represents the position of the 250kDa molecular weight marker, and of the Ca\textsubscript{v}3.1 protein. Below is the corresponding β-actin loading control. Panel (B) shows a bar graph of Ca\textsubscript{v}3.1 mRNA expression, relative to the endogenous control, HPRT1 (Hypoxanthine phosphoribosyltransferase 1), in samples of HSVSMCs from 6 different patients at P2 to P6. Samples were analysed in triplicate and represented as mean ± s.e.m.
Figure 6.4 Expression of the Ca\textsubscript{v}3.2 T-type Ca\textsuperscript{2+} channel in HSVSMCs

Bar graph of Ca\textsubscript{v}3.2 mRNA expression relative to the endogenous control, HPRT1, detectable in only two patient samples of HSVSMCs. Samples were at P3 and P4, analysed in triplicate and represented as mean ± s.e.m.
Figure 6.5 Growth characteristics of HSVSMCs

Line graph showing the daily counts of HSVSMCs in response to 0.4% (grey line) or 10% serum-containing media (black line), over a 4 day time-course, n=4. Data are represented as mean ± s.e.m., and data were analysed by two-way repeated measures ANOVA with sample matching by time point. This was followed by Sidak’s multiple comparison test between control and treated groups for each time point, * p<0.05, *** p<0.001.
Figure 6.6 Mibefradil inhibits HSVSMC proliferation

Bar graph showing the proliferative response of HSVSMCs (left y-axis) to increasing concentrations of mibefradil (A). The overlaid red plot (right y-axis) shows the corresponding non-viable cell count. Data were analysed by ratio repeated measures one-way ANOVA with Dunnett’s multiple comparison test, *** p<0.001 vs Day 4 Control, n=4. Line graph of the effects of 3µM mibefradil over a 4 day time-course (B), data were analysed by two-way repeated measures ANOVA with sample matching by time point. This was followed by Sidak’s multiple comparison test between control and treated groups for each time point, ** p<0.01, n=4. Data are represented as mean ± s.e.m.
Figure 6.7 Mibefradil inhibits HCASMC proliferation

Bar graph showing the proliferative response of HCASMCs (left y-axis) to increasing concentrations of mibefradil (A). The overlaid red plot shows the corresponding non-viable cell count (right y-axis). Data were analysed by ratio repeated measures one-way ANOVA with Dunnett’s multiple comparison test, * p<0.05, **** p<0.0001 vs Day 4 Control, n=5. Line graph of the effects of 3µM mibefradil over time (B), data were analysed by two-way repeated measures ANOVA with sample matching by time point. This was followed by Sidak’s multiple comparison test between control and treated groups for each time point, * p<0.05, n=4. Data are represented as mean ± s.e.m.
period of 4 days to assess the proliferative response of 3µM mibefradil over time; producing a 4 day time-course. Cell proliferation was inhibited by 34% and 39% in the presence of 3µM mibefradil on day 4, as shown in Figure 6.6 (A) and (B) respectively. Despite the fact that 3µM mibefradil has been demonstrated to have non-selective effects in A7r5 cells, this concentration produced visible effects on human VSMC proliferation, without causing cytotoxicity as assessed via non-viable cell counts. Given that inhibition of L-type Ca^{2+} channels by 2µM nifedipine did not cause significant inhibition of cell proliferation in A7r5 cells, as shown in Figure 4.21 (Chapter 4), one can speculate that any off-target effects of mibefradil on L-type Ca^{2+} channels would therefore, not significantly inhibit cell proliferation. Additionally, mibefradil was the most selective T-type blocker available at the time of these experiments. HCASMCs appeared more sensitive; 3µM mibefradil caused 5% cell death, and higher concentrations were increasingly cytotoxic, as shown in Figure 6.7 (A). Cell proliferation was inhibited by 52% and 35% in the presence of 3µM mibefradil on day 4, as shown in Figure 6.7 (A) and (B) respectively. However, the combination of all day 4 counts to produce n=9 demonstrates that cell proliferation was inhibited by 43% in the presence of 3µM mibefradil (graph not shown). In summary, T-type Ca^{2+} channel inhibition by 3µM mibefradil limits proliferation of HSVSMC and HCASMC to similar extents.

6.2.3 The effect of CO on HSVSMC and HCASMC proliferation
CORM-3 inhibited the proliferation of HSVSMCs and HCASMCs in a concentration dependent manner without causing effects on cell viability. HSVSMC number was reduced by 45% in the presence of 10µM CORM-3, as shown in Figure 6.8. HCASMC number was reduced by 22% and 34% in the presence of 10µM CORM-3, as shown in Figure 6.9 (A) and (B) respectively. However, the combination of all day 4 counts to produce n=7 indicated that cell proliferation was inhibited by 25% in the presence of 10µM CORM-3 (graph not shown).

6.2.4 The effect of HO-1 modulation on HSVSMC and HCASMC proliferation
Immunocytochemistry of HSVSMC in Figure 6.10 illustrates that HO-1 is induced by 3µM CoPPIX (panel A) and 3µM hemin (panel B) over 24h. Figure 6.11 illustrates the change in HO-1 protein expression after treatment with increasing concentrations of CoPPIX. Panels (A) and (B) show the levels of HO-1 protein expression at 48h and at
Figure 6.8 CORM-3 inhibits HSVSMC proliferation

Bar graph showing the proliferative response of HSVSMCs (left y-axis) to increasing concentrations of CORM-3 (right y-axis). The overlaid red plot shows the corresponding non-viable cell count. Data are represented as mean ± s.e.m., and data were analysed by ratio repeated measures one-way ANOVA with Dunnett's multiple comparison test, ** p<0.01, *** p<0.001 vs Day 4 Control, n=4.
Figure 6.9 CORM-3 inhibits HCASMC proliferation

Bar graph showing the proliferative response of HCASMCs (left y-axis) to increasing concentrations of CORM-3 (A). The overlaid red plot shows the corresponding non-viable cell count (right y-axis). Data were analysed by ratio repeated measures one-way ANOVA with Dunnett’s multiple comparison test, * p<0.05, *** p<0.001 vs Day 4 Control, n=4. Line graph of the effects of 10µM CORM-3 over time (B). Data were analysed by two-way repeated measures ANOVA with sample matching by time point. This was followed by Sidak’s multiple comparison test between control and treated groups for each time point, * p<0.05, n=3. Data are represented as mean ± s.e.m.
**Figure 6.10 HO-1 induction in HSVSMCs**

Immunocytochemistry of HO-1 induction (green) in HSVSMCs. Panel (A) illustrates HO-1 induction after a 24h incubation with 3μM CoPPIX. Panel (B) illustrates HO-1 induction after a 24h incubation with 3μM hemin. Panel (C) shows a control image without HO-1 induction. Cell nuclei were stained blue with DAPI. Cells were utilised at P4, and are representative images of 8 fields of view from n=4 experimental repeats.
Figure 6.11 CoPPIX induces HO-1 protein expression in HSVSMCs

Bar graphs showing the relative HO-1 protein expression in HSVSMCs; densitometric analyses were normalised to β-actin at 48h (A) and 96h (B), n=3. CoPPIX treatment was added at 0h and 48h. Data are represented as mean ± s.e.m. and data were analysed by one-way ANOVA with Dunnett’s multiple comparison test, * p<0.05 vs Control levels. Representative western blots of HO-1 and the corresponding β-actin loading control at 48h (C) and 96h (D). The arrows represent the position of the molecular weight markers (top, 37KDa; bottom, 25kDa).
96h, and corresponding representative western blots are shown in panels (C) and (D). HO-1 expression was increased in a concentration-dependent manner in response to CoPPIX. Expression was maintained at 96h by re-application of CoPPIX when the media was changed at 48h, and HO-1 was subsequently induced to a higher level at 96h. Figure 6.12 (A) shows the proliferative response of HSVSMCs to increasing concentrations of CoPPIX, with no effect on cell viability, as shown by the red line plot. Proliferation of HSVSMCs was significantly inhibited by 3µM and 10µM CoPPIX; cell number was reduced by 42% and 45% respectively. The proliferative response of HSVSMCs to 3µM CoPPIX was assessed daily over a 4 day period to produce a time-course; HSVSMC proliferation was inhibited by 39% on day 4, as shown in Figure 6.12 (B), which is comparable to the extent of inhibition demonstrated in response to 3µM CoPPIX shown in Figure 6.12 (A). Co-application of 3µM mibefradil and 3µM CoPPIX did not cause additive inhibitory effects on HSVSMC proliferation when assessed over a 4 day time-course, as shown in Figure 6.13. Cell number was reduced by 10% and 47% in response to CoPPIX and mibefradil respectively. However, cell number was reduced by 47% in response to simultaneous application of CoPPIX and mibefradil. CoPPIX limited cell proliferation in HCASMCs at a concentration of 3µM or higher. Cell death was less than 1%, 1.6%, and 3% in response to 3µM, 10µM and 30µM CoPPIX respectively. HCASMC number was reduced by 43% and 52% in the presence of 3µM CoPPIX, as shown in Figure 6.14 (A) and (B) respectively. However, the combination of all day 4 counts to produce n=8 indicates that cell proliferation was inhibited by 48% in the presence of 3µM CoPPIX (graph not shown).

HO-1-targeting siRNA was employed to prevent basal HO-1 expression and HO-1 induction in HSVSMCs, in order to assess the subsequent proliferative response. A range of HO-1-targeting siRNA concentrations were applied to the cells for 48h, and western blots performed to evaluate HO-1 protein knock-down. As HO-1 is an inducible protein, the optimal time-point at which to apply CoPPIX to the cells was investigated to ensure that the optimal window of mRNA knock-down was utilised. The cell response to the application of CoPPIX immediately post transfection or on the day following transfection was assessed. Figure 6.15 (A) shows HO-1 protein expression levels in response to 3µM CoPPIX application immediately after the transfection solutions were removed, proceeding transfection with 25nM, 50nM, and 100nM HO-1-targeting siRNA. From these western blots it was concluded that 100nM HO-1-targeting siRNA was the optimal concentration to knock-down HO-1 expression. Figure 6.15 panels (B) and (C)
Figure 6.12 CoPPIX inhibits HSVSMC proliferation

Bar graph showing the proliferative response of HSVSMC (left y-axis) to increasing concentrations of CoPPIX. The overlaid red plot shows the corresponding non-viable cell count (right y-axis). Data were analysed by ratio repeated measures one-way ANOVA with Dunnett’s multiple comparison test, ** p<0.01, *** p<0.001 vs Day 4 Control, n=4. Line graph of the effects of 3µM CoPPIX over time (B). Data were analysed by two-way repeated measures ANOVA with sample matching by time point. This was followed by Sidak’s multiple comparison test between control and treated groups for each time point, ** p<0.01, n=3. Data are represented as mean ± s.e.m.
Figure 6.13 Co-application of CoPPIX and mibefradil inhibits HSVSMC proliferation

Bar graph showing the mean (±s.e.m.) day 4 counts of HSVSMC after treatment with 3µM CoPPIX, 3µM mibefradil, or simultaneous application of 3µM mibefradil and 3µM CoPPIX. Data were analysed by one-way ANOVA followed by Tukey’s multiple comparison test. ** p<0.01 vs control. Control n=12, CoPPIX n=3, mibefradil n=4, CoPPIX and mibefradil n=5.
Figure 6.14 CoPPIX inhibits HCASMC proliferation

Bar graph showing the proliferative response of HCASMCs (left y-axis) to increasing concentrations of CoPPIX (A). The overlaid red plot shows the corresponding non-viable cell count (right y-axis). Data were analysed by ratio repeated measures one-way ANOVA with Dunnett’s multiple comparison test, *** p<0.001 vs Day 4 Control, n=4. Line graph showing the effects of 3µM CoPPIX over a 4 day time-course (B). Data were analysed by two-way repeated measures ANOVA with sample matching by time point. This was followed by Sidak’s multiple comparison test between control and treated groups for each time point, * p<0.05, n=4. Data are represented as mean ± s.e.m.
Figure 6.15 Optimisation of HO-1-targeting siRNA in HSVSMCs

Western blots of HO-1 expression after transfection with 25nM, 50nM, and 100nM HO-1-targeting siRNA (A); 3µM CoPPIX was added to the cells upon removal of the transfection solution. Panels (B) and (C) show western blots of HO-1 expression after transfection with 100nM HO-1-targeting siRNA; 3µM CoPPIX was added to the cells the day following transfection (B), or added to the cells upon removal of the transfection solution (C). The arrows represent the position of the molecular weight markers (top, 37KDa; bottom, 25kDa). M=Mock, T=Transfected.
show HO-1 induction in response to 3µM CoPPIX applied the day following transfection, or applied immediately post-transfection respectively, proceeding transfection with 100nM. These western blots show that the window of adequate HO-1 knock-down begins immediately post-transfection, therefore CoPPIX was applied at this time-point in subsequent experiments. Proliferation was assessed by a 4 day time-course immediately following transfection with 100nM HO-1-targeting siRNA; day 0 counts were taken at this time-point. The western blots in Figure 6.16 (A) demonstrate that the HO-1 mRNA was sufficiently knocked-down for the 4 day period, as CoPPIX did not induce protein expression in the transfected cell group. Figure 6.16 (B) shows the proliferative response of the mock and transfected groups, with or without the addition of 3µM CoPPIX. CoPPIX inhibited the cell proliferation of the mock cells by 22% on day 4, with no effect on the transfected cells. This also demonstrates that the HO-1 mRNA was sufficiently knocked-down. However, the presence of the HO-1-targeting siRNA negatively affected the proliferative response of the HSVSMCs. Unexpectedly, cell proliferation was reduced by 57% in the presence of HO-1-targeting siRNA.

In summary, 3µM CoPPIX limits proliferation of HSVSMC and HCASMC to similar extents. The anti-proliferative effect of CoPPIX and mibebradil simultaneously does not appear to be additive. 100nM HO-1-targeting siRNA prevents HO-1 induction by CoPPIX, yet the presence of the siRNA negatively regulated cell proliferation.

6.3 Discussion

Smooth muscle α-actin is the most abundant protein in smooth muscle cells, and smooth muscle myosin heavy chain is the most distinguishing marker of smooth muscle cells (Owens et al., 2004). Despite the abundance of smooth muscle α-actin, this protein was not demonstrated clearly in all cells in Figure 6.1 (A) and (E). The synthesis of smooth muscle α-actin has been shown to decrease in the presence of serum stimulation in parallel with cell proliferation, as demonstrated by thymidine incorporation (Owens et al., 1986). Indeed, smooth muscle α-actin was shown to decrease during culture conditions and remain at low levels during cell proliferation (Campbell et al., 1989). As HSVSMCs were plated at sparse densities for immunocytochemistry, the expression of smooth muscle α-actin may therefore have
Figure 6.16 The effect of 100nM HO-1-targeting siRNA in HSVSMCs

Western blots of HO-1 expression after transfection with 100nM HO-1-targeting siRNA at 48h, 72h, and 96h (A); 3µM CoPPIX was added to the cells immediately upon removal of the transfection solution. The arrows represent the position of the molecular weight markers (top, 37KDa; bottom, 25kDa). Line graph showing the proliferative response over 4 days of Mock and Transfected cells, ±3µM CoPPIX treatment, after transfection with 100nM HO-1-targeting siRNA (B), n=3, data are represented as mean ± s.e.m. M=Mock, T=Transfected.
been limited during these conditions. This is in line with a more recent study which demonstrated that the expression of contractile proteins; (smooth muscle α-actin and smooth muscle myosin heavy chain), was lower in synthetic VSMCs than in contractile VSMCs (Worth et al., 2001). Furthermore, the cytoskeletal protein, vimentin, was expressed at higher levels in synthetic cells, indicating that expression of this intermediate filament is increased upon phenotypic modulation of VSMCs (Kocher et al., 1985; Worth et al., 2001). In canine airway smooth muscle cells, vimentin expression increased in proliferating cells, and decreased as cells reached confluence, implying vimentin could be a marker of smooth muscle cell dedifferentiation (Halayko et al., 1996). Limited co-localisation of smooth muscle α-actin and smooth muscle myosin heavy chain has been demonstrated in synthetic cells (Worth et al., 2001), which coincides with the limited co-localisation illustrated in Figure 6.1 (D). The HSVSMCs examined in the present study were synthetic VSMCs, and the arrangement of cytoskeletal and contractile proteins shown in Figure 6.1 reflected this cell phenotype. The images of the cells in Figure 6.1 represent HSVSMC at P5, implying that the maintenance of these cells in culture for 5 weeks sustains a proliferative phenotype, which was also ensured by preventing the cells from reaching confluence (Campbell et al., 1989).

The expression levels of Ca\(_{\text{3.1}}\) and Ca\(_{\text{3.2}}\) in HSVSMCs, as shown in Figures 6.3 and 6.4, are much higher than the expression levels in A7r5 cells (Chapter 4, Figures 4.3 and 4.4), yet there was no correlation with passage number in either cell type. Despite these higher levels of expression, identification of Ca\(_{\text{3.1}}\) by membrane enrichment remained challenging, and Ca\(_{\text{3.2}}\) could not be detected. Immunoprecipitation of the T-type Ca\(^{2+}\) channels was attempted on two occasions without success. Ca\(_{\text{3.1}}\) is expressed at higher levels than Ca\(_{\text{3.2}}\) in both cell types, which is also suggested by immunocytochemistry in Figure 6.2. Indeed, the Ca\(_{\text{3.1}}\), but not the Ca\(_{\text{3.2}}\) T-type Ca\(^{2+}\) channel has been shown to be a requirement for murine VSMC proliferation (Tzeng et al., 2012). The localisation of Ca\(_{\text{3.1}}\) positive staining at peri-nuclear regions, as shown in Figure 6.2, could be indicative of increased Ca\(_{\text{3.1}}\) protein synthesis and trafficking in response to the synthetic phenotype of the HSVSMCs. The Golgi network and the rough endoplasmic reticulum have been described as prominent features of injured VSMCs, and are likely to play a role in the regenerative response of VSMCs (Poole et al., 1971; Chamley-Campbell et al., 1979). The β1b auxiliary subunit has been shown to increase functional Ca\(_{\text{3.1}}\) T-type Ca\(^{2+}\) channel expression, and a possible role as a
chaperone was suggested (Dolphin et al., 1999). This study also demonstrated that the α2-δ auxiliary subunit influenced the expression of the Ca$_{3.1}$ T-type Ca$^{2+}$ channel at the cell membrane, in addition to the amplitude of the current. Yet, recombinant Ca$_{3.1}$ T-type Ca$^{2+}$ channels exhibit similar currents to those of native channels, therefore α1 subunits do not require accessory subunits to function adequately (Perez-Reyes, 2006). To validate the idea that the Ca$_{3.1}$ T-type Ca$^{2+}$ channel becomes localised within the Golgi network during proliferative phases, a fluorescent probe targeted against the Golgi, such as CellLight® Golgi marker (Molecular Probes), could be employed simultaneously with a Ca$_{3.1}$ targeted probe to assess co-localisation.

HCASMCs consistently proliferated to a greater extent than HSVSMCs in all proliferation assays. Contrastingly, HCASMC proliferation was inhibited to a lesser extent by CORM-3 than HSVSMC proliferation, as shown in Figure 6.8 and 6.9 (A). Based on the proliferative responses one could speculate that HCASMCs have a higher expression level of T-type Ca$^{2+}$ channels than HSVSMCs, yet this contradicts the hypothesis that CO inhibits cell proliferation via T-type Ca$^{2+}$ channels. If time had permitted, elucidation of the T-type Ca$^{2+}$ channel expression levels via immunocytochemistry and RT-PCR could have explained these disparate proliferative profiles. Venous VSMCs have been shown to proliferate more than paired arterial VSMCs (Turner et al., 2007), however the arterial and venous VSMCs employed in the present study were not paired, and different cell requirements necessitated different growth media, which negates any physiological conclusions drawn from direct comparisons. The fact that HSVSMCs have a higher expression level of the T-type Ca$^{2+}$ channel subtypes than A7r5 cells may explain the differing responses of the cell types to CORM-3. Figure 5.4 in Chapter 5 demonstrates the minimal inhibition of proliferation of A7r5 cells in response to CORM-3, in contrast to the significant inhibition of HSVSMC proliferation shown in Figure 6.8.

The proliferative responses of HSVSMCs and HCASMCs to the T-type inhibitor mibebradil were similar when the drug was applied at 3μM. The corresponding non-viable cell counts, as demonstrated by the red plots in Figures 6.6 and 6.7, corroborate the effects seen on A7r5 cells (Chapter 4); that mibebradil is cytotoxic at high concentrations. However, there was an apparent difference in the extent of the anti-proliferative effects produced in response to 3μM mibebradil in HCASMCs in Figure 6.7.
(A) and (B). The cells utilised in the concentration-response assay ranged from P2 to P6, whereas the cells utilised in the time-course assay ranged from P3 to P6, therefore the cell ages were similar. The control cell group for the time-course assay proliferated to a greater extent than the control group for the concentration-response assay, which may explain why 3µM mibebradil limited cell growth to a greater extent in the concentration-response assay.

There is a larger standard error associated with day 4 counts of HCASMCs than with HSVSMCs, as the proliferative response of the former cell type diminished with subsequent cell passage, and was particularly apparent at P5 and P6. Higher passage numbers were utilised for the time-course assays assessing the effects of CORM-3 and CoPPIX. This suggests the development of replicative senescence. Senescent cell cultures can be described as those exhibiting a decline in cell proliferation after a phase of exponential proliferation (Matsumura et al., 1979), although the cell cultures detailed in this study were examined over much longer periods of 60 weeks, compared to the 6 week period over which HCASMCs were assessed in the present study. Increased cell doubling time and lower population densities have been attributed to an ageing process of sub-cultured VSMCs (Chamley-Campbell et al., 1979). The number of senescent human VSMCs was shown to be directly related to the age of the donor (Ruiz-Torres et al., 1999), although studies in different species are less consistent. Replication efficiency of rat aortic VSMCs is higher in cells isolated from aged animals than from young animals (McCaffrey et al., 1988; Li et al., 1997), whereas the data regarding mouse aortic VSMCs is conflicting (Moon et al., 2001; Moon et al., 2003). It is possible that the phenotype of the HCASMCs was modified with each subsequent passage, producing an increasing number of senescent cells. An assessment of T-type Ca$^{2+}$ channel expression at each passage would have been advantageous to assess whether the expression of the channels declined over the 6 week period.

HO-1 induction in HSVSMCs was demonstrated by immunocytochemistry following a 24h incubation with CoPPIX, and the associated western blots show that HO-1 protein expression is maintained at 48h and 96h. CoPPIX did not inhibit proliferation in a concentration-dependent manner in both HSVSMCs and HCASMCs, suggesting that low concentrations of CoPPIX do not reach the threshold required to induce HO-1 protein expression. This is verified by the lack of HO-1 protein bands in response to 0.1µM and 0.3µM CoPPIX in Figure 6.11. As noted previously, there was a large
variation in day 4 HCASMC counts due to the use of older passages. The inhibitory effects of CoPPIX on HSVSMCs and HCASMCs proliferation begin to appear at day 2, whereas the inhibitory effects on A7r5 cells appear at day 3. This could be due to the fact that A7r5 cells have lower expression levels of T-type Ca^{2+} channels than HSVSMCs. Co-application of mibefradil and CoPPIX did not cause additive effects on proliferation. Moreover, the extent of proliferation inhibition by simultaneous application of the compounds equalled that of mibefradil treatment, implying there was competition for the same cellular target. However, the extent of inhibition by CoPPIX in Figure 6.13 was much lower than that shown in Figure 6.12, which is due to the combination of control data from 12 assays. These HSVSMC were sourced from 12 different patients therefore, inherent differences will have undoubtably contributed to the extent of which the cells proliferated, and possibly how they responded to the HO-1 inducer, CoPPIX.

In contrast to the effects of CORM-3, CoPPIX inhibited HCASMC proliferation to a greater extent than HSVSMC proliferation. The fact that the HSVSMCs utilised in the present study were isolated from patients undergoing coronary artery bypass graft (CABG) surgery is noteworthy. To necessitate the need for CABG surgery, these patients will no doubt have coronary artery disease (CAD), and therefore the corresponding HSVSMCs may have inherent modifications as a result. In contrast, the HCASMCs were derived from normal, plaque free coronary arteries. The saphenous vein is subject to lower blood pressure and less shear stress than an artery (Turner et al., 2007), yet the risk factors of CAD, such as hypercholesterolemia, diabetes mellitus, and cigarette smoke, will likely be detrimental to all vessels (Vogel, 1997). Furthermore, such risk factors have been linked with a long microsatellite polymorphism (GT)$_n$ in the HO-1 promoter, and with the development of CAD (Kaneda et al., 2002). Another study also found that longer (GT)$_n$ repeats were associated with CAD susceptibility in patients with diabetes mellitus (Chen et al., 2002). Although neither study found a significant correlation between the long length polymorphism and CAD without such risk factors, there was a trend towards this relationship. The longer (GT)$_n$ genotype has been shown to limit HO-1 expression, which suggests that patients with risk factors for CAD have a reduced capacity for HO-1 induction and vessel protection in response to stresses such as ROS and oxLDL (Chen et al., 2002; Kaneda et al., 2002). These findings can be extended to the data shown here; proliferation was inhibited to a greater extent in HCASMCs than in HSVSMCs, which could be a result of differing extents of HO-1 induction. If time had permitted, western blots of HO-1 induction in HCASMCs could have clarified this hypothesis.
Preliminary assessment of the effect of HO-1-targeting siRNA indicated that 100nM was the optimal concentration, and the adequate window of HO-1 knock-down began immediately post-transfection. The finding that HO-1 knock-down negatively regulated cell proliferation was unexpected, although the fact that CoPPIX had no further inhibitory effect on the transfected cells implies that the siRNA effectively targeted HO-1 mRNA. Therefore, the inhibitory effects of HO-1 knock-down are difficult to explain.

The mock cells proliferated 3.5 fold over the course of the assay, yet the growth of the control cells in all proliferation assays involving HSVSMCs ranged from 3.3 to 5.8 fold. This range can be explained by the fact that cells were sourced from numerous different patients and consequently will contain inherent differences. It can be assumed, therefore, that the transfection procedure itself was not the cause of the diminished proliferative response of the transfected cells. HO-1 has markedly different effects on proliferation depending on the cell type. In contrast to the anti-proliferative effects of HO-1 in VSMCs and fibroblasts, HO-1 is pro-proliferative in keratinocytes, endothelial cells, pancreatic cancer cells, lung cancer cells, hepatoma, sarcoma, and melanoma (Jozkowicz et al., 2007). In numerous cancers HO-1 is induced or constitutively expressed, which confers resistance to apoptosis (Jozkowicz et al., 2007). Indeed, our research group has demonstrated that HO-1-derived CO confers resistance to apoptosis in medulloblastoma DAOY cells (Al-Owais et al., 2012). As reported by Jozkowicz et al. (2007), the effects of HO-1 on proliferation are conflicting, and the involvement of numerous mediators confers complex cellular responses. Despite the fact that HO-1 has been shown to have definitive anti-proliferative effects in VSMCs (Kim et al., 2011b), it is possible that in addition to HO-1 mRNA knock-down, the siRNA caused off-target effects which subsequently affected proliferation.

The use of human VSMCs in the present study has added a clinically relevant aspect to the project as a whole, which has progressed from the use of a recombinant expression system, to a vascular cell line, to primary cells. The anti-proliferative effects of HO-1 and CO are conserved in human VSMCs, and the role of the T-type Ca\textsuperscript{2+} channel in proliferation has been indicated by the use of mibefradil. The previously documented non-specific effects associated with mibefradil are a limiting factor of these experiments. A novel, selective T-type Ca\textsuperscript{2+} channel inhibitor, ML218, has demonstrated inhibition of T-type Ca\textsuperscript{2+} current in subthalamic neurons (Xiang et al., 2011). Additional experiments assessing ML218 as a pharmacological tool would be useful. Stronger conclusions could be drawn about the effects of CO on T-type Ca\textsuperscript{2+} channels in human VSMCs if microfluorimetry data was available. However, such data
proved difficult to acquire, as stable baseline recordings of $[\text{Ca}^{2+}]_i$ could not be obtained. To test further the hypothesis of T-type Ca$^{2+}$ channel inhibition by CO, electrophysiological recordings via whole-cell patch clamp would generate more specific data about T-type Ca$^{2+}$ channel currents, as these currents could be isolated and pharmacological modulation assessed. However, this is technically demanding given the small currents shown in previous reports, as reviewed by (Kuo et al., 2011).
CHAPTER 7

Conclusions

7.1 Principle Findings

**HEK293/Ca,3.2 cells**
- Over-expression of the Ca,3.2 T-type Ca\(^{2+}\) channel produced higher basal [Ca\(^{2+}\)]\(_i\), which was reduced by T-type Ca\(^{2+}\) channel inhibition, CO exposure, and HO-1 induction
- The Ca,3.2 T-type Ca\(^{2+}\) channel augments proliferation
- Augmented proliferation is decreased by T-type Ca\(^{2+}\) channel inhibition, therefore T-type Ca\(^{2+}\) channels are central to the proliferative response
- CO is anti-proliferative and potentially acts via the T-type Ca\(^{2+}\) channel

**A7r5 cells**
- Ca,3.1 T-type Ca\(^{2+}\) channels are the more prominent subtype in A7r5 cells
- Both L-type and T-type Ca\(^{2+}\) channels are expressed in A7r5 cells, and L-type Ca\(^{2+}\) channels appear to have a more prominent role in Ca\(^{2+}\) oscillations
- L-type Ca\(^{2+}\) channels do not have a role in cell proliferation
- Ca,3.1 T-type Ca\(^{2+}\) channels do have a role in cell proliferation, as evidenced by the effects of Ni\(^{2+}\)
- CORM-3, but not iCORM-3, reduced [Ca\(^{2+}\)]\(_i\), and Ca\(^{2+}\) oscillation frequency in A7r5 cells upon modest depolarisation
- CORM-3 did not affect Ca\(^{2+}\) influx when A7r5 cells were strongly depolarised
- CORM-3 had minimal anti-proliferative effects in isolation, but was anti-proliferative when L-type Ca\(^{2+}\) channels were blocked
- HO-1 induction and over-expression inhibited A7r5 cell proliferation and there was a trend towards reduced [Ca\(^{2+}\)]\(_i\)
Human VSMCs

- T-type Ca²⁺ channels are expressed at higher levels in HSVSMCs than A7r5 cells
- Ca₃.1 T-type Ca²⁺ channels are the more prominent subtype in HSVSMCs
- T-type Ca²⁺ channel inhibition, CO exposure and HO-1 induction have anti-proliferative effects in human VSMCs
- Simultaneous HO-1 induction and T-type Ca²⁺ channel inhibition do not cause additive inhibitory effects on proliferation
- HO-1 induction and CO exposure had a greater inhibitory capacity in conjunction with a higher expression level of the Ca₃.1 T-type Ca²⁺ channel in HSVSMC than A7r5 cells

7.2 Summary and clinical relevance

As the level of T-type Ca²⁺ channel expression has been shown to increase in synthetic VSMCs (House et al., 2008), along with the concurrent induction of HO-1 activity (Kim et al., 2011b), and the fact that our research group has recently demonstrated that CO is able to inhibit the T-type Ca²⁺ current, the possibility that the T-type Ca²⁺ channel is a therapeutic target for HO-1 was investigated. My data indicate that CO can inhibit the T-type Ca²⁺ channel. The physiological effects of this inhibition present as a decrease in cell proliferation and a reduction in [Ca²⁺]ᵢ. This conclusion is strengthened by the fact that both CO exposure and HO-1 induction conferred a greater anti-proliferative effect in cells with higher expression levels of the T-type Ca²⁺ channels. CO appears to affect both the Ca₃.1 and Ca₃.2 T-type Ca²⁺ channels, as shown by the effects on HEK293/Ca₃.2 cells and HSVSMCs. The T-type Ca²⁺ channel is an important mediator of VSMC proliferation (Cribbs, 2006), yet the commonly used pharmacological antagonist of this channel, mibefradil, has limited specificity and associated side effects in vivo (Nilius et al., 1997; Mullins et al., 1998; Eller et al., 2000; Strege et al., 2005). The inhibitory effect of CO on the T-type Ca²⁺ current is a novel finding by our research group, and as CO is an endogenous signalling molecule, the associated anti-proliferative effects could be exploited as a therapy for cardiovascular disorders involving excessive VSMC proliferation. By directly enhancing CO availability at the site of vascular injury, or by increasing HO-1 expression and activity in VSMCs, pathological proliferation could be reduced, thereby limiting the ensuing complications associated with a compromised vessel. The idea of gaseous CO as a therapy is not unreasonable, considering the fact that nitric oxide gas is currently
used as a treatment for pulmonary hypertension (Bloch et al., 2007). However, there is a narrow margin between the cytoprotective and detrimental effects of gaseous CO exposure, and targeting the gas to the desired endogenous tissues could pose difficulties. Adequate monitoring of blood COHb levels would also be necessary (Motterlini & Otterbein, 2010). The advent of CORMs suggests that CO delivery could be specifically directed to the site of injury, for instance, by the use of a CORM-coated stent to limit restenosis (Motterlini & Otterbein, 2010). This notion is particularly appealing given that CO has the ability to limit VSMC proliferation and concurrently promote endothelial cell proliferation (Wu & Wang, 2005). Experimentation of such a specifically targeted drug-eluting stent was recently discussed by Curcio et al. (2011), whereby delivery of the phosphatidylinositide-3-kinase, p85, limited VSMC proliferation without effecting endothelial cells. Regarding the potential therapeutic use of gaseous CO, a CO delivery system has recently been developed; the Covox DS (Ikaria), and both gaseous CO and CORMs are currently being assessed for safety and efficacy in Phase III clinical trials. (Motterlini & Otterbein, 2010). The suggestion that CO can limit VSMC proliferation by inhibiting T-type Ca\(^{2+}\) channel activity is an important finding and certainly offers potential for further investigation. However, an understanding of the exact mechanism of inhibition is required in order to support the development of a therapy tailored to this endogenous pathway.

7.3 Further Work
Investigating native T-type Ca\(^{2+}\) channel activity poses numerous challenges. Identification of the T-type Ca\(^{2+}\) channel by western blotting and RT-PCR has proved difficult, due to the relatively low level of expression in VSMCs, in combination with the fact that expression levels can vary in proliferative cells. The use of microfluorimetry recordings added scope to the data generated from proliferation assays, yet the elucidation of the specific T-type Ca\(^{2+}\) channel response using this methodology on cells expressing both voltage-gated T- and L-type Ca\(^{2+}\) channels was dependent on the use of pharmacological agents. Therefore, whole-cell patch clamp electrophysiological recordings would provide further information about distinct T-type Ca\(^{2+}\) channel activity, and the extent of T-type Ca\(^{2+}\) current inhibition by both antagonists and CO. The inclusion of electrophysiology data demonstrating the inhibitory effects of CO on the T-type Ca\(^{2+}\) current would allow a more definitive conclusion to be drawn. The availability of a novel, more specific, T-type Ca\(^{2+}\) channel blocker, ML218, will aid the verification of T-type Ca\(^{2+}\) channel effects in subsequent investigations (Xiang et al., 2011).
The limited data shown here regarding the potential involvement of redox modulation on T-type Ca\(^{2+}\) channel activity warrants further investigation. Oxidative stress is a feature of many cardiovascular disorders (Paravicini & Touyz, 2006; Kim et al., 2011b; Chung et al., 2013); therefore, exploration of the various sources of ROS and their subsequent effects on T-type Ca\(^{2+}\) channel activity and CO-mediated inhibition may help elucidate the exact mechanism of modulation. Endogenous ROS are produced from numerous sources including NADPH oxidase, xanthine oxidase, uncoupled NOS, and the mitochondria (Mueller et al., 2005), and CO has been shown to modulate NADPH oxidase (Taille et al., 2005) and cytochrome c oxidase (Zuckerbraun et al., 2007). Therefore, the use of anti-oxidants such as MitoQ, and inhibitors of potential sources of ROS such as allopurinol, apocynin, and antimycin A, as previously examined by our research group with respect to L-type Ca\(^{2+}\) channel inhibition by CO (Scragg et al., 2008), are pertinent pathways to explore. This may be aided by T-type Ca\(^{2+}\) channel mutagenesis in order to specifically isolate potential redox sites within the channel protein. The thioredoxin and glutaredoxin systems serve to maintain cellular redox balance (Yamawaki et al., 2003), and transient receptor potential channels have been shown to be modulated by thioredoxin (Beech & Sukumar, 2007), therefore these systems may be another potential direction of investigation.

To extend the clinical relevance of this project, in vivo experiments assessing CO-mediated modulation of the T-type Ca\(^{2+}\) channel would be appropriate. The effects of CO on neointima formation could be assessed in T-type knock-out mice. It would be advantageous to examine the effects of CO on both Ca\(_{\text{v}3.1}\) and Ca\(_{\text{v}3.2}\) mice, as one group found that the Ca\(_{\text{v}3.1}\) T-type Ca\(^{2+}\) channel is required for intimal hyperplasia (Tzeng et al., 2012), yet the Ca\(_{\text{v}3.2}\) subtype is documented as the prominent subtype in the cardiovascular system (Catterall et al., 2005; Cribbs, 2006).


GE Healthcare. Amersham ECL Western Blotting System. 2012. Ref Type: Online Source


209

yl)propyl]-N-methylamino)ethyl]-6-fluoro-1,2, 3,4-tetrahydro-1-isopropyl-2-naphthyl
cyclopropanecarboxylate dihydrochloride: a new selective inhibitor of T-type calcium
channels. J Pharmacol Exp Ther 309, 193-199.

Huber WJ, III, Marohnic CC, Peters M, Alam J, Reed JR, Masters BS, & Backes WL
chemically defined assay system. Drug Metab Dispos 37, 857-864.

Huc S, Monteil A, Bidaud I, Barbara G, Chemin J, & Lory P (2009). Regulation of T-
type calcium channels: signalling pathways and functional implications. Biochim
Biophys Acta 1793, 947-952.

prevents in-stent stenosis in rat and rabbit models by inducing heme-oxygenase-1. J


of down-regulation of L-type Ca(2+) channel in the proliferating smooth muscle cells of

Janssen LJ (1997). T-type and L-type Ca2+ currents in canine bronchial smooth

rat vascular smooth muscle cell proliferation through regulation of cyclin D and p21.
Arch Pharm Res 32, 375-382.

function via heme oxygenase-1 in human endothelial cells. Hypertension 48, 950-957.

friend? Antioxid Redox Signal 9, 2099-2117.

Kaneda H, Ohno M, Taguchi J, Togo M, Hashimoto H, Ogasawara K, Aizawa T,
Ishizaka N, & Nagai R (2002). Heme oxygenase-1 gene promoter polymorphism is
associated with coronary artery disease in Japanese patients with coronary risk factors.
Arterioscler Thromb Vasc Biol 22, 1680-1685.

molecular determinant of nickel inhibition in Cav3.2 T-type calcium channels. J Biol
Chem 281, 4823-4830.


